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CHAPTER I 
 
INTRODUCTION 
                           
The nervous system is responsible for receiving, integrating, relaying and 
responding to information from both the internal and external environments. 
Anatomically, the nervous system can be broadly divided into two components, the 
central nervous system (CNS) and the peripheral nervous system (PNS). The CNS is 
comprised of brain and spinal cord, while the PNS contains nerves (afferent and efferent) 
and ganglia which mediate local communication and connect the CNS to the rest of the 
body. The PNS can be further divided into two major parts, the somatic nervous system 
and the autonomic nervous system. The somatic nervous system controls voluntary 
movements through afferent and efferent innervation to and from the muscles and 
sensory organs, whereas the autonomic nervous system regulates internal organ function.  
The autonomic nervous system is comprised of the sympathetic and parasympathetic 
nervous systems, which typically act in an opposing manner to maintain homeostasis. 
The nervous system is made up of different types of cells, the largest group being 
the neurons. Neurons communicate with each other and with other cells primarily 
through the release of neurotransmitters. Our primary interest involves neurotransmission 
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mediated by cholinergic neurons and the neurobiology of the neurotransmitter released 
by these neurons, acetylcholine (ACh). 
Cholinergic neurotransmission 
Cholinergic neurons are abundant in both the CNS and PNS. Within the CNS, six 
cholinergic nuclei (Ch1-Ch6) send axons to innervate different regions of the brain 
(reviewed in Pope, 2005). In the PNS, cholinergic neurons innervate striated muscles, 
heart, viscera, airways and autonomic ganglia. The cholinergic nervous system 
participates in the regulation of many vital processes including memory, learning, 
behavioral arousal, sleep, analgesia, respiration and others (Winkler et al., 1995; 
Kitabatake et al., 2003; reviewed in Sarter and Parikh, 2005;  Zimmermann, 2008).  
Acetylcholine, the transmitter released by all cholinergic neurons, is synthesized 
in the pre-synaptic nerve terminal from the co-factor acetyl coenzyme A and substrate 
choline by the action of synthetic enzyme choline acetyltransferase (Jope and Jenden 
1980; Matsuura et al., 1997). Following synthesis, ACh molecules are transported and 
stored into synaptic vesicles by a vesicular acetylcholine transporter through an energy 
dependent process (Zimmermann, 1987; Parsons, 2000; Rizzoli and Betz, 2004).  
During normal cholinergic neurotransmission (as shown in Figure 1), arrival of an 
action potential at the pre-synaptic terminal leads to membrane depolarization and entry 
of calcium into the cell through voltage-gated calcium channels (Cohen-Cory, 2002). The 
entry of calcium into the cell triggers the fusion of ACh-laden vesicles with the pre-
synaptic plasma membrane, leading to exocytosis and subsequent release of ACh into the 
synapse (reviewed in Sudhof, 2004; Martyn, 2009). Several soluble N-ethylmaleimide-
sensitive-factor attachment receptor (SNARE) proteins, e.g. synaptotagmin, syntaxin and 
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synaptobrevin, are involved in the vesicular fusion process (Heidelberger, 2007; 
Fagerlund and Eriksson, 2009). ACh molecules are released as “quanta” into the synapse 
(Katz, 1971; Wang et al., 2004). The ACh molecules thus released into the synapse act on 
post-synaptically located cholinergic receptors (muscarinic and nicotinic) thereby 
modifying the post-synaptic cell’s activity.   
ACh signaling is effectively terminated by the enzyme acetylcholinesterase 
(AChE, EC 3.1.1.7) (Rosenberry, 1975 and 1979). AChE is a highly conserved enzyme, 
playing a vital role in cholinergic neurotransmission in species from planaria to man 
(Silver, 1974). AChE is abundantly expressed in the CNS and PNS, but is also found in 
blood (primarily in the erythrocytes) (Nigg and Knaak, 2000). A related enzyme, 
butyrylcholinesterase, is also widely distributed but has no known function (Eriksson and 
Augustinsson, 1979; Masson et al., 1996; Nicolet et al., 2003; Giacobini, 2004).  
AChE has an active site which is located at the bottom of a 20Ao aromatic gorge 
(Sussman et al., 1991; Mallender et al., 2000).  The active site is made up of two subsites: 
1) anionic subsite and 2) esteratic subsite. The anionic subsite stabilizes the choline 
moiety of ACh. The esteratic subsite is made up of the catalytic triad (serine200, 
histidine440 and glutamate327). The active site also has an acyl binding site and 
oxyanion hole (Szegletes et al., 1999). The electrophilic oxyanion hole not only attracts 
but also stabilizes the carbonyl oxygen of ACh (Harel et al., 1995). The enzyme also has 
a peripheral anionic binding site. The negative charge of the peripheral anionic site 
attracts the positively charged ACh molecule (i.e., the quaternary nitrogen) leading to the 
formation of a transient enzyme-substrate complex (Johnson et al., 2003). Ligand binding 
at the peripheral anionic site can lead to either activation or inhibition of AChE activity. 
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The serine oxygen of catalytic triad in the active site gorge attacks and forms a covalent 
bond with the ACh molecule. AChE hydrolyses ACh resulting in the formation of an 
acetylated enzyme and free choline. Deacetylation of AChE is rapid and occurs due to a 
nucleophilic attack by a hydroxyl ion of water releasing acetate (reviewed in Zimmerman 
and Soreq, 2006; Colletier et al., 2006). The turnover rate of AChE is 103-104 ACh 
molecules per second, one of the most active enzymes in the body (Lawler, 1961; 
Sultatos, 1994).  
Following ACh hydrolysis, approximately 50% of the choline is cycled back into 
the pre-synaptic terminal by a high affinity choline transporter (HACU) and used for the 
synthesis of new ACh molecules (Collier and Katz, 1974; Happe and Murrin, 1993; 
Ribeiro et al., 2006). The HACU system is an ATP dependent process and is highly 
specific for cholinergic terminals. In contrast, acetate formed by ACh hydrolysis can be 
utilized in intermediary metabolism. The efficient degradation of ACh by AChE is 
essential in the regulation of cholinergic transmission by preventing prolonged activation 
of muscarinic acetylcholine receptors (mAChR) and nicotinic acetylcholine receptors 
(nAChR) throughout the nervous system (Lawler HC, 1961; Downes and Granato, 2004). 
 
 
 
 
 
 
 
 Figure1. General events that occur
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Cholinergic muscarinic receptors 
As noted above, ACh activates two basic types of cholinergic receptors, i.e., 
muscarinic acetylcholine receptors (mAChRs) and nicotinic acetylcholine receptors 
(nAChRs) (Kawashima et al., 1990; Wessler et al., 2001). The mAChRs have been 
classified pharmacologically as M1, M2, M3 and M4 subtypes. Based on molecular 
cloning techniques, five receptor subtypes have been identified, i.e., M1-M5 (Caulfield 
and Birdsall 1998; Bonner, 1989; Wess, 2003). The mAChRs are widely expressed in 
different regions of the brain and in the periphery, and are highly conserved across 
species (Peralta et al., 1987; Bonner, 1989, Dorje et al., 1991). Because of homology 
between the subtypes and due to a lack of highly selective ligands for each receptor 
subtype, it has been difficult to study the role of these receptor subtypes using 
pharmacological agonists or antagonists (Wess, 2004 and 2007). Some examples of 
subtype-preferential receptor antagonists are pirenzipine (M1), methoctramine (M2), 
AFDX 116 (M2), AFDX 384 (for M2 and M4), 4-diphenylacetoxy-N-methylpiperidine 
methiodide (4-DAMP, M3) and himbacine (M4). Examples of some agonists used to 
study muscarinic receptor function are oxotremorine, carbachol and bethanechol (Eglen 
et al., 1985). While these drugs are not entirely selective, they can often be used to study 
mechanisms of receptor-mediated actions of acetylcholine at the different muscarinic 
receptors.  
The mAChRs are G-protein coupled receptors. They are made up of seven 
transmembrane domains that span across the cell membrane and are connected both 
extracellularly and intracellularly by three loops on each side (Wess, 1996; Caulfield and 
Birdsall 1998; Nathanson, 2000). M1, M3 and M5 receptors couple to stimulatory G 
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proteins (Gs) and act through phospholipase C (PLC) activation (reviewed in Ishii and 
Kurachi, 2006). Stimulation of PLC results in the hydrolysis of phosphotidylinositol bis-
phosphate (PIP2) and production of the signaling molecules inositol triphosphate (IP3) 
and diacylglycerol (DAG). IP3 stimulates the release of Ca2+ from endoplasmic reticulum 
and activates calmodulin whereas DAG activates protein kinase C. Protein kinase C and 
calmodulin can modify the post-synaptic cell’s response through a cascade of 
biochemical reactions (Lanzafame et al., 2003). In contrast, M2 and M4 receptors are 
coupled to the inhibitory type (Gi/Go) G proteins and act through inhibition of adenylyl 
cyclase. M2 receptors are located both pre-synaptically (Saito et al., 1991; Levey et al., 
1991) and post-synaptically (Rouse et al., 1997). A detailed mechanism of M2 receptor 
activation will be discussed in subsequent sections.   
The mAChRs are involved in regulating a variety of physiological functions. M1 
receptor is the major muscarinic receptor subtype in cerebral cortex, thalamus, amygdala, 
caudate putamen and plays an important role in learning and memory (Levey et al., 1991; 
Wolfe and Yasuda, 1995; Anagnostaras et al., 2003; Oki et al., 2005). Studies with M1 
knockout mice have shown that the M1 receptor is responsible for eliciting 
cholinergically-mediated seizures (Hamilton, 1997). The M2 and M3 subtypes participate 
in contraction of smooth muscles in the gastrointestinal tract and glandular tissues 
(Caulfield, 1993; Eglen, 1996; Beroukas et al., 2002; Kitazawa et al., 2007) and are 
involved in contraction of smooth muscles (detrussor) in the urinary bladder (Fetscher et 
al., 2002; Ehlert et al., 2005; Tran et al., 2006). Activation of cardiac M2 receptors 
reduces heart rate, force of contraction and automaticity (Brodde and Michel, 1999; 
Stengel, 2000; Krejci and Tucek, 2002; LaCroix et al., 2008). M2 receptors in the brain 
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are known to play a role in learning, memory, motor coordination, cognition, body 
temperature regulation and analgesia (Gomeza et al., 1999; Bernardini et al., 2002; 
Tzavara et al., 2003(a); Seeger et al., 2004), and appear to be the major muscarinic 
autoreceptor in many brain regions. M4 receptors are abundant in the cerebral cortex, 
corpus striatum and thalamus (Felder et al., 2000). M4 receptors appear to play an 
important role in anti-nociception and are thought to be the primary muscarinic 
autoreceptor in the striatum (Duttaroy et al., 2002; Wess, 2004). 
The nAChRs are ionotropic receptors present at neuromuscular junctions, 
autonomic ganglia and throughout the CNS, primarily at pre-synaptic terminals 
(reviewed in Millar and Denholm, 2007). These receptors are made up of five subunits 
from at least 17 different subunits that have been identified (α1-10, β1-4, γ, δ and ε). For 
each receptor, these subunits form pentamers around a central ion channel (Millar, 2003; 
Wang et al., 2003; Changeux and Edelstein, 2005). Binding of ACh to the nAChR results 
in opening of these ion channels and increased permeability to sodium, potassium and/or 
calcium ions (Harkness and Millar, 2002; Khiroug et al., 2002; Fagerlund and Eriksson, 
2009). Activation of the nAChR at neuromuscular junctions elicits skeletal muscle 
contractions, activation of ganglionic nAChR stimulates parasympathetic and 
sympathetic activity, and activation of CNS nicotinic receptors typically modulates 
neurotransmitter release at a variety of cholinergic and non-cholinergic neuronal synapses 
(Corringer et al., 1999; McKay et al., 2007; Exley and Cragg, 2008).  
In summary, following depolarization of the cholinergic pre-synaptic terminal, the 
ACh released can activate cholinergic muscarinic or nicotinic receptors. The activation of 
these receptors elicits different functions depending on the cell type or organ in which 
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these receptors are located. Continuous activation of these receptors following 
accumulation of ACh in some neurotoxicological conditions (e.g. OP poisoning) can lead 
to cholinergic toxicity.   
Organophosphates  
Organophosphorus (OP) compounds (OPs) are an economically important class of 
chemical compounds with a variety of uses including pesticides, industrial fluids and 
therapeutics. OPs are the most widely used insecticides in the United States (Abou-Donia 
et al., 2003), leading to widespread potential for environmental exposures. Philippe de 
Clermont synthesized the first OP compound, tetraethyl pyrophosphate in 1854. During 
the Second World War, a number of nerve agents such as sarin, soman and tabun were 
synthesized by Gerhard Schrader and his colleagues in Germany (reviewed in Costa, 
2006; Pope et al., 2005). Later a number of different OP compounds were synthesized 
and evaluated as insecticides, subsequently replacing many uses for the organochlorine 
insecticides that were being banned in the 1970’s. Thirty-eight different OP 
anticholinesterases are currently registered for use as pesticides in the United States 
(Pope, 1999). 
OP compounds are generally highly lipophilic and can be easily absorbed from 
skin, respiratory and gastrointestinal tracts (Kamanyire and Karalliedde, 2004). OP 
exposure may occur in occupational settings or around the home. In the general 
population, exposure to OPs may be possible through consumption of residues on fruits 
and vegetables or through the household or garden environment. In some countries, 
intentional (suicidal) poisonings by OPs are relatively common (Eddleston et al., 1998; 
Van der Hoek et al., 1998). According to a recent study, around 200,000 people die each 
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year in developing countries because of self-poisoning with OPs (Eddleston, 2000; 2008). 
According to the World Health Organization, approximately 3 million people are in some 
degree exposed to pesticides each year (Walker and Nidiry, 2002). 
OP insecticides can be broadly classified into three groups based on presence or 
absence of a sulfur atom: 
1) Phosphates (no sulfur atom) 
2) Phosphorothioates (one sulfur atom) 
3) Phosphorodithioates (two sulfur atoms) 
The general structure of OPs and also the chemical structures of OP compounds 
used in our studies are shown in Figure 2. In a prototype OP insecticide, the R group is 
typically either a methyl or ethyl group, and R’ is generally the same but can be one of a 
number of different substituents. The leaving group, X, can be either a cyanide, halide or 
phenoxy moiety. Organophosphorus derivatives are referred to as 1) an organophosphate 
if there is an oxygen bonded to phosphorus at both R and R’, 2) an organophosphonate if 
there is one oxygen bonded to phosphorus at either the R or R’ site, and 3) an 
organophospinate if there is no oxygen bonded to phosphorus at either the R or R’ 
group. Thus, use of the term “organophosphate” to refer to all organophosphorus 
toxicants can be a misnomer, but this term is in general use in the toxicological 
community.  
 
 
 
 
 
 
 
 
 Figure 2. Chemical Structures of Organophosphorus Anticholinesterases
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Parathion is a prototype OP insecticide (Gaines, 1960). Although its use has been 
banned in the US, it is still used as a pesticide in many developing countries. 
Chlorpyrifos is one of the most commonly used insecticides in the US and worldwide 
(Davis and Ahmed, 1998; Lemus and Abdelghani, 2000). Parathion and chlorpyrifos 
elicited different degrees of cholinergic toxicity at dosages leading to similar levels of 
cholinesterase inhibition, i.e., parathion-treated rats showed more extensive signs of 
toxicity (Pope et al., 1995; Liu and Pope 1998; Liu et al., 2002). The comparative 
absence of overt signs of cholinergic toxicity following dosages of chlorpyrifos that elicit 
extensive cholinesterase inhibition has been the basis for a longterm research project 
within our laboratory.  
Parathion and chlorpyrifos are “parent” compounds which undergo bioactivation 
by cytochrome P450-dependent monooxygenases to their active oxygen metabolites 
(oxons), paraoxon and chlorpyrifos oxon (Sultatos, 1985; Forsyth and Chambers, 1989; 
Murray and Butler, 1994; Furlong, 2007). These metabolites are roughly 1000-fold more 
potent than the parent insecticides at inhibiting cholinesterases (Sultatos, 1994). Paraoxon 
and chlorpyrifos oxon are detoxified by the action of carboxylesterases distributed 
throughout the body. In addition, “A-esterases” such as PON1 are thought to be more 
important in the detoxification of chlorpyrifos oxon. Comparing the toxic effects of 
parent compounds relative to their active metabolites can often provide important 
toxicokinetic and mechanistic insights.  
Anticholinesterases have been used in veterinary medicine for the control of ticks 
and for the treatment of internal parasites such as flukes. Anticholinesterases have also 
been used in human medicine for the treatment of cholinergic disorders such as 
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Alzheimer’s disease and myasthenia gravis (Pope et al., 2005). These compounds have 
also been used for the treatment of glaucoma, incontinence, to stimulate GI peristalis, as 
well as other purposes (Nagabukuro et al., 2004). Unfortunately, OP compounds have 
also been used in chemical terrorism, e.g. sarin use in Japan in the mid 1990’s by the 
Aum Shinrikyo terrorist group (Murata et al., 1997).  
Cholinergic toxicity  
OPs inhibit AChE by phosphorylating the serine hydroxyl group in the active site 
of AChE leading to the formation of a stable, phosphylated enzyme (Radic and Taylor, 
2001; Casida and Quistad, 2005). This covalent modification blocks subsequent substrate 
(ACh) binding and hydrolysis. With extensive AChE inhibition, accumulation of ACh 
leads to persistent activation of post-synaptic cholinergic receptors and signs of 
cholinergic toxicity (Pope et al., 2005). The clinical expression of toxicity depends on the 
types of receptors prominently activated and their location within the body, which can 
also be influenced by the structure of the OP itself (e.g. some anticholinesterases have 
difficulty crossing the blood brain barrier and thus primarily affect the PNS). When 
mAChR in the periphery are activated, autonomic signs including excessive secretions 
(salivation, lacrimation, defecation and urination), nausea, abdominal cramps, 
bronchorrhea, severe respiratory distress, blurred vision, miosis, hypotension, 
conjunctival congestion, nasal discharge, ciliary spasm and bradycardia can be observed 
(Lotti, 1995; Paudyal, 2008). On the other hand, activation of mAChR in the brain can 
lead to anxiety, ataxia, tremors, seizures, hypothermia and depression of respiratory 
centers (Costa, 2006). Activation of the nAChR results in muscle fasciculations, 
diaphragmatic failure and ganglionic stimulation. During later stages of OP poisoning 
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however signaling involving other neurotransmitters such as GABA and glutamate can be 
recruited. Death in severe cases typically occurs due to respiratory failure from increased 
airway secretions, decreased respiratory muscle tone, and depression of central 
respiratory control centers (reviewed in Pope et al., 2005).  
There are four main types of toxicity elicited by OPs: 
1) Acute cholinergic toxicity is due to inhibition of AChE and characterized by signs of 
cholinergic toxicity such as SLUD signs and involuntary movements. This is due to 
prolonged stimulation of post-synaptically located cholinergic receptors by accumulating 
synaptic ACh (Nallapaneni et al., 2006). 
2) Intermediate syndrome is generally seen 24-96 hours after resolution of acute 
cholinergic toxicity following insecticide intoxication. Signs and symptoms include 
paralysis of proximal muscle groups of the face, neck and respiratory muscles and can 
lead to rapid onset respiratory failure and death (De Bleecker, 1995; Samuel, 1995; Senel 
et al., 2001). 
3) Organophosphorous-induced delayed polyneuropathy is seen 2-3 weeks following 
OP exposure. This form of OP toxicity is related to the inhibition of another esterase 
enzyme called neuropathy target esterase, and associated with degeneration of selected 
nerves in the CNS and PNS. This disorder is characterized by distal muscle weakness 
which can progress to paralysis. Recovery is very slow, and some signs may not recover 
at all due to CNS involvement (Johnson, 1993; Pope et al., 1993; Johnson and Glynn, 
1995; Ehrich, 1997; Singh et al., 2004).  
4) Persistent neurological sequelae seen in patients severely intoxicated with OP 
insecticides. Symptoms include confusion, lethargy, irritability, impaired memory and 
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psychosis (Wesseling et al., 2002; Colosio et al., 2003). The molecular basis for such 
persistent neurological consequences following acute intoxication is unknown.  
Other targets of OPs 
The primary target of OP compounds for eliciting acute toxicity is AChE. Several 
studies have reported, however that some OPs can bind to other enzymes in addition to 
AChE, as well as to some cell surface receptors (Pope, 1999). As noted above, some OPs 
can elicit organophosphorous-induced delayed polyneuropathy by inhibiting neuropathy 
target esterase. Many OP compounds can bind to and inhibit other esterases such as 
butyrylcholinesterase (Thiermann et al., 2007; Eddleston et al., 2008; Aurbek et al., 2009) 
and carboxylesterases. As noted before, carboxylesterases play an important role in the 
detoxification of many OP compounds (Chanda et al., 1997; Karanth et al., 2000, 2004). 
Some OPs can interact directly with muscarinic (Silveria et al., 1990; Jett et al., 1991; 
Howard et al., 2002), nicotinic (Eldefrawi and Eldefrawi, 1983; Rao et al., 1987; Ray and 
Richards, 2001) and glutamate receptor subytpes (Idriss et al., 1986; Pope et al., 1999). 
For example, Liu et al (2002) showed that in presence of the carbamate anticholinesterase 
physostigmine and the non-selective muscarinic receptor blocker, atropine, some OPs 
could directly interact with muscarinic autoreceptors in rat striatal slices. Interstingly, 
paraoxon and methyl paraoxon acted as agonists to decrease ACh release while 
chlorpyrifos oxon acted as an antagonist and increased ACh release. Ward et al (1993) 
reported that paraoxon and malaoxon blocked binding to the ligand [3H]cis-
methyldioxolane (CD), an M2 preferential agonist, in rat hippocampal and cortical 
membranes.  
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Quistad and coworkers (2001, 2002 and 2006) reported that some OPs can 
selectively interact with different components of the endocannabinoid signaling pathway, 
a neuromodulatory pathway that is widely distributed in the mammalian nervous system. 
These investigators also showed that some OP compounds can inhibit several other serine 
hydrolases. Knowledge about the interaction of OPs with non-cholinesterase targets 
could lead to better treatment of OP intoxications (Casida et al., 2005; Nomura et al., 
2006). 
Current therapeutic approach to OP intoxication and drawbacks 
 
The traditional therapeutic approach for treating OP poisoning involves three 
drugs: 1) a muscarinic receptor antagonist (typically atropine) to block the activation of 
post-synaptic mAChRs, 2) an enzyme reactivator that dephosphorylates and thereby 
chemically restores AChE activity and 3) a benzodiazepine to block seizures.  
There are several potential weaknesses of this treatment regimen. While atropine 
effectively counteracts some of the muscarinic signs of cholinergic toxicity (e.g. excess 
salivation), it may block the adaptive activation of pre-synaptic autoreceptors that 
mediate feedback inhibition of ACh release. Blockade of the pre-synaptically located 
autoreceptors can lead to increased ACh in the synapse which has the potential to activate 
the nicotinic receptors and can thus exacerbate OP toxicity. In severe cases of OP 
poisoning such as nerve agent poisoning, seizures may develop. These seizures are 
sensitive to atropine treatment only in the early stages of acute intoxication, becoming 
resistant to antimuscarinic therapy later. Although seizures are initiated by accumulating 
ACh, they are thought to be maintained by the recruitment of downstream glutamatergic 
signaling pathways (Shih and McDonough, 1997; Solberg and Belkin, 1997; Weissman 
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and Raveh, 2008). Conventional therapy does not consider the excitotoxic effects of 
glutamatergic signaling. Furthermore, patients treated with atropine to block acute signs 
and symptoms can show persistent neurological deficits (Colosio et al., 2003). Atropine 
could contribute to these persistent neurobehavioral changes by blocking adaptive 
changes in ACh release. Moreover, atropine can lead to ventricular fibrillations in anoxic 
patients, thus exacerbating acute lethality (Bowden and Krenzelok, 1997). Second, the 
enzyme reactivator (e.g. pralidoxime) is useful only before ageing (i.e. spontaneous loss 
of an alkyl group) of the enzyme-inhibitor complex occurs (Worek et al., 1999; Eddleston 
et al., 2002; Buckley et al., 2005; Eyer and Buckley, 2006). Once the enzyme ages, the 
reactivator is ineffective and actually contraindicated as it has anticholinesterase activity 
on its own. Care should be taken while using pralidoxime and other reactivators since 
overdosage can lead to muscle spasms. Another drawback of this treatment regimen is 
that it does not consider effects of nAChR activation throughout the body, leading to 
skeletal muscle fasciculations and incoordinated contractions as well as modulation of 
neurotransmitter release centrally.  
Alternative strategies 
The current pharmacological strategy for OP intoxication emphasizes blockade of 
the effects of accumulating ACh. Drugs that can decrease ACh levels may improve this 
overall strategy. Several neurochemical processes could potentially be manipulated to 
decrease ACh release from the pre-synaptic terminal. Inhibition of HACU, blocking of 
synaptic vesicle fusion, or activating muscarinic autoreceptors could potentially be 
therapeutically advantageous. A number of pre-synaptically located heteroreceptors (e.g. 
adenosine, cannabinoid CB1 receptors) may also be therapeutically useful and in fact, 
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activation of adenosine receptors to decrease ACh release has been previously evaluated 
as a therapeutic strategy (Van Helden et al., 1998; Van helden and Bueters, 1999; Bueters 
et al., 2002). Our studies focused on two pre-synaptic receptors regulating ACh release, 
i.e., muscarinic M2 and cannabinoid CB1 receptors and their role in the expression of OP 
toxicity.  
We hypothesize that drugs that can enhance endocannabinoid levels (e.g. 
inhibitors of enzymes that degrade endocannabinoids) and M2 selective agonists could be 
useful for the treatment of OP poisoning and might negate some of the negative aspects 
of traditional therapy. For example, since eCB signaling can inhibit the release of non-
cholinergic neurotransmitters, cannabinomimimetics may not only inhibit ACh release 
but may also block the effects of other neurotransmitters such as glutamate that are 
thought to be involved in some aspects of cholinergic toxicity. Therefore, utilizing drugs 
that can decrease ACh levels through activation of either pre-synaptic muscarinic M2 or 
cannabinoid CB1 receptors may potentially improve the therapy of OP poisoning. Figure 
3 shows how muscarinic M2 and cannabinoid CB1 receptors may modulate OP toxicity 
by regulating ACh release from the cholinergic terminal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3. Role of pre-synaptic M2 and CB1 receptors in regulating ACh release in 
OP toxicity. 
As noted above, AChE inhibition by an OP leads to cholinergic to
stimulation of post-synaptic cholinergic receptors
signaling pathways. Excess ACh can increase the synthesis and release of eCBs, however, by 
activation of M1 and M3 receptors. 
neurotransmitters (e.g. GABA, glutamate) also occurs. e
activation of group I mGluR.
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Muscarinic receptor-mediated regulation of ACh release 
 
The mAChR subtypes are involved in a variety of physiological functions 
(Caulfield, 1993). The presence of M2 receptors on pre-synaptic terminals implies a role 
for this receptor in adaptive responses, in particular in feed-back regulation of transmitter 
release (Rouse and Levey, 1997; Hajos et al., 1998). Previous studies using synaptosomal 
preparations, brain slices and microdialysis indicate that M2 receptors indeed play a role 
in inhibiting ACh release from the cholinergic pre-synaptic terminal (Levey et al., 1995; 
Kitaichi et al., 1999; Galli et al., 2001). Zhang and coworkers (Zhang et al., 2002) using 
brain slices from M2, M4 and M2/M4 knockout mice reported that the M2 receptor is the 
primary autoreceptor regulating ACh release in cortex and hippocampus, whereas M4 
appeared to be the prominent autoreceptor in mouse striatum. Moreover, studies have 
also shown that ACh levels can be elevated by blocking M2 autoreceptors using M2 
selective antagonists (Quirion et al., 1995; Stillman et al., 1996). As noted before, ACh 
accumulation following anti-cholinesterase exposure can activate M2 receptors, leading 
to lesser ACh release, potentially minimizing the accumulation of ACh into the synapse 
and thereby the toxicity of anti-cholinesterases. Thus, targeting of the M2 receptor may 
be useful in modulating cholinergic neurotransmission and impairing the expression of 
cholinergic toxicity.  
Binding of ACh to the pre-synaptic M2 receptor activates the Gi protein, which is 
a heterotrimeric molecule (comprised of α, β and γ subunits) associated with the guanine 
nucleotide, GDP. Upon activation, the GDP is exchanged for GTP, and the G protein 
dissociates into αi and βγ subunits. The αi subunit inhibits adenylyl cyclase and thereby 
reduces the synthesis of cAMP (Olianas et al., 1983; reviewed in Krejci et al., 2004). 
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cAMP activates protein kinases which, among other things, phosphorylate voltage-
sensitive calcium channel subunits. Channel subunit phosphorylation enhances channel 
opening allowing more entry of calcium ions into the terminal. Calcium is required for 
the fusion and exocytosis of synaptic vesicles (Beech et al., 1992; Allen and Brown 1993; 
Bajjalieh and Scheller, 1995). Since adenylyl cyclase is inhibited by M2 receptor 
activation, less calcium enters the terminal leading to a net reduction in transmitter 
release. In addition to the αi subunit, the βγ subunits can also regulate ACh release. The 
βγ subunits also directly bind to and inhibit voltage-sensitive calcium channels, leading to 
decreased influx of calcium into the pre-synaptic terminal (Beech et al., 1992; Herlitze et 
al., 1996). The βγ subunits bind to and activate inwardly rectifying potassium channels, 
leading to increased efflux of K+ ions and consequent hyperpolarization of the terminal 
(Logothetis et al., 1987; Yamada et al., 1998). Hyperpolarization thus decreases release 
of ACh by preveting the activation of voltage-sensitive calcium channels. Additionally, 
βγ subunits appear to interact directly with some proteins of the exocytotic machinery, 
preventing the fusion of synaptic vesicles with the plasma membrane and thereby 
blocking ACh release. Hydrolysis of GTP to GDP by the αi subunit which has intrinsic 
GTPase activity results in reassociation of the three subunits to again form the 
heterotrimeric G protein molecule. Thus, the binding of agonist to the M2 receptor results 
in decreased ACh release through multiple mechanisms involving both αi and βγ 
subunits. 
Previous in vitro and ex vivo studies from our lab using rat brain slices suggested 
that selective effects on muscarinic autoreceptor function may play a role in the 
differential toxicity of the OP insecticides parathion and chlorpyrifos. To extend these 
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studies, we proposed to investigate the role of M2 receptor signaling in OP toxicity using 
a mouse model lacking the M2 receptor. Since the M2 receptor acts as an autoreceptor to 
inhibit ACh release, we hypothesized that deletion of the M2 receptor would exacerbate 
OP toxicity. 
Cannabinoids 
Natural cannabinoids (phytocannabinoids) are bioactive compounds derived from 
the plant Cannabis sativa (Gaoni and Mechoulam, 1971). Cannabis and products from it 
have been used for centuries for their medicinal and psychoactive properties. Cannabis 
has been used for analgesics, antiemetics, antispasmodics and for producing euphoria 
(Pertwee 2000; Kreitzer and Stella, 2009). The major psychoactive component in these 
extracts was identified as delta-9-tetrahydrocannabinol (THC) (Gaoni and Mechoulam, 
1971). These natural cannabinoids bind to a specific receptor to elicit their neurologic 
actions, termed the cannabinoid type 1 (CB1) receptor (Devane et al., 1988; Matsuda et 
al., 1990). The discovery of the specific receptors for phytocannabinoids led to a search 
for endogenous ligands for these receptors. The first endogenous cannabinoid 
(endocannabinoid, eCB) discovered was arachidonylethanolamide from porcine brain, 
referred to as anandamide (Devane et al., 1992). The name “anandamide” was derived 
from the Sanskrit word ananda which means “bliss” or “happiness”, in reference to the 
euphoric effects of Cannabis (Vander Stelt and Di Marzo, 2005). Another eCB 
subsequently isolated from canine gut was 2-arachidonyl glycerol (2-AG) (Mechoulam, 
1995; Sugiura et al., 1995; Pertwee and Ross, 2002). 2-AG is present in higher 
concentrations compared to anandamide in the brain and is also more efficacious 
compared to anandamide (Grotenhermen, 2005). Other endogenous ligands for 
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cannabinoid receptors have also been reported such as 2-arachidonyl glycerol ether 
(noladin ether) and O-arachidonylethanolamine (virodhamine) (Bisogno et al., 2000; 
Kano et al., 2002; Porter et al., 2002). Unlike classical neurotransmitters which are pre-
packaged into synaptic vesicles, eCBs are synthesized “on demand” in post-synaptic cells 
following depolarization and diffuse from the cell into the synapse to bind to pre-synaptic 
receptors, hence eCB signaling is termed “retrograde signaling” (Di Marzo, 1999; 
Piomelli et al., 1998; Hillard and Jarrahian, 2000; Wegener and Koch, 2009). 
Endocannabinoid signaling 
The eCB signaling system consists of eCBs, the enzymes responsible for their 
synthesis and degradation, specific cannabinoid receptors and a putative membrane 
transporter for reuptake into the neuron. Anandamide is synthesized from N-arachidonoyl 
phosphatidyl ethanolamine by the enzyme, N-acyltransferase phosphatidyl ethanolamine- 
phospholipase D (NAPE-PLD, Freund et al., 2003; Di Marzo et al., 2004; Pertwee, 
2005). Like anandamide, 2-AG is also synthesized from membrane phospholipids, but by 
the action of diacylglycerol lipase (DAGL). Endocannabinoid action is thought to be 
terminated by reuptake into either the pre-synaptic terminal or the post-synaptic cell, 
followed by enzymatic degradation. Anandamide is primarily degraded by the enzyme 
fatty acid amide hydrolase (FAAH) while 2-AG is primarily inactivated by the enzyme 
monoacylglycerol lipase (MAGL) (Dinh et al., 2002; Wilson and Nicoll, 2002; 
Hashimotodani et al., 2007).  
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Figure 4. Synthesis and degradation of endocannabinoids 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anandamide and 2-AG are formed from lipid precursors by the action of the enzymes NAPE-PLD and 
DAGL and are degraded by the enzymes FAAH and MAGL, respectively. 
 
As noted before, cholinergic neurotransmission is mediated by ACh released into 
the synapse to activate post-synaptic cholinergic receptors. The activation of these 
receptors can potentially lead to post-synaptic cell depolarization mediated by M1, M3 or 
M5 receptors (via production of the second messengers inositol triphosphate and diacyl 
glycerol). With AChE inhibition ACh accumulates, leading to prolonged post-synaptic 
mAChR activation, persistent production of second messengers, and increased 
intracellular calcium levels and the potential for depolarization. The synthetic enzymes 
for both anandamide and 2-AG are calcium-dependent. Furthermore, M1 and M3 
receptors are directly coupled to the synthesis and release of eCBs (Kim et al., 2002; 
Ohno-Shosaku et al., 2003). AChE inhibition and consequent ACh accumulation should 
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therefore increase eCB signaling. During later stages of OP poisoning, release of other 
neurotransmitters (e.g. glutamate) is also increased. Group I metabotropic glutamate 
receptors are also directly coupled to synthesis of eCBs, again potentially leading to 
enhanced eCB signaling (Maejima et al.,et al., 2001; Ohno-Shosaku et al., 2002). 
Similar to the mAChR, the CB1 receptor is a member of the G-protein coupled 
receptor superfamily (Matsuda et al., 1990; Wiley and Martin, 2002). These receptors are 
made up of seven transmembrane domains, with the extracellular domain containing the 
amino terminal and the intracellular domain the C terminal. A second type of cannabinoid 
receptor referred to as CB2 has also been identified, but it appears primarily associated 
with immune cells/functions (Howlett 1995; Kaminski, 1996; Elphick and Egertova 
2001). CB1 receptors are the most abundant GPCR in the brain (Herkenham et al., 1990; 
Pertwee, 1997 and 2001). In the nervous system, CB1 receptors are primarily located on 
pre-synaptic terminals and act as heteroreceptors, regulating the release of variety of 
neurotransmitters including ACh, GABA, and glutamate (Wilson and Nicoll 2002; 
Takahashi and Castillo 2006). Within the brain, CB1 receptors are abundantly expressed 
in the substantia nigra pars reticulata, globus pallidus, hippocampus and cerebellum 
(Herkenham et al., 1990). CB1 receptors are also present in the periphery in association 
with the neurons in organs such as heart, liver and the gastrointestinal tract. As noted 
above, CB2 receptors are primarily localized in immune-related tissues and cells such as 
spleen, B lymphocytes, monocytes and natural killer cells (reviewed in Howlett et al., 
2002; Pertwee and Ross, 2002; Mackie, 2005). Of interest for CNS function, CB2 
receptors are localized on microglia, the resident macrophages within the brain. CB1 and 
CB2 receptors can be activated by both phytocannbinoids and eCBs. Endocannabinoid 
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signaling is involved in diverse processes including analgesia, thermoregulation, synaptic 
plasticity, food intake, immune function, cognition and a variety of other physiological 
functions (Pacher et al., 2006). Furthermore, more recent evidence suggests that eCBs 
may work through additional though yet defined receptor subtypes (e.g. CB3; Kano et al., 
2009). 
Cannabinoid receptor-mediated regulation of ACh release 
Endocannabinoid signaling modulates neurotransmission throughout the 
mammalian brain by modulating the release of neurotransmitters including acetylcholine 
(ACh) (Misner and Sullivan, 1999; Hajos et al., 2001; Hoffman and Lupica, 2000; Irving 
et al., 2000; Schlicker and Kathmann, 2001; Takahashi and Castillo, 2006). 
Endocannabinoids are the signal molecules controlling depolarization induced 
suppression of excitation (DSE) and depolarization induced suppression of inhibition 
(DSI), two forms of synaptic plasticity. Inhibition of glutamate release is the basis for 
DSE (Sullivan, 1999; Hajos and Freund, 2002), while inhibition of GABA release is 
responsible for DSI. These processes are referred to as “endocannabinoid-mediated 
plasticity” (Mackie, 2008; Herkenham et al., 1990; Kano et al., 2009).  
Once released by a post-synaptic cell, eCBs bind to and inhibit voltage gated N-
P/Q and L-type calcium channels, blocking entry of calcium into the pre-synaptic 
terminal (Caulfield and Brown, 1992; Twitchell et al., 1997; Guo and Ikeda 2004; 
Zhuang et al., 2005). Since calcium is required for vesicular exocytosis and transmitter 
release, decreased calcium influx into the terminal will inhibit further ACh release. 
Cannabinoids also bind to and inhibit inwardly rectifying potassium channels and 
activate voltage sensitive K+ channels (Deadwyler et al., 1993; Henry and Chavkin, 1995; 
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Mackie et al., 1995). These actions result in increased efflux of  K+ ions across the pre-
synaptic membrane, normalizing the membrane potential and thereby inhibiting further 
release of ACh (Elphick and Egertova 2001; Freund et al., 2003; Kim et al., 2002). 
Activation of CB1 receptors also inhibits adenylyl cyclase, leading to decreased cAMP 
formation and reduced activation of protein kinase A (PKA) (Howlet, 1985; Pertwee and 
Ross, 2002). As PKA is important for phosphorylation of a variety of proteins in the cell, 
including A-type potassium channels, a net result is the activation of A-type potassium 
channels, increasing potassium efflux and impairing further depolarization (Mu et al., 
1999; Kulkarni and Ninan, 2001).  
Several in vitro and in vivo studies have suggested the role of CB1 receptor in 
regulating ACh release in hippocampus (Carta et al., 1998; Gessa et al., 1998; Gifford 
and Ashby 1996; Gifford et al., 1997 and 2000). In rats, the synthetic cannabinoid 
receptor agonist WIN 55,212-2 decreased hippocampal ACh release in vivo, whereas 
SR141716A, a CB1 receptor antagonist, increased ACh release (Tzavara et al., 2003(b). 
CB1 receptor antagonists increased extracellular ACh levels in hippocampus, a response 
that was absent in tissues from CB1 knockout mice (Degroot et al., 2006). Previous 
studies from our lab showed that WIN 55,212-2 reduced the acute toxicity of the OPs 
paraoxon and DFP (Nallapaneni et al., 2006, 2008). We hypothesized that eCB signaling 
plays an important role in the expression of OP toxicity. As ACh accumulation can lead 
to increased synthesis and release of endocannabinoids by post-synaptic cells, increased 
activation of CB1 receptors could inhibit further release of ACh (Wilson et al., 2001; 
Yoshida et al., 2002 and Ohno-Shosaku et al., 2003) and decrease expression of 
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cholinergic toxicity. We hypothesize that in the absence of CB1, loss of the inhibition of 
ACh release will increase sensitivity to OP anticholinesterases.  
The pre-synaptic regulation of neurotransmitter release may therefore be a target 
for modulation of anticholinesterase toxicity. In our studies, we focused on two different 
pre-synaptic regulatory signaling pathways for controlling ACh release, i.e., signaling via 
the M2 autoreceptor and the CB1 heteroreceptor. Our overall hypothesis is that genetic 
deletion of either the M2 or the CB1 receptor will enhance the expression of cholinergic 
signs of OP toxicity by disrupting adaptive changes in acetylcholine release following OP 
exposure.  
Specific aims 
We hypothesized that deletion of the M2 or CB1 receptor would increase 
sensitivity to OP toxicity due to loss of the feedback (or retrograde) inhibition of ACh 
release. As OPs lead to excess ACh accumulation, activation of either M2 or CB1 
receptors should decrease functional signs of toxicity associated with OP poisoning. 
Thus, both M2 and CB1 receptor activation can decrease ACh release, with the potential 
to influence expression of anti-ChE toxicity.   
Knockout mice can serve as viable models to study the role of a particular gene. 
We used M2 and CB1 knockout mice to understand the role of cholinergic and 
cannabinergic signaling in modulating OP toxicity as well as the regulatory role of M2 
and CB1 receptors as autoreceptors and heteroreceptors in regulation of acetylcholine 
release. The project was designed as three specific aims.  
Specific Aim 1: To evaluate the effects of M2 receptor deletion on acute sensitivity to 
selected OP compounds. 
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Specific Aim 2: To evaluate the effects of CB1 receptor deletion on acute sensitivity to 
selected OP compounds. 
Specific Aim 3: To evaluate ACh release as affected by OP exposure in vitro and ex vivo 
in slices from M2-/-, CB1-/- mice and their respective wildtype littermates.
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CHAPTER II 
 
METHODS 
 
Chemicals 
Chlorpyrifos (CPF, O,O’-diethyl-O-(3,5,6-trichloro-2-pyridinyl-phosphorothioate, 
99% purity), chlorpyrifos oxon (CPO, O, O’-diethyl-O-(3, 5, 6-trichloro-2-pyridinyl-
phosphate, 99.1% purity), parathion (PS, O, O’-diethyl-O-4-nitrophenyl-
phosphorothioate, 99% purity) and paraoxon (PO, O, O’-diethyl-O-4-nitrophenyl-
phosphate, 99.1% purity) were purchased from Chem Service (West Chester, PA) and 
stored in a desiccator under nitrogen at 4oC.  
Acetylcholine iodide (acetyl-3H; specific activity = 76.0 mCi/mmol), choline 
chloride (methyl- 3H; specific activity = 66.5 Ci/mmol) were purchased from Perkin 
Elmer (Boston, MA) and stored at -70oC. Ethanol, atropine sulfate, Tris (hydroxymethyl 
aminomethane), sodium hydroxide, hydrochloric acid, ethylenediamine tetra acetic acid 
(EDTA), heparin, acetylcholine iodide, polyethylenimine (PEI), sodium chloride, sodium 
sulfate, potassium phosphate (mono and dibasic), triton X-100, chloroacetic acid, sodium 
potassium tartrate, bovine serum albumin (BSA), cupric sulfate, sodium carbonate, Folin 
& Ciocalteu’s phenol reagent, p-nitrophenol, p-nitrophenyl acetate (p-NPA), ethidium 
bromide, agarose, sodium borate dehydrate, boric acid, sodium phosphate (dibasic), 
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potassium chloride, magnesium sulfate, calcium chloride, d-glucose, sodium bicarbonate, 
hemicholinium-3, PPO (2,5-diphenyloxazole), POPOP (1,4-bis[5-phenyl-2-
oxazolyl]benzene) and acetylcholinesterase (Type V-S), WIN 55,212-2 (R(+)-[2,3-
dihydro-5-methyl-3-(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl](1-
napthalenyl)methanone mesylate, oxotremorine (1-[4-(1-Pyrrolidinyl)-2-butynyl]-2-
pyrrolidinone) were all purchased from Sigma-Aldrich (St. Louis, MO). Isoamyl alcohol, 
toluene and acetone were purchased from Fisher Scientific (Houston, TX). Primers for 
genotyping were also purchased from Sigma-Aldrich (St. Louis, MO). For PCR, all 
buffers and enzymes were purchased from Takara (Shiga, Japan).  Reagent grade 
chemicals were used for all studies. 
     Animals 
Maintenance and breeding of knockout and wildtype mice 
M2 knockouts 
A breeding pair of M2 knockout (KO) mice was a generous gift from Dr. Jurgen 
Wess at the National Institute of Diabetes and Digestive and Kidney diseases (NIDDK, 
Bethesda, MD). These M2 knockouts were a cross between CF1 and 129J1 strains 
(50%/50%). The mice were initially produced by replacing a 0.67-kilobase NheI-NsiI 
fragment with PGK-neomycin resistance gene (Gomeza et al., 1999). Crossbred wildtype 
mice (WT) with the same genetic backgrounds (i.e., without littermate controls) were 
used in our initial studies. 
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CB1 knockouts 
Two breeding pairs of homozygous CB1 KO mice were obtained from Dr. Jim 
Pickel at the National Institute of Neurological Disorders and Stroke (NINDS, Bethesda, 
MD). The mice were initially generated by disrupting the coding region of the CB1 gene 
between the amino acids 32 and 448 with PGK-neomycin construct in embryonic stem 
cells. Chimeric mice obtained from these embryonic stem cells were bred to C57Bl/6 
mice. Homozygous CB1 KO mice were then generated by inter-matings of heterozygotes 
(Zimmer et al., 1999). C57Bl/6 (i.e., CB1 WT) mice were purchased from Charles River.  
For breeding purposes, two adult females (8 weeks of age) were kept with one 
male. Nesting squares were kept in each cage to encourage mating. The mice were placed 
in polycarbonate cages and maintained on a 12-h light/dark cycle. The mice were 
provided Mouse Diet 5015 (PMI, Walnut Creek CA) and water ad libitum. Pregnant 
females were separated from cage-mates upon visible evidence of pregnancy. After birth, 
pups remained with the dam until 21 days of age, after which they were sexed and 
weaned. Male mice at 8 weeks of age were used for in vivo studies whereas the females 
were either discarded or used for further breeding. In all cases, genotype was confirmed 
by PCR using tail DNA. All procedures involving animals were in accordance with 
protocols of NIH/NRC “Guide for the Care and Use of Laboratory Animals” and were 
approved by Institutional Laboratory Care and Use Committee (IACUC) of Oklahoma 
State University prior to use. 
Maintenance and breeding of +/+ and -/- littermates   
For obtaining littermate (LM) controls of both M2 and CB1 KO mice, two adult 
WT females (8 weeks of age) were housed with one KO male to obtain heterozygote 
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progeny (HZ). Male and female HZ at 8 weeks of age were then placed together for 
breeding to obtain +/+, +/- and -/- LM mice. WT/LM and KO male mice at 8 weeks of 
age were used for the subsequent studies. HZ male and female mice were either discarded 
or used for further breeding. Confirmation of the genotype was by PCR of tail DNA. 
Mice were ear notched after genotyping for subsequent identification. 
Genotyping 
Extraction of tail DNA 
The distal tail (about 2 cm) was collected for DNA extraction. Tails were cut into 
small pieces to ensure efficient digestion and extraction of DNA. The Qiagen DNeasy 
blood and tissue kit for isolation of genomic DNA was used according to the 
manufacturer’s instructions (Qiagen Inc, Valencia, CA). In brief, 180 µl of ATL buffer 
and 20 µl of proteinase K were added to Eppendorf tubes containing tissues and vortexed. 
The tissues were allowed to lyse in the buffer mixture at 56°C for 6 to 8 hours. Later, 200 
µl of AL buffer and 200 µl of absolute ethanol were added. The mixture was then passed 
through a DNeasy mini spin column and centrifuged at 6000 × g for 1 minute. The flow-
through was discarded. AW1 (500 µl) buffer was added, followed by centrifugation at 
6000 × g for 1 minute. The same process was repeated with AW2 buffer, followed by 
centrifugation at 20,000 × g for 3 minutes. Again, the flow through was discarded. 
Finally, 200 µl of AE buffer was added directly into the DNeasy mini spin column, 
followed by incubation for 1 minute at 37° C and centrifugation at 6000 × g for 1 minute. 
The flow-through was collected for use into sterile Eppendorf tubes. Concentration of 
DNA in the sample was estimated using a spectrophotometer (Nanodrop Products, 
Wilmington, DE). 
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PCR 
M2 KO and WT mice 
The following primers were used for M2 KO mice: 
M2-A6:   5'-GCT ATT ACC AGT CCT TAC AAG ACA- Forward primer 
NEO-1:   5'-CAG CTC ATT CCT CCC ACT CAT GAT –Reverse primer 
The following primers were used for WT mice: 
M2-A6:   5'-GCT ATT ACC AGT CCT TAC AAG ACA-Forward primer 
M2-B5:   5'-CCA GAG GAT GAA GGA AAG AAC C –Reverse primer 
CB1 KO and WT mice 
The following primers were used for CB1 KO mice:  
CTGCTATTGGGCGAAGTG - Forward primer 
TAGCCAACGCTATGTCCTG - Reverse primer  
The following primers were used for WT mice: 
CCCTCTGCTTGCGATCATGGTGTATG – Forward primer 
TATCTAGAGGCTGCGCAGTGCCTTC – Reverse primer  
The following reaction mixture was used for PCR of tail DNA: 
DNA                              5 µl    (10 ng/µl) 
H2O                               5.25 µl 
PCR Buffer (10 X)        2.5 µl 
dNTP (2.5 mM)            2 µl 
Forward primer            5 µl (10 ng/µl) 
Reverse primer             5 µl (10 ng/µl) 
TaKaRa Taq                0.25 µl (5 U/µl) 
 Total:                           25 µl
 
PCR Conditions: 
95oC for 5 min; 95oC for
for 10 min. Sample were 
PCR was done using DNA isolated from the tail samples. PCR products were
loaded onto a 1.5% agarose gel with 
borate decahydrate and 7.7 mM boric acid for 1L of water; 
the gel. The PCR products were diluted 5
diluted samples being loaded into the wells. For comparison of molecular weights, a 1 kb 
DNA ladder was loaded 
at 100 volts for 30 min. The separated products were visualized using a UV Gel Doc (Gel 
Doc 2000; Bio-Rad Laboratories, Hercules, CA).
The following bands for M2 
1. M2-A6+M2-B5 ---
2. M2-A6+NEO-1---
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 30 sec; 55oC for 30 sec; 72oC for 1 min (30 cycles)
stored at 4 oC. 
ethidium bromide. 1x SB buffer (19.9 mM sodium 
pH = 8.0) was used to prep
 times with loading buffer, with 
into one lane. PCR products were electrophoretically se
 
KO and WT mice were obtained (Gomeza et al.,
 M2 WT band 435 bp and  
 M2 KO band 476 bp 
Figure 5: Genotyping of 
WT and M2 KO mice.
 
M2 receptor PCR products of 
the expected size were 
observed for both wildtype 
(435 bp) and M2 knockout 
(476 bp) mice
 
 
 
 
 
 and 72oC             
 
are 
15 µl of the 
parated 
 1999): 
                                  
 
. 
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The following bands for CB1 KO and WT mice were obtained (Zimmer et al., 1999): 
 
1. WT band 199 bp  
2. CB1 KO band 400 bp 
 
 
Figure 6: Genotyping of WT 
and CB1 KO mice. 
 
CB1 receptor PCR products of the 
expected size were observed for both 
wildtype (199 bp) and CB1 knockout 
(400 bp) mice. 
 
 
 
In vivo studies 
Evaluation of functional signs of OP toxicity 
 Involuntary movements were graded for severity as described by Moser et al. (1988): 
2 = normal quivering of vibrissae, head and limbs; 3 = mild, fine tremor typically seen in 
the forelimbs and head; 4 = whole body tremor; 5 = myoclonic jerks and 6 = clonic 
convulsions. Autonomic signs of cholinergic toxicity (salivation, lacrimation, urination, 
diarrhea commonly called as SLUD) were graded as: 1 = normal, no excessive secretions; 
2 = slight, one SLUD sign or very mild multiple signs; 3 = moderate, multiple overt 
SLUD signs and 4 = severe multiple, extensive SLUD signs.  
Dose determination studies with WT and M2 KO mice 
Research from our laboratory has primarily focused on rat models for evaluating 
toxicity of OP compounds. Since there was relatively little information available in the 
literature for sublethal dosages of parathion in mice, preliminary dose response studies 
Standard 
500  bp
400 bp
300 bp
200 bp
100 bp
WT1     WT2                KO1    KO2                -ve ctrl   
CB1
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were conducted in WT and M2 KO mice. Peanut oil was used as vehicle for all OP 
compounds. Parathion was prepared in peanut oil and administered subcutaneously (15, 
25 or 35 mg/kg, 1 ml/kg) using a 100 µl Hamilton syringe with a 26 gauge needle. 
Control mice were treated with peanut oil only. Mice were evaluated for functional signs 
of toxicity at 2, 4, 8, 12 and 24 hrs after dosing.  Following the final observations, mice 
were sacrificed and tissues were collected for biochemical assays. 
Initial studies using M2 KO without littermate controls 
M2 KO and WT mice (n = 4-6/treatment group) were treated with parathion (35 
mg/kg), chlorpyrifos (300 mg/kg), paraoxon (1 mg/kg) or chlorpyrifos oxon (5 mg/kg). 
All the doses used were based on preliminary dose response studies. Toxicity following 
exposure to the oxons (i.e., paraoxon and chlorpyrifos oxon) is rapid while functional 
toxicity occurs later after exposure to the parent insecticides. Functional signs were 
therefore evaluated for four hrs (paraoxon and chlorpyrifos oxon), 24 hrs (parathion) or 
72 hrs (chlorpyrifos). The onset of cholinergic signs of toxicity was different following 
parathion and chlorpyrifos exposure. Hence different timepoints were selected for studies 
with parathion and chlorpyrifos. Following the final functional observations, body 
weights were recorded, mice were sacrificed by decapitation and tissues were collected 
for biochemical assays.  
Initial studies using CB1 KO without littermate controls 
CB1 KO and WT mice (n = 4-6/treatment group) were treated with vehicle 
(peanut oil), parathion (20 mg/kg) or chlorpyrifos (300 mg/kg) and functional signs of 
toxicity were evaluated for 48 hrs. The dose of parathion was selected based on previous 
studies with FAAH knockout mice (which also has a C57bl/6 genetic background). 
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Following the final functional observations, body weights were recorded, mice were 
sacrificed by decapitation and tissues were collected for biochemical assays. 
M2 KO studies with WT/LM controls 
Subsequent studies comparing toxicity in M2 KO used littermate controls, 
following heterozygote breedings and genotyping of the progeny. M2 KO and WT/LM 
mice (n = 4-6/treatment group) were treated with vehicle (peanut oil), parathion (27.5 or 
35 mg/kg), chlorpyrifos (300 mg/kg) or the muscarinic agonist oxotremorine (0.5 mg/kg). 
Parathion treated mice were evaluated for functional signs of toxicity graded for 24-48 
hrs whereas chlorpyrifos treated mice were evaluated for 72 hrs. For studies with 
oxotremorine, WT/LM and KO mice were treated with either vehicle (deionized water, 1 
ml/kg) or oxotremorine and observed for cholinergic signs of toxicity for 90 minutes. At 
the end of each study, body weights were recorded, mice were sacrificed by decapitation 
and tissues were collected for biochemical assays.  
CB1 KO studies with WT/LM controls 
Our initial studies evaluating toxicity in CB1 KO (without LM controls) 
suggested differences in the extent of cholinesterase inhibition following exposure to 
either parathion or chlorpyrifos (see results). To control properly for such differences, 
WT littermates were used for all subsequent toxicity studies. CB1 KO and WT/LM mice 
(n = 4-6/treatment group) were treated with vehicle (peanut oil), parathion (20 or 27.5 
mg/kg) or chlorpyrifos (300 mg/kg) and functional signs of toxicity evaluated for 24-48 
hrs. At the end of each study, body weights were recorded, mice were sacrificed by 
decapitation and tissues were collected for biochemical assays.  
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Biochemical assays 
Tissue collection and preparation 
Brain, liver, heart, blood (for plasma) and tail were collected. Hippocampus, 
cerebellum and cortex were dissected from whole brain. The heart was rinsed with 10 
mM Tris buffer (pH 7.4) containing 1 mM EDTA and minced before freezing. Liver was 
rinsed in normal saline solution. Blood was collected into heparinized 1.5 ml Eppendorf 
tubes (20 µl heparin; 10,000 units/ml) and immediately centrifuged at 12,000 rpm for 10 
minutes to separate plasma. All tissues were stored at -70°C until assayed. Cholinesterase 
was measured in hippocampus, cortex, cerebellum and heart. The rationale for selecting 
these brain regions was because of the high abundance of cholinergic signaling and also 
due to involvement of these regions in memory, learning and motor control. 
Carboxylesterase activity was measured in plasma and liver. On the day of the assay, 
tissues were thawed on ice, weighed and an appropriate volume of 50 mM potassium 
phosphate buffer, pH 7.0 added based on the specific tissues (hippocampus, 30 volumes; 
cortex, 40 volumes; cerebellum, 40 volumes; heart, 30 volumes and liver, 20 volumes). 
Tissues were homogenized using a Polytron PT 3000 homogenizer (Brinkmann 
Instruments, Westbury, NY) at 28,000 rpm for 20 seconds. For heart, the minced tissues 
were washed with normal saline solution, blotted on tissue paper and then homogenized 
two times for 30 seconds each, with a 20 second between homogenizations. In each case, 
tissue homogenates were used for cholinesterase or carboxylesterase assays. Protein 
content in homogenates was measured using the method of Lowry and coworkers (1951) 
using bovine serum albumin as the standard.  
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Cholinesterase assay 
Cholinesterase activity was measured using a radiometric method (Johnson and 
Russell, 1975). Briefly, twenty µl of tissue homogenate was added to 60 µl of 1% Triton 
X-100 in potassium phosphate buffer (50 mM, pH 7) in 7 ml scintillation vials and 
vortexed. Twenty µl of 5 mM [3H]acetylcholine iodide (1 mM final concentration) was 
added at staggered intervals (10 seconds), vortexed and incubated at room temperature. 
Incubation times were preselected for each tissue based on attaining linear rates of 
substrate hydrolysis. For a positive control in each assay, purified electric eel AChE was 
used in duplicate vials to determine complete substrate hydrolysis. For determining non-
enzymatic hydrolysis of the substrate, paired blank samples were analyzed containing no 
tissue (or other enzyme source). The reaction was stopped by the addition of 100 µl of an 
acidified stop solution, which not only terminates the reaction but also protonates the 
acetate product essential for the analysis of enzymatic activity in this system. Five ml of a 
toluene-based organic scintillation cocktail was then added to the vials followed by 
vortexing to separate aqueous and organic phases, after which radioactivity was measured 
directly in the reaction vial. ChE activity in the samples was then normalized by protein 
content and expressed as nmol ACh hydrolyzed/min/mg protein. 
Preparation of purified AChE (electric eel) 
AChE (electric eel) was purchased as a lyophilized powder (1070 units/mg 
protein). Working stocks of eel AChE were prepared by dissolving 50 units enzyme 
activity in 1 ml of 50 mM potassium phosphate buffer (pH 7.0). Aliquots (50 µl) were 
stored at -70°C. On the day of each assay, twenty µl of eel AChE stock solution was 
added into paired vials and maximal substrate hydrolysis determined.  
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Preparation of radiolabeled substrate ([3H]acetylcholine iodide)  
The radiolabeled substrate for the cholinesterase assay was prepared by dissolving 
1 mCi of [3H]acetylcholine iodide in 2 ml of 50 mM potassium phosphate buffer (pH 
7.0). An aliquot (150 µl) of this stock radioligand solution was added to 10 ml of 9.90132 
mM non-radiolabelled acetylcholine iodide, and the volume was adjusted to 20 ml by 
adding 9.85 ml of 50 mM potassium phosphate buffer (pH 7.0). Aliquots of substrate 
solutions were then aliquoted (800 µl each) and stored at -70°C until use. 
Preparation of the reaction terminating solution  
Stop solution was prepared from chloroacetic acid (1 M), sodium hydroxide (0.5 
M) and sodium chloride (1.9 M) in deionized water. This solution was stored at 4°C until 
use. 
Preparation of organic scintillation cocktail for the cholinesterase assay 
The scintillation cocktail for the cholinesterase assay was prepared by mixing the 
scintillants 2,5-diphenyloxazole (PPO; 22.6 mM) and 1,4-bis[5-phenyl-2-
oxazolyl]benzene (POPOP; 0.8 mM) in 100 ml of isoamyl alcohol and 900 ml of toluene. 
This cocktail was vortexed until in solution and stored at room temperature. 
Carboxylesterase assay  
The assay for carboxylesterase activity was conducted essentially as described by 
Clement and Erhardt (1990), as modified by Karanth and Pope (2000). In brief, 10 µl of 
tissue homogenate or plasma was added to 240 µl of 0.1 M Tris-HCl buffer (pH 7.8) 
containing 2 mM EDTA. This mixture was then pre-incubated for 5 min at 37°C. The 
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reaction was initiated by the addition of 10 µl of 12.5 mM p-nitrophenyl acetate (NPA) in 
100% acetone (0.5 mM final concentration). The reaction time was selected from 
preliminary time course assays to elicit linear rates of substrate hydrolysis. Absorbance at 
405 nm was recorded against a blank that contained only buffer and substrate. A standard 
curve with p-nitrophenol was used to determine carboxylesterase activity, which was 
expressed as nmoles of p-NPA hydrolyzed/min/mg protein or /ml of plasma.  
Estimation of protein content in tissue samples 
Protein content was estimated using the method of Lowry et al. (1951). A 
standard curve was made for each assay with different concentrations of bovine serum 
albumin (BSA). Paired tubes contained 0, 10, 25, 50, 75 or 100 µg of BSA and were 
processed along with unknown samples. An equal volume of buffer corresponding to that 
amount of buffer in unknown samples was added to each of the BSA standard tubes to 
account for any influence on protein estimation. The volume was adjusted to 200 µl in 
both standard and unknown sample tubes with deionized water. Later, 2 ml of working 
reagent 1 (see below) was added to all tubes including the standards, followed by 
incubation at room temperature for 10 min. After this incubation, 200 µl of working 
reagent 2 (see below) was added to all tubes. The tubes were then vortexed and incubated 
for 30 min at room temperature. Absorbance was read using a UV-Vis 
Spectrophotometer (Beckman-Coulter, Fullerton, CA) at 720 nm. Protein content in the 
unknown samples was then estimated based on absorbance changes in the standard curve. 
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Preparation of BSA  
Working stock solutions of BSA were prepared by dissolving BSA in deionized 
water (1 mg/ml) and these were aliquoted and stored at -20°C until use.   
Preparation of working reagents 1 and 2 for the protein assay 
Working reagents 1 and 2 were prepared fresh on the day of the assay. Working 
reagent 1 was prepared by adding 1 part of 0.5% copper sulfate and 1 part of 1% sodium 
potassium tartrate to 100 parts of 2% sodium carbonate in 0.1N sodium hydroxide. The 
copper sulfate and sodium potassium tartrate solutions were prepared in advance in 
deionized water and stored at 4°C. The sodium carbonate solution in 0.1N sodium 
hydroxide was stored at room temperature. Working Reagent 2 was prepared by adding 
equal parts of Folin & Ciocalteu’s Phenol reagent and deionized water. 
Ex vivo studies  
 M2 KO studies with WT/LM controls 
M2 KO and WT mice (n = 4-6/treatment group) were treated with vehicle (peanut 
oil, 1 ml/kg) or parathion in peanut oil (27.5 mg/kg). Mice were graded for 48 hrs for 
functional signs of OP toxicity. After the final functional observations, mice were 
sacrificed by decapitation and hippocampus, cortex and striatum were rapidly dissected 
on ice and slices were prepared as described below to measure acetylcholine release ex 
vivo.  
CB1 KO studies with WT/LM controls 
CB1 KO and WT mice (n = 4-6/treatment group) were treated with vehicle, 
parathion (27.5 mg/kg) or chlorpyrifos (300 mg/kg) and graded for functional signs of 
44 
 
toxicity for 24-48 hrs. Mice were then sacrificed by decapitation and ACh release 
subsequently evaluated in hippocampal and striatal slices prepared as described below  
 Ex vivo acetylcholine release in brain slices 
Brain slices were prepared essentially as described before (Zhang et al., 2002). In 
brief, mice were sacrificed by decapitation and whole brain was immediately removed 
and dissected on ice to separate the different brain regions. Hippocampal, striatal and 
cortical slices (250 µm, unidirectional) were prepared using a McIlwain Tissue Slicer. 
These slices were dispersed by gentle trituration (4-5 x) with a pasteur pipette. The slices 
were first  pre-incubated for 20 min at 33°C under constant oxygenation in Krebs Ringer 
Bicarbonate buffer (KRB: 1.3 mM CaCl2, 1.2 mM KH2PO4, 4.7 mM KCl, , 1.2mM 
MgSO4, 25 mM NaHCO3, 118 mM NaCl, and 11 mM d-glucose). The slices were then 
washed with fresh KRB and then incubated with 2 ml of KRB containing 15 µl of 
[3H]choline (113 nM final concentration, specific activity 66.5 Ci/mmol) for 30 min at 
37°C. Hemicholinium-3 (10 µM) was added to all buffers to block high affinity choline 
uptake (this allows measurement of released acetylcholine even when 
acetylcholinesterase is active; Liu et al., 2002). The slices were then transferred to a 
superfusion apparatus (SF12/Brandel Inc., Gaithersburg, MD) and perfused with KRB 
containing hemicholinium-3 (0.5 ml/min for 60 min, 37°C). ACh release was stimulated 
twice by perfusing the slices for five minutes (i.e., at 20 - 25 [S1] and 60 – 65 [S2] 
minutes) with depolarizing buffer (25 mM NaHCO3, 1.2 mM MgSO4, 1.3 mM CaCl2, 11 
mM d-glucose, 10 µM hemicholinium-3 containing elevated potassium and equivalently 
reduced sodium levels). The concentration of KCl and NaCl in the buffer varied 
depending on the tissue: cortex; 30 mM KCl, 87.7 mM NaCl, hippocampus; 25 mM KCl 
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92.7 mM NaCl, and for striatum; 20 mM KCl, 97.7 mM NaCl. Twenty 5-min fractions 
were collected. At the end of the assay, 250 µl of the each fraction was pipetted into 7 ml 
scintillation vials, 4 ml of scintillation fluid was added, the vials were vortexed and the 
radioactivity in each vial was measured using a liquid scintillation counter. The tissue 
slices from each well were transferred carefully from the chambers to tubes containing 2 
ml of 1N NaOH and allowed to digest for 1 hr at 72°C. After 1 hr, 200 µl of each tissue 
digest was transferred to 7 ml scintillation vials, and the total residual radioactivity in 
tissues was measured using liquid scintillation counting. Although slices were stimulated 
twice with depolarizing buffer, for the ex vivo release studies only data from the S1 peak 
was used to determine OP-related effects. The size of the peak (S1) was related to total 
amount of radioactivity in all fractions and the residual tissue. Effects of in vivo OP 
exposure on release were related to release in the respective vehicle treated controls. 
In vitro studies  
M2 KO studies with WT/LM controls 
The in vitro effects of OPs on ACh release were studied in cortical, hippocampal 
and striatal slices from WT and M2 KO mice. Brain slices (n = 5-8 animals/treatment 
group) were exposed to either vehicle, paraoxon (100 µM) or chlorpyrifos oxon (100 
µM) and changes in acetylcholine release were evaluated. 100 mM stock solutions of 
oxons were prepared in absolute ethanol and then serially diluted to obtain 100 µM 
concentrations.  The muscarinic agonist, oxotremorine (10 µM) was used as a positive 
control. 
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CB1 KO studies with WT/LM controls 
Hippocampal and striatal slices from WT and CB1 KO mice were used to study 
the in vitro effects of OPs on ACh release. Brain slices (n = 6-8 animals/treatment 
condition were exposed to either vehicle, to paraoxon (100 µM) or chlorpyrifos oxon 
(100 µM). The cannabinoid agonist, WIN 55,212-2 (1 µM) was used as a positive 
control. 
In vitro acetylcholine release in brain slices 
The ACh release method for in vitro studies was essentially the same as described 
above for ex vivo studies. To study the effects of an exogenous chemical (e.g. paraoxon) 
on ACh release, either vehicle or the chemical under study was added 20 minutes before 
the second pulse of potassium (S2). The ratio of S2/S1 was then used as a normalized 
index of ACh release under the influence of the exogenous test chemical. 
Statistical Analyses 
The body weight data and biochemical data (acetylcholinesterase, 
carboxylesterase and ACh release) were expressed as mean ± standard error (SE) and 
analyzed using one-way ANOVA and post hoc analysis using Tukey’s test. Functional 
data (IM and SLUD signs) were expressed as median ± interquartile range (IQR). 
Functional data were transformed (square root) and were analyzed for statistical 
significance by two-way ANOVA and post hoc analysis was performed with Bonferroni 
correction. In the absence of normally distributed data such as ranked observations, data 
transformations including the square root transformation can be conducted with 
subsequent statistical analysis by parametric methods (Singer et al., 2004). For all 
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statistical analyses the GraphPad Prism® statistical software was used. Statistical 
differences were considered significant at p < 0.05. 
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CHAPTER III 
RESULTS 
 
Studies with Muscarinic M2 Receptor Knockout Mice 
Specific Aim 1A: To evaluate the effects of M2 receptor deletion on acute sensitivity 
to selected OP compounds: Initial Studies 
We used four different OPs (parathion, chlorpyrifos, paraoxon and chlorpyrifos 
oxon) for these studies. Wildtype and M2 knockout mice of 8 weeks of age were used for 
all studies. Dose determination studies were first conducted.  
A) Parathion toxicity in wildtypes and M2 knockouts  
Preliminary dose-response studies were first conducted with parathion. Mice were treated 
with parathion (0, 15, 25 or 35 mg/kg, sc) and functional signs of toxicity were graded at 
2, 4, 8, 12 and 24 hrs after dosing. Figure 7 shows the dose dependent effects of parathion 
on involuntary movements. Wildtype mice exposed to the lowest dosage (15 mg/kg) 
exhibited tremors at 24 hrs while the same dosage had no effect in M2 knockout mice. 
With 25 mg/kg, parathion elicited tremors in wildtype mice by 8 hrs after treatment and 
significant differences were noted between wildtypes and knockouts at 24 hrs after 
dosing. The highest dosage of parathion (35 mg/kg) elicited more extensive and 
49 
 
severe tremors by 12 hrs after dosing, persisting until the end of the observation period. 
The extent of tremors elicited by parathion at 35 mg/kg exposure was significantly 
different in wildtype and M2 knockout mice at both 12 and 24 hrs after dosing. When 
tremors (involuntary movements) were used as the toxicity endpoint, wildtypes exhibited 
more severe responses than M2 knockouts.  
Figure 8 shows the effects of parathion in wildtypes and M2 receptor knockouts 
on autonomic indicators of toxicity (i.e., SLUD signs). All three dosages of parathion 
elicited SLUD signs in wildtype mice at 12 and 24 hrs after exposure. The two higher 
dosages (25 and 35 mg/kg) elicited SLUD signs in the knockout mice at 12 and 24 hrs 
after dosing. A significant difference in the expression of SLUD signs was noted between 
wildtype and knockout mice at 12 hrs following exposure to the highest dosage (35 
mg/kg).  
Figure 9 shows inhibition of hippocampal cholinesterase activity following 
parathion exposure in wildtype and M2 receptor knockout mice. Parathion inhibited 
cholinesterase activity in both wildtypes and knockouts, but more extensive inhibition 
was noted in tissues from wildtypes. Interestingly, all three dosages caused relatively 
similar degrees of cholinesterase inhibition in wildtype mice (15 mg/kg, 85.7 ± 0.4%; 25 
mg/kg, 89.8 ± 0.2%; 35 mg/kg, 91.2 ± 0.8%). In M2 knockouts, significantly lower 
inhibition was noted with the lowest dosage, but the two highest dosages did not elicit 
different degrees of inhibition (15 mg/kg, 47.5 ± 5.6; 25 mg/kg, 76.1 ± 6.9%; 35 mg/kg, 
74.5 ± 7.7%). As both functional and biochemical analyses suggested that wildtype mice 
were more sensitive to the acute toxicity of parathion, further studies were conducted 
with the highest dosage of parathion (35 mg/kg). 
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Figure 7: Dose-related effects of parathion on involuntary movements in wildtype and 
M2 knockout mice.  
Mice (n = 4-7/group) were exposed to either vehicle or parathion (15, 25 or 35 mg/kg, sc) 
and were graded for functional signs of toxicity as described in methods section. 
Functional signs were expressed as median ± interquartile range. An asterisk indicates a 
significant difference between wildtype control and wildtype treatment group. A dollar 
sign indicates a significant difference between knockout control and knockout treatment 
group. A pound sign indicates a significant difference between wildtype and M2 
knockout mice. Mice in wildtype and M2 knockout control group did not show any signs 
throughout the observation period. 
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Figure 8: Dose-related effects of parathion on SLUD signs in wildtype and M2 knockout 
mice.  
Mice (n = 4-7/group) were exposed to either vehicle or parathion (15, 25 or 35 mg/kg, sc) 
and were graded for functional signs as described in methods section. Functional signs 
were expressed as median ± interquartile range. An asterisk indicates a significant 
difference between wildtype control and wildtype treatment group. A dollar sign 
indicates a significant difference between knockout control and knockout treatment 
group. A pound sign indicates a significant difference between wildtype and M2 
knockout mice. Mice in wildtype and M2 knockout control group did not show any signs 
throughout the observation period. 
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Figure 9: Dose-related effects of parathion on hippocampal cholinesterase activity in 
wildtype and M2 knockout mice.  
Mice (n = 4-7/group) were exposed to either vehicle or parathion (15, 25 or 35 mg/kg, sc) 
and were sacrificed 24 hrs after treatment. Hippocampus was collected and subsequently 
analyzed for cholinesterase activity. Data (mean ± standard error) represent enzyme 
activities (nmol of substrate hydrolyzed/minute/mg protein) and are expressed as percent 
of respective control values. An asterisk indicates a significant difference compared to 
controls, a pound sign indicates a significant difference between wildtype and knockout 
treatment groups, and a dollar sign indicates a significant difference with respect to other 
dosing groups within wildtype or knockout mice. Cholinesterase activity in hippocampus 
of control animals was 36.4 ± 1.6 nmol/min/mg protein in wildtypes and 38.7 ± 0.2 
nmol/min/mg protein in M2 knockouts.  
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Effect of parathion (35 mg/kg, sc) on functional signs and esterase activities in wildtype 
and M2 knockouts 
Mice were treated with vehicle or parathion (35 mg/kg, sc) and were observed for 
functional signs of toxicity for 24 hrs. Parathion exposure reduced body weight in both 
wildtype and M2 knockout mice with no significant differences between the treatment 
groups (WT: 14.6 ± 2.2%; KO: 11.1 ± 3.5%).  
Figure 10 shows the effects of parathion on cholinergic signs of toxicity 
(involuntary movements, excessive secretions, i.e. SLUD signs) and cholinesterase 
inhibition in hippocampus.  
Tremors were seen in wildtypes at 8 hrs after dosing, which became progressively 
more severe by 24 hours. Tremors were also seen in M2 knockouts, but only 24 hrs after 
dosing. The extent of involuntary movements in wildtypes was significantly different 
from M2 knockouts at 8, 12 and 24 hrs after parathion treatment.  
  Parathion exposure elicited SLUD signs in wildtypes by 8 hrs after dosing, which 
increased in intensity by 12 hours. Moderate SLUD signs were observed at 24 hrs after 
dosing in wildtypes. In contrast, M2 knockout mice showed relatively few SLUD signs at 
12 hrs but these gradually increased in severity by 24 hrs after dosing. A significant 
difference in SLUD signs between wildtype and M2 knockout mice was observed at both 
8 and 12 hrs after dosing.         
  Basal cholinesterase levels were similar between wildtype and M2 knockout 
mice. Extensive inhibition was observed in both wildtype and knockout mice (WT: 91.2 
± 0.9%, KO: 75.3 ± 7.4%). Table 1 summarizes cholinesterase inhibition in other brain 
regions following parathion exposure in these same animals. Parathion significantly 
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reduced cholinesterase activity in both wildtypes and M2 knockouts in all brain regions 
but a moderately greater reduction was noted in the wildtypes in both hippocampus and 
cortex. In contrast, relatively similar degrees of cerebellar cholinesterase inhibition were 
noted between wildtypes and knockouts. Extensive inhibition was noted in both wildtype 
and M2 knockout mice in heart (WT: 85.5 ± 1.0%, KO: 72.4 ± 6.6%). 
  Again, basal liver carboxylesterase levels were similar in both wildtype and M2 
knockout mice. Parathion inhibited liver carboxylesterase in both wildtype and M2 
knockout mice (WT: 88.6 ± 0.9%, KO: 71.3 ± 2.9%). Interestingly, M2 knockouts had 
significantly higher basal plasma carboxylesterase levels compared to wildtypes. 
Parathion caused relatively similar changes in plasma carboxylesterase activity in both 
wildtype and M2 knockout mice (WT: 30.9 ± 6.1%, KO: 31 ± 10.6%). To summarize, 
parathion exposure elicited severe functional signs and extensive brain regional 
cholinesterase inhibition, with somewhat greater cholinesterase inhibition in wildtype 
mice compared to M2 knockout mice in selected tissues.  
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Figure 10: Effects of parathion treatment on 
a) involuntary movements b) SLUD signs c) 
hippocampal cholinesterase activity in 
wildtype and M2 knockout mice.  
 
Mice (n = 4-7/group) were exposed to either 
vehicle or parathion (35 mg/kg) and were 
graded for functional signs of toxicity for 24 
hrs as described in methods section. At the 
end of 24 hrs mice were sacrificed and 
hippocampus collected and analyzed for 
cholinesterase activity. Functional signs were 
expressed as median ± interquartile range. 
Cholinesterase data (mean ± standard error) 
represent enzyme activities (nmol of 
substrate hydrolyzed/minute/mg protein) and 
are expressed as percent of control values. 
An asterisk indicates significant difference 
compared to respective control and a dollar 
sign indicates a significant difference 
between knockout control and knockout 
treatment group. A pound indicates 
significant difference between wildtype and 
knockout mice. Cholinesterase activity in 
hippocampus of control animals was 36.4 ± 
1.6 nmol/min/mg protein in wildtypes and 
38.7 ± 0.2 nmol/min/mg protein in M2 
knockouts. 
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B) To evaluate comparative sensitivity of wildtypes and M2 knockouts to chlorpyrifos 
  Mice were treated with either vehicle (peanut oil) or chlorpyrifos (300 mg/kg, sc) 
in peanut oil. Mice were graded for functional signs of toxicity for the subsequent 72 
hours. Body weights were monitored before and 72 hrs after treatment. Chlorpyrifos 
produced a significant reduction (21 ± 6%) in body weight in wildtype mice, but had no 
effect on weight in M2 knockouts.    
Figure 11 shows the effects of chlorpyrifos on involuntary movements and 
cholinesterase inhibition in hippocampus. Chlorpyrifos treatment had relatively little 
effect on autonomic signs (SLUD) of toxicity in either wildtypes or knockouts. 
  Mild tremors were observed in wildtype mice, at 48 and 72 hrs, but absent from 
M2 knockout mice during the 72 hrs after dosing.      
  Significant inhibition of hippocampal cholinesterase was observed in both 
wildtype and M2 knockout mice, but markedly greater inhibition was noted in the 
wildtypes (WT: 80.4 ± 4.4%, KO: 37.5 ± 13.7%). Table 1 summarizes cholinesterase 
inhibition following chlorpyrifos exposure in the other brain regions evaluated in 
wildtype and M2 knockout mice. Chlorpyrifos exposure elicited significantly greater 
inhibition in wildtypes compared to knockouts in hippocampus and cerebellum. In cortex, 
chlorpyrifos exposure was associated with significant inhibition only in wildtypes. 
Chlorpyrifos had relatively similar effects on heart cholinesterase activity in wildtypes 
(87.5 ± 2.6%) and M2 knockouts (59.2 ± 6.3%).       
  In contrast to the differing degrees of cholinesterase inhibition noted above, 
relatively similar inhibition of liver carboxylesterase was observed in wildtypes and M2 
knockout mice (WT: 79.1 ± 0.4%, KO: 81.2 ± 2.3%). We also evaluated plasma 
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carboxylesterase inhibition following chlorpyrifos exposure. Chlorpyrifos resulted in 
significant inhibition of plasma carboxylesterase activity in both wildtype and M2 
knockout mice, with greater inhibition observed in M2 knockouts (WT: 29.6 ± 3.7%, 
KO: 46.5 ± 1.6%). Similar to results from the parathion dosing study shown above, 
wildtype mice appeared somewhat more sensitive to chlorpyrifos based on the extent of 
cholinesterase inhibition, but showed either similar or lesser inhibition of 
carboxylesterase activity in liver and plasma.  
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Figure 11: Effects of Chlorpyrifos treatment on a) involuntary movements b) hippocampal 
cholinesterase activity in wildtype and M2 knockout mice.  
Mice (n = 4-7/group) were exposed to either vehicle or chlorpyrifos (300 mg/kg) and were graded 
for functional signs of toxicity for 72 hrs as described in methods section. At the end of 72 hrs 
mice were sacrificed and hippocampus collected and analyzed for cholinesterase activity. 
Functional signs were expressed as median ± interquartile range. Cholinesterase data (mean ± 
standard error) represent enzyme activities (nmol of substrate hydrolyzed/minute/mg protein) and 
are expressed as percent of control values. An asterisk indicates significant difference compared 
to respective control and a dollar sign indicates a significant difference between knockout control 
and knockout treatment group. A pound indicates significant difference between wildtype and 
knockout mice Cholinesterase activity in hippocampus of control animals was 36.4 ± 1.6 
nmol/min/mg protein in wildtypes and 38.7 ± 0.2 nmol/min/mg protein in M2 knockouts. 
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C) Effect of paraoxon and chlorpyrifos oxon in wildtype and M2 knockout mice 
 
As noted above, wildtypes and M2 knockouts appeared differentially sensitive to 
both parathion and chlorpyrifos, based on functional signs of toxicity and/or extent of 
cholinesterase inhibition. As both parathion and chlorpyrifos require bioactivation 
(Sultatos et al., 1985) the differences noted could be due to differences in bioactivation of 
the parent insecticides. We therefore compared the toxicity of the active metabolites of 
these insecticides in wildtype and M2 knockout mice.  
1) Sensitivity of wildtypes and M2 knockouts to paraoxon  
Mice were treated with either vehicle or paraoxon (1 mg/kg, sc) and graded for 
functional signs of toxicity for 4 hours Paraoxon elicited significant body weight 
reductions in both wildtypes and M2 knockouts, with more extensive changes noted in 
M2 knockouts compared to wildtype mice (WT: 4 ± 2%, KO: 11 ± 5%).   
 Figure 12 shows the effects of paraoxon on cholinergic signs of toxicity 
(involuntary movements, excessive secretions, i.e. SLUD signs) and cholinesterase 
inhibition in hippocampus.  
Tremors were observed in both wildtype and M2 knockout mice by 1 hr after 
dosing but differed significantly from controls only in wildtypes. Severe tremors were 
observed at 2 hours and continued throughout the experimental period in both wildtype 
and M2 knockout mice. Moderate SLUD signs were observed in both wildtypes and M2 
knockouts which were significantly different from controls at 2, 3 and 4 hrs after dosing. 
There were, however no differences in the expression of functional signs of toxicity 
between wildtypes and M2 knockouts. 
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Paraoxon markedly inhibited hippocampal cholinesterase activity in both wildtype 
and M2 knockout mice (WT: 75.1 ± 5.8%, KO: 94.2 ± 0.8%). Table 1 summarizes 
cholinesterase inhibition in other brain regions following paraoxon exposure. Paraoxon 
significantly reduced cholinesterase activity in both wildtypes and M2 knockouts in all 
brain regions, with greater reduction in M2 knockouts (Table 1). Paraoxon caused a 
significant reduction in heart cholinesterase activity but no significant differences 
between wildtypes and M2 knockouts (WT: 78.4 ± 3.5%, KO: 83.8 ± 2.9%). 
Paraoxon elicited significant inhibition of liver carboxylesterases in M2 
knockouts (30 ± 6%), but no effect in wildtypes. Relatively similar changes were noted in 
plasma carboxylesterase, i.e., paraoxon reduced plasma carboxylesterase in M2 
knockouts (40 ± 6%) but had no effect on plasma carboxylesterase activity in wildtypes. 
In contrast to our studies with the parent insecticide parathion, wildtype and M2 knockout 
mice exhibited relatively similar signs of cholinergic toxicity following paraoxon 
exposure, although knockouts showed significantly greater body weight reductions. 
Moreover, more extensive brain cholinesterase and carboxylesterase inhibition were 
observed in M2 knockouts compared to wildtype mice, the reverse of what was noted in 
response to parathion. 
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Figure 12: Effects of paraoxon treatment on a) 
involuntary movements b) SLUD signs c) 
hippocampal cholinesterase activity in 
wildtype and M2 knockout mice.  
 
Mice (n = 4-7/group) were exposed to either 
vehicle or paraoxon (1 mg/kg) and were 
graded for functional signs of toxicity for 4 
hrs as described in methods section. At the 
end of 4 hrs mice were sacrificed and 
hippocampus collected and analyzed for 
cholinesterase activity. Functional signs were 
expressed as median ± interquartile range. 
Cholinesterase data (mean ± standard error) 
represent enzyme activities (nmol of substrate 
hydrolyzed/minute/mg protein) and are 
expressed as percent of control values. An 
asterisk indicates significant difference 
compared to respective control and a dollar 
sign indicates a significant difference between 
knockout control and knockout treatment 
group. A pound indicates significant 
difference between wildtype and knockout 
mice. Cholinesterase activity in hippocampus 
of control animals was 36.4 ± 1.6 
nmol/min/mg protein in wildtypes and 38.7 ± 
0.2 nmol/min/mg protein in M2 knockouts. 
 
0 1 2 3 4
0
1
2
3
4
5
WT/PO KO/PO
* * **
$ $ $A
Time after treatment (hrs)
Sc
o
r
e
0 1 2 3 4
0
1
2
3
4
WT/PO KO/PO
* * *
$ $ $B
Time after treatment (hrs)
Sc
o
r
e
W
T/C
trl
KO
/Ct
rl
W
T/P
O
KO
/PO
0
20
40
60
80
100
120
* #
*
C
C
hE
 
ac
ti
v
it
y 
(%
 
co
n
tr
o
l)
 62 
 
2) Sensitivity of wildtype and M2 knockout mice to chlorpyrifos oxon 
Mice were treated with vehicle or chlorpyrifos oxon (5 mg/kg, sc) and graded for 
functional signs of toxicity for 4 hours. Chlorpyrifos oxon exposure resulted in 
significant body weight reductions in wildtypes (8 ± 2%) but had no effect in M2 
knockouts.  
Figure 13 shows the effects of chlorpyrifos oxon on cholinergic signs of toxicity 
(involuntary movements, excessive secretions, i.e. SLUD signs) and cholinesterase 
inhibition in hippocampus.  
Both wildtype and M2 knockout mice exposed to chlorpyrifos oxon exhibited 
involuntary movements, but the onset of signs was earlier in the wildtypes. The extent of 
involuntary movements was significantly different in wildtypes compared to M2 
knockout mice at 1, 2 and 3 hrs after dosing. Only wildtypes exhibited SLUD signs, the 
extent of which was significantly different from M2 knockout mice at 3 and 4 hrs after 
exposure to chlorpyrifos oxon. Thus based on both involuntary movements and SLUD 
signs, wildtype mice exhibited more extensive functional signs compared to M2 
knockouts following chlorpyrifos oxon exposure. 
Extensive inhibition of hippocampal cholinesterase activity was observed, but 
with no significant differences between wildtypes and M2 knockouts (WT: 93 ± 1.1%, 
KO: 91 ± 2.1%).  Similar findings were also observed in other brain regions (Table 1). 
We also observed a marked and similar degree of inhibition of heart cholinesterase 
activity in both wildtype and M2 knockout mice (WT: 90 ± 2%, KO: 89 ± 2%). 
Chlorpyrifos oxon exposure had relatively little effect in wildtypes, whereas it 
elicited more extensive inhibition in M2 knockouts (WT: 12 ± 7%, KO: 30 ± 5%). In 
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plasma however, there was significant inhibition of carboxylesterase activity in both 
wildtype and M2 knockout mice, with no significant difference between the groups (WT, 
47 ± 2%, KO: 54 ± 1%). Data based on changes in functional signs thus suggested that 
wildtype mice may be more sensitive than knockouts at earlier time points after exposure. 
Wildtype and M2 knockout mice appeared equally sensitive to chlorpyrifos oxon 
exposure at later time points, however.  
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Figure 13: Effects of chlorpyrifos oxon 
treatment on a) involuntary movements b) 
SLUD signs c) hippocampal cholinesterase 
activity in wildtype and M2 knockout mice.  
 
Mice (n = 4-7/group) were exposed to either 
vehicle or chlorpyrifos oxon (5 mg/kg) and 
were graded for functional signs of toxicity 
for 4 hrs as described in methods section. At 
the end of 4 hrs mice were sacrificed and 
hippocampus collected and analyzed for 
cholinesterase activity. Functional signs 
were expressed as median ± interquartile 
range. Cholinesterase data (mean ± standard 
error) represent enzyme activities (nmol of 
substrate hydrolyzed/minute/mg protein) 
and are expressed as percent of control 
values. An asterisk indicates significant 
difference compared to respective control 
and a dollar sign indicates a significant 
difference between knockout control and 
knockout treatment group. A pound 
indicates significant difference between 
wildtype and knockout mice. Cholinesterase 
activity in hippocampus of control animals 
was 36.4 ± 1.6 nmol/min/mg protein in 
wildtypes and 38.7 ± 0.2 nmol/min/mg 
protein in M2 knockouts. 
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Table 1: Effect of selected OPs on cholinesterase activity in cortex and cerebellum from 
wildtype and M2 knockout mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mice (n = 4-7/group) were exposed to either vehicle or selected OPs and were graded for 
functional signs of toxicity as described in methods section. Mice were sacrificed and 
tissues analyzed for cholinesterase assay. Data (mean ± standard error) represent enzyme 
activities in terms of nmol of substrate hydrolyzed/minute/mg protein. Values in 
parentheses indicate percent cholinesterase inhibition with respect to control values. 
a
 indicates a significant difference compared to respective control.  
b
 indicates a significant difference between wildtype and M2 knockout mice. 
 
 
Tissue/ 
genotype 
 
Control 
 
 
Parathion 
 
Chlorpyrifos Paraoxon Chlorpyrifos 
oxon 
Cortex/WT 39.5 ± 2.1  3.8 ± 0.4ab (90) 
17.2 ± 3.6 a 
(56) 
7.5 ± 1.1a 
(81) 
3.2 ± 0.4a 
(92)  
Cortex/KO 31.7 ± 1.9 9.8 ± 2.4a (69) 
35.6 ± 10.2  
(-12) 
2.9 ± 0.5ab 
(90) 
5.5 ± 0.8a 
(83)  
Cerebellum/WT 12.2 ± 0.5 3.4 ± 0.2a (72) 
2.9 ± 0.3ab 
(76) 
2.6 ± 0.3a 
(78) 
7.6 ± 0.6 a 
(37)  
Cerebellum/KO 14.9 ± 0.9 5.6 ± 1.1a (62) 
5.3 ± 0.8a  
(64) 
1.5 ± 0.1 ab 
(90) 
7.8 ± 0.7 a 
(48)  
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Specific Aim 1B: To evaluate the effects of M2 receptor deletion on sensitivity to 
different OP compounds: Studies with +/+ and -/- littermates 
Our preliminary studies reported above compared the acute sensitivity of wildtype 
and M2 knockout mice to the OPs parathion and chlorpyrifos. In contrast to our 
hypothesis, wildtype mice exhibited higher sensitivity (based on functional signs) than 
M2 knockouts to both OPs. Interestingly, the more extensive signs of toxicity noted in 
wildtypes were associated with more extensive brain regional cholinesterase inhibition. 
There did not appear to be differences in the extent of carboxylesterase inhibition 
between wildtype and M2 knockout mice, however. Parathion and chlorpyrifos are both 
parent insecticides which require bioactivation by cytochrome P450 (cyp450) enzymes to 
their active oxygen metabolites, paraoxon and chlorpyrifos oxon. Differences in the 
degree of cholinesterase inhibition in this context could therefore be due to differences in 
bioactivation between wildtypes and M2 knockouts.  To evaluate further this possibility, 
relative sensitivity to paraoxon and chlorpyrifos oxon was then studied (see above). Both 
wildtypes and M2 knockouts exhibited relatively similar signs of cholinergic toxicity 
following paraoxon treatment. Interestingly, paraoxon led to significantly higher 
inhibition in M2 knockouts compared to wildtypes. Chlorpyrifos oxon exposure elicited 
cholinergic signs in both wildtype and M2 knockout mice, but the signs were more 
extensive in wildtype mice compared to M2 knockouts in spite of relatively similar 
changes in cholinesterase activity. Such differences in sensitivity could be due to 
differences in liver detoxification since more extensive carboxylesterase inhibition was 
observed in M2 knockouts. These results suggested that continuous inbreeding of non-
littermates could potentially be responsible for changes in bioactivation and/or 
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detoxification between the wildtype and M2 knockout mice used in our initial studies. 
We concluded that additional studies using appropriate littermate controls were required 
to investigate the role of M2 receptor deletion on OP toxicity. A breeding program was 
initiated using heterozygous mice to obtain homozygous wildtype and M2 knockout 
littermates for all further studies reported below.  
A) Comparative effects of parathion (35 mg/kg, sc) on body weight, functional signs and 
esterase activities in wildtype/LM and M2 knockout mice 
Mice were treated with either peanut oil or parathion (35 mg/kg, sc) and 
functional signs of cholinergic toxicity were graded at 8, 12 and 24 hrs after dosing. 
Parathion led to relatively similar body weight reductions in both wildtype/LM and M2 
knockouts (WT/LM: 15 ± 1%; KO: 14 ± 4%). 
Figure 14 shows the effects of parathion on cholinergic signs of toxicity 
(involuntary movements, excessive secretions, i.e. SLUD signs) and cholinesterase 
inhibition in cortex.  
Parathion elicited signs of cholinergic toxicity in both wildtype/LM and M2 
knockout mice. The extent of involuntary movements in wildtype mice was significantly 
different from M2 knockout mice at 12 and 24 hrs after dosing. Parathion exposure 
elicited moderate to severe SLUD signs in both wildtype/LM and M2 knockout mice 
which were significantly different from control mice at 8, 12 and 24 hrs. Differences in 
the degree of SLUD signs between wildtype/LM and M2 knockout mice were observed 
at 12 hrs after exposure to parathion. At this dosage, parathion elicited substantial and 
relatively similar proportionate lethality in both wildtype/LM and knockout mice (WT: 
5/9; KO: 7/13). 
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Extensive inhibition of cortical cholinesterase activity was observed in both 
wildtype/LM and M2 knockouts, but with no significant difference between the groups 
(WT/LM: 96 ± 0.2%, KO: 96 ± 0.8%). Similar findings were also observed in cerebellum 
(Table 2). Marked inhibition of heart cholinesterase activity was also observed in both 
wildtype/LM and M2 knockout mice (WT/LM: 98 ± 0.4%, KO: 98 ± 0.2%).  
Carboxylesterase was extensively inhibited in wildtype/LM and M2 knockouts in 
both liver (WT/LM: 87.4 ± 0.6%; KO:  88 ± 1.4%) and plasma (WT/LM: 80.5 ± 1.1%; 
KO: 78.3 ± 1.1%). There were no differences in the degree of inhibition of either 
cholinesterase or carboxylesterase activities between wildtype/LM and M2 knockout 
mice following parathion exposure. In contrast to studies where littermate controls were 
not used, both WT/LM and M2 knockout mice exhibited similar, severe signs of 
cholinergic toxicity, although the wildtype/LM mice did appear slightly more sensitive 
early after exposure.  
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Figure 14: Effects of parathion treatment on 
a) involuntary movements b) SLUD signs 
c) cortical cholinesterase activity in 
wildtype/LM and M2 knockout mice.  
 
Mice (n = 4-7/group) were exposed to either 
vehicle or parathion (35 mg/kg) and were 
graded for functional signs of toxicity for 
24 hrs as described in methods section. At 
the end of 24 hrs mice were sacrificed and 
cortex collected and analyzed for 
cholinesterase activity. Functional signs 
were expressed as median ± interquartile 
range. Cholinesterase data (mean ± standard 
error) represent enzyme activities (nmol of 
substrate hydrolyzed/minute/mg protein) 
and are expressed as percent of control 
values. An asterisk indicates significant 
difference compared to respective control 
and a dollar sign indicates a significant 
difference between knockout control and 
knockout treatment group. A pound 
indicates significant difference between 
wildtype/LM and knockout mice. 
Cholinesterase activity in cortex of control 
animals was 57 ± 0.9 nmol/min/mg protein 
in wildtype/LM and 67 ± 6 nmol/min/mg 
protein in M2 knockouts.  
 
 
 
0 4 8 12 16 20 24
0
1
2
3
4
5
6
WT/PS KO/PS
*
#
*
#
*
A
Time after treatment (hrs)
Sc
o
r
e
0 4 8 12 16 20 24
0
1
2
3
4
WT/PS KO/PS
*
#
*
*
B
Time after treatment (hrs)
Sc
o
r
e
W
T/C
trl
KO
/Ct
rl
W
T/P
S
KO
/PS
0
20
40
60
80
100
120
* *
C
C
hE
 
a
ct
iv
it
y 
(%
 
c
o
n
tr
o
l)
 70 
 
B) Comparative effects of parathion (27.5 mg/kg, sc) on body weight, functional signs 
and esterase activities in wildtype/LM and M2 knockout mice 
The high dosage of parathion used in the studies above (35 mg/kg, sc) led to 
almost complete inhibition of cholinesterase in both wildtype/LM and M2 knockouts, and 
also caused marked lethality in both wildtype/LM and M2 knockouts. One explanation 
for the lack of obvious differences in sensitivity to parathion between wildtype/LM and 
M2 knockouts could be that the M2 receptor only has a protective role in modulating OP 
toxicity when less extensive acetylcholinesterase inhibition occurs, with less extensive 
accumulation of synaptic ACh levels. To evaluate this possibility, we studied the effects 
of M2 receptor deletion in response to a lower parathion dosage.  
Mice were treated with vehicle or parathion (27.5 mg/kg) and observed for 
functional signs of toxicity for 48 hrs. Under these conditions, parathion led to relatively 
similar reductions in body weight in both wildtype/LM and M2 knockouts (WT/LM: 18.5 
± 4.5%; KO: 20 ± 7%).  
Figure 15 shows the effects of parathion on cholinergic signs of toxicity 
(involuntary movements, excessive secretions, i.e. SLUD signs) and cholinesterase 
inhibition in cortex.  
Tremors were noted in both wildtype/LM and M2 knockouts, the extent of which 
was significantly different from controls at 24 and 48 hrs after dosing. Signs of toxicity at 
this dosage were less extensive than noted in studies using the higher dosage of parathion 
(35 mg/kg). There were no differences in involuntary movements between wildtype/LM 
and M2 knockouts following exposure to this lower parathion dosage. SLUD signs were 
significantly different from controls at 12 and 24 hrs in wildtype/LM mice and at 24 hrs 
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in M2 knockout mice. Thus, there appeared to be little difference in functional response 
between wildtype/LM and M2 knockouts at the lower dosage of parathion. There was, 
however, a difference in lethality noted, with wildtypes showing higher lethality than M2 
knockouts (WT/LM: 4/10; KO: 1/7). It should be stressed that if anything, this higher 
lethality in wildtype mice argues against a protective role of M2 receptors in expression 
of OP toxicity.  
Relatively similar degrees of inhibition were seen in both wildtype/LM and M2 
knockout mice in cortex (WT/LM: 81.5 ± 2.6%, KO: 89.5 ± 0.8%) and similar findings 
were also observed in cerebellum (Table 2). Again, relatively similar degrees of 
inhibition were observed in wildtype and M2 knockout mice in heart (WT/LM: 83 ± 
2.5%, KO: 87.7 ± 1.5%)  
Significant inhibition of liver carboxylesterases was observed in both 
wildtype/LM and M2 knockouts, with no differences between the groups (WT/LM: 88 ± 
0.7%, KO: 87 ± 1.3%). Plasma carboxylesterases were also inhibited in both 
wildtype/LM and M2 knockout mice following exposure to parathion (WT/LM: 71 ± 
3.5%, KO: 73 ± 3%). Thus, wildtype/LM and M2 knockout mice appeared similarly 
sensitive to a lower dosage of parathion (27.5 mg/kg). These findings suggest that M2 
receptor deletion has relatively little effect on the expression of classical signs of 
cholinergic toxicity following parathion exposure, but may indeed reduce lethality under 
some dosing conditions.  
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Figure 15: Effects of parathion treatment on 
a) involuntary movements b) SLUD signs c) 
cortical cholinesterase activity in 
wildtype/LM and M2 knockout mice.  
Mice (n = 4-7/group) were exposed to either 
vehicle or parathion (27.5 mg/kg) and were 
graded for functional signs of toxicity for 48 
hrs as described in methods section. At the 
end of 48 hrs mice were sacrificed and 
cortex collected and analyzed for 
cholinesterase activity. Functional signs 
were expressed as median ± interquartile 
range. Cholinesterase data (mean ± standard 
error) represent enzyme activities (nmol of 
substrate hydrolyzed/minute/mg protein) 
and are expressed as percent of control 
values. An asterisk indicates significant 
difference compared to respective control 
and a dollar sign indicates a significant 
difference between knockout control and 
knockout treatment group. A pound 
indicates significant difference between 
wildtype/LM and knockout mice. 
Cholinesterase activity in cortex of control 
animals was 57 ± 0.9 nmol/min/mg protein 
in wildtype/LM and 67 ± 6 nmol/min/mg 
protein in M2 knockouts.  
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C) Comparative effects of chlorpyrifos on body weight, functional signs and esterase 
activities in wildtype/LM and M2 knockout mice 
Wildtype/LM and M2 knockout mice were treated with a high dosage of 
chlorpyrifos (300 mg/kg, sc) and observed for functional signs of toxicity for 72 hrs. 
Chlorpyrifos had no effect on body weight or cholinergic signs of toxicity in any 
treatment groups (data not shown). We did not observe any involuntary movements 
following chlorpyrifos exposure in wildtype/LM and M2 knockout mice. Similarly, no 
SLUD signs were noted following chlorpyrifos exposure in either wildtype/LM or M2 
knockout mice. 
Figure 16 shows cholinesterase inhibition in cortex following exposure to 
chlorpyrifos. Extensive reduction in cortical cholinesterase activity was observed in both 
wildtype/LM and M2 knockout mice (WT/LM: 79 ± 1.7%, KO: 85 ± 4.6%). Similar 
results were obtained in cerebellum (Table 2). Chlorpyrifos also inhibited heart 
cholinesterase activity in both wildtype/LM and M2 knockouts, but with no significant 
differences between groups (WT/LM: 76 ± 4.4%, KO: 80 ± 3.8%).  
Chlorpyrifos caused significant inhibition of liver (WT/LM: 89 ± 0.7%, KO: 87 ± 
4.0%) and plasma (WT/LM: 78 ± 3%, KO: 83 ± 1.2%) carboxylesterases, but again with 
no significant differences between groups. Thus, wildtype/LM and M2 knockout mice 
showed few signs of cholinergic toxicity in spite of extensive brain cholinesterase 
inhibition (~80%). 
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Figure 16: Effect of chlorpyrifos on cortical cholinesterase activity in wildtype/LM and 
M2 knockout mice.  
Mice (n = 4-5/group) were exposed to either vehicle or chlorpyrifos (300 mg/kg, sc) and 
were graded for functional signs for 72 hrs. Mice were sacrificed and cortex collected and 
analyzed for cholinesterase activity. Data (mean ± standard error) represent enzyme 
activities (nmol of substrate hydrolyzed/minute/mg protein) and are expressed as percent 
of control values. An asterisk indicates a significant difference compared to respective 
controls. Cholinesterase activity in cortex of control animlas was 65 ± 1.5 nmol/min/mg 
protein in wildtype/LM and 61 ± 3.8 nmol/min/mg protein in M2 knockouts. 
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Table 2: Effect of selected OPs on cholinesterase activity in cerebellum from 
wildtype/LM and M2 knockout mice. 
 
Tissue/genotype Control 
 
 
Parathion 
 
(35 mg/kg) 
 
Parathion 
 
(27.5mg/kg) 
 
Chlorpyrifos 
 
(300 mg/kg) 
Cerebellum 
WT/LM 11.4 ± 0.8 
3.1 ± 0.3a 
(73) 
1.9 ± 0.1a 
(83) 
4.1 ± 0.5a 
(64) 
Cerebellum/KO 12.7 ± 0.6 2.6 ± 0.5a (80) 
1.9 ± 0.3a  
(85) 
4.1 ± 0.4 a 
(68) 
 
 
Mice (n = 4-5/group) were exposed to either vehicle or selected OPs and were graded for 
functional signs of toxicity as described in methods section. Mice were sacrificed and 
tissues analyzed for cholinesterase inhibition. Data (mean ± standard error) represent 
enzyme activities in terms of nmol of substrate hydrolyzed/minute/mg protein. Values in 
parentheses indicate percent cholinesterase inhibition with respect to control values. 
a
 indicates a significant difference compared to respective control.  
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D) Effect of oxotremorine on functional signs and body temperature in wildtype/LM and 
M2 knockout mice 
Parathion (27.5 and 35 mg/kg, sc) elicited involuntary movements (tremors) in 
both wildtype/LM and M2 knockouts (Figures 14 and 15). Interestingly, previous studies 
(Gomeza et al., 1999) reported that the non-selective muscarinic agonist (oxotremorine) 
did not elicit tremors in mice lacking the M2 receptor. To determine whether tremors 
could be elicited by oxotremorine in M2 knockouts in our hands, we evaluated 
involuntary movements in wildtype/LM and M2 knockouts in response to this muscarinic 
agonist.  
Wildtype/LM and M2 knockout mice were challenged with oxotremorine (0.5 
mg/kg, sc) and observed for involuntary movements, SLUD signs and also for changes in 
body temperature. Body temperatures were recorded before treatment and at 30 and 60 
minutes after dosing.  
Figure 17 shows the effects of oxotremorine on cholinergic signs of toxicity 
(involuntary movements, excessive secretions, i.e. SLUD signs) and body temperature in 
wildtype/LM and M2 knockout mice.  
Oxotremorine did elicit severe tremors in wildtype/LM mice, while tremors were 
absent in the M2 knockouts. Oxotremorine also produced moderate SLUD signs in both 
wildtype/LM and M2 knockouts, a response thought to be primarily mediated through 
M3 muscarinic receptors. There was a significantly greater reduction in body temperature 
(another function mediated primarily through M2 receptors) in wildtype/LM compared to 
M2 knockouts at 30 and 60 minutes after treatment. These results were therefore in 
general agreement with those of Gomeza and coworkers (1999) and suggest that the M2 
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receptor is essential for cholinergically-mediated tremors and hypothermia. The basis for 
involuntary movements elicited by anti-cholinesterases is unclear, however, as they were 
elicited in mice lacking the M2 receptor.  
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Figure 17: Effects of oxotremorine on A) 
involuntary movements, B) SLUD signs, 
and C) body temperature in wildtype/LM 
and M2 knockout mice.  
 
 
Mice (n = 4/group) were exposed to either 
vehicle or oxotremorine (0.5 mg/kg) and 
were graded for functional signs for 90 
minutes as described in methods section. 
An asterisk indicates significant difference 
between wildtype/LM and knockout mice. 
SLUD signs (Figure B) were significantly 
different when compared to the respective 
controls but M2 receptor deletion had no 
significant effect on them. 
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Specific Aim 3: To evaluate ACh release as affected by OP exposure ex vivo and in 
vitro in slices from M2-/- and their respective wildtype/LM mice. 
A) Effect of parathion on ex vivo ACh release in wildtype and M2 knockout brain slices  
Wildtype/LM and M2 knockout mice were exposed to parathion (27.5 mg/kg, sc) 
and were graded for functional signs of toxicity for 48 hrs. At the end of 48 hrs mice 
were sacrificed and brain was immediately dissected on ice. Brain slices were prepared 
later to measure ACh release ex vivo as described in methods section.  
Table 3 shows that parathion exposure had no apparent effect on ACh release ex 
vivo in cortical, hippocampal or striatal slices from either wildtype/LM or M2 knockout 
mice. 
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Table 3: Effect of parathion exposure on ex vivo ACh release in wildtype/LM and M2 
knockout mice. 
Tissue/genotype Control 
 
Parathion 
 
Cortex 
WT/LM 5.7 ± 0.5 5.9 ± 0.6
 
 
Cortex 
KO 6.9 ± 0.7 7.8 ± 1.0
 
 
Hippocampus 
WT/LM 2.6 ± 0.7 2.3 ± 0.3 
Hippocampus 
KO 2.3 ± 0.4 2.1 ± 0.1
 
 
Striatum 
WT/LM 8.3 ± 1.1 8.9 ± 0.2
 
 
Striatum 
KO 8.1 ± 0.9 7.9 ± 0.4
 
 
 
 
Mice (n = 4-6/group) were exposed to either vehicle or parathion (27.5 mg/kg) and were 
graded for functional signs for 48 hrs. Brain slices were incubated with [3H]choline to 
label endogenous acetylcholine. Prelabeled slices were then loaded into a suprafusion 
apparatus. Release was stimulated by exposing the slices once to a depolarizing buffer 
containing a high concentration of KCl as described in methods section. Values (mean ± 
standard error) shown are proportionate (percent) release, i.e., the total amount of 
radioactivity in the peak following depolarization compared to total radioactivity in all 
other fractions and the residual tissue (x 100).  
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B) Effects of the muscarinic agonist oxotremorine and selected OP compounds on ACh 
release in vitro in brain slices from wildtype/LM and M2 knockout mice  
Mice were sacrificed and brain was immediately removed to prepare slices as 
described in methods section. ACh release was then measured in hippocampal, cortical 
and striatal slices from wildtype/LM and M2 knockout mice. We studied the effects of 
oxotremorine (10 µM), paraoxon (100 µM) and chlorpyrifos oxon (100 µM) on in vitro 
ACh release in wildtype/LM and M2 knockout brain slices. The S1 values did not differ 
between wildtype/LM and M2 knockout brain slices. 
Figure 18 shows the effect of oxotremorine and the two oxons on in vitro ACh 
release in cortical slices. Oxotremorine resulted in a significant decrease in ACh release 
only in wildtype/LM cortical slices (WT/LM: 10.9 ± 2.8%; KO: 8 ± 5.1%). Paraoxon had 
no effect on ACh release in cortical slices while chlorpyrifos oxon caused a significant 
decrease in ACh release in both wildtype/LM and M2 knockout mice (WT/LM: 16.8 ± 
3.4%; KO: 23.8 ± 2.5%).  
Figure 19 shows the effect of oxotremorine and the two oxons on in vitro ACh 
release in hippocampal slices. A significant reduction in release was observed in 
hippocampal slices from wildtype/LM mice following exposure to oxotremorine, while a 
much lesser and statistically insignificant effect was seen in slices from M2 knockouts 
(WT/LM: 29.8 ± 2.4%; KO: 7.7 ± 1.6%). Paraoxon had no effect in slices from either 
wildtype/LM or M2 knockout mice. Surprisingly, chlorpyrifos oxon caused a significant 
increase in ACh release in hippocampal slices from wildtype/LM (WT/LM: 9.1 ± 2.9%). 
In contrast, chlorpyrifos oxon had no effect on release in slices from M2 knockouts. 
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Figure 20 shows the effect of oxotremorine and the two oxons on in vitro ACh 
release in striatal slices. Oxotremorine caused a significant decrease in ACh release in 
slices from both wildtype/LM and M2 knockout mice (WT/LM: 14.4 ± 3.2%; KO: 18.5 ± 
1.8%). Similarly, paraoxon decreased ACh release in slices from both wildtype/LM and 
M2 knockout mice (WT/LM: 12.1 ± 4.5%; KO: 16.8 ± 2.1%). Similar to changes noted 
in hippocampal slices, chlorpyrifos oxon increased ACh release (41.5 ± 8.3%) in striatal 
slices from wildtype/LM mice, but had no effect in tissues from M2 knockouts. 
The muscarinic agonist oxotremorine decreased ACh release in cortical and 
hippocampal slices of wildtype/LM mice; release was unaffected in slices from M2 
knockouts, suggesting that the decrease in ACh release in these tissues is mediated by the 
M2 receptor. These findings are similar to those reported by Zhang et al., (2002). In 
contrast, oxotremorine decreased ACh release in striatal slices from both wildtype and 
M2 knockout mice, suggesting that pre-synpatic modulation of ACh release in this tissue 
is independent of M2 receptors. Again, these findings are similar to those reported by 
Zhang et al., (2002).  Several studies reported that the M4 receptor subtype plays an 
important role in regulating ACh release in striatum. The decrease in striatal ACh release 
seen here is likely mediated by activation of M4 receptors and thus intact in tissues from 
both wildtype and M2 knockout mice.  
Paraoxon affected (decreased) ACh release in vitro only in the striatum, but in 
tissues from both wildtype/LM and M2 knockout mice, i.e., suggesting the M4 receptor 
may be involved in modulating ACh release in this brain region after exposure to 
paraoxon or its parent insecticide (parathion). Chlorpyifos oxon decreased ACh release in 
cortical slices from both wildtype/LM and M2 knockouts. Chlorpyrifos oxon actually 
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increased ACh release in hippocampal and striatal slices of wildtype/LM mice. Thus, the 
effects of these oxons on brain regional ACh release and the qualitative nature of the 
changes themselves suggest a complex interaction between OP compounds and pre-
synaptic control.  
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Figure 18: Effect of oxotremorine, paraoxon and chlorpyrifos oxon on ACh release in 
vitro in cortical slices from wildtype/LM and M2 knockout mice.  
Cortical slices (n = 4-7) were incubated with [3H]choline to label endogenous 
acetylcholine. Prelabelled slices were then loaded into a suprafusion apparatus and 
perfused with physiological buffer. Release was stimulated twice (S1 and S2) by 
exposing the slices to a depolarizing buffer containing high concentration of KCl (30 
mM). Drugs were added 20 minutes before the second pulse of potassium. The ratio of 
S2/S1 is a normalized index of ACh release. Data (mean ± standard error) represent ACh 
release expressed as percent of control values. An asterisk indicates a significant 
difference compared to respective control. ACh release (S2/S1) in control animals was 
0.79 ± 0.02 in wildtype/LM and 0.85 ± 0.02 in M2 knockouts. 
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Figure 19: Effect of oxotremorine, paraoxon and chlorpyrifos oxon on ACh release in 
vitro in hippocampal slices from wildtype/LM and M2 knockout mice.  
Hippocampal slices (n = 4-7) were incubated with [3H]choline to label endogenous 
acetylcholine. Prelabelled slices were then loaded into a suprafusion apparatus and 
perfused with physiological buffer. Release was stimulated twice (S1 and S2) by 
exposing the slices to a depolarizing buffer containing high concentration of KCl (25 
mM). Drugs were added 20 minutes before the second pulse of potassium. The ratio of 
S2/S1 is a normalized index of ACh release. Data (mean ± standard error) represent ACh 
release expressed as percent of control values. An asterisk indicates a significant 
difference compared to respective control and a pound indicates a significant difference 
between wildtype and M2 knockout hippocampal slices. ACh release (S2/S1) in control 
animals was 0.83 ± 0.1 in wildtype/LM and 0.82 ± 0.1 in M2 knockouts. 
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Figure 20: Effect of oxotremorine, paraoxon and chlorpyrifos oxon on ACh release in 
vitro in in striatal slices from wildtype/LM and M2 knockout mice.  
Striatal slices (n = 4-7) were incubated with [3H]choline to label endogenous 
acetylcholine. Prelabelled slices were then loaded into a suprafusion apparatus and 
perfused with physiological buffer. Release was stimulated twice (S1 and S2) by 
exposing the slices to a depolarizing buffer containing high concentration of KCl (20 
mM). Drugs were added 20 minutes before the second pulse of potassium. The ratio of 
S2/S1 is a normalized index of ACh release. Data (mean ± standard error) represent ACh 
release expressed as percent of control values. An asterisk indicates a significant 
difference compared to respective control and a pound indicates a significant difference 
between wildtype and M2 knockout striatal slices. ACh release (S2/S1) in control 
animals was 0.8 ± 0.03 in wildtype/LM and 0.8 ± 0.05 in M2 knockouts. 
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Studies using CB1 receptor knockout mice 
Specific Aim 2A: To evaluate the effects of CB1 receptor deletion on acute 
sensitivity to selected OP compounds: Preliminary studies 
 A) Parathion toxicity in wildtypes and CB1 knockouts  
Wildtype and CB1 knockout mice were treated with parathion (20 mg/kg, sc) and 
observed for functional signs of cholinergic toxicity for the following 48 hrs. Parathion 
treatment led to a significant reduction (27 ± 3%) in body weight in the CB1 knockouts 
but no significant effect in the wildtype mice.  
Figure 21 shows the effect of parathion on involuntary movements, SLUD signs 
and hippocampal cholinesterase activity in these same mice. CB1 knockouts exhibited 
significantly more severe tremors than wildtypes at 24 and 48 hrs after dosing, with 
essentially no sign of tremors in the wildtypes. Detectable SLUD signs were noted only 
in the CB1 knockouts.  
Extensive hippocampal cholinesterase inhibition was noted in both wildtypes and 
CB1 knockouts (WT: 64 ± 6.9%, KO: 78.4 ± 0.6%). Surprisingly, significantly greater 
inhibition was noted wildtypes despite similar basal cholinesterase levels. Relatively 
similar findings were also observed in other brain regions (cortex and cerebellum) as 
shown in Table 4. Parathion also inhibited heart cholinesterase activity in both wildtype 
and CB1 knockout mice. While a trend towards greater inhibition of heart cholinesterase 
activity was also noted in the knockouts, there was no significant difference between the 
groups (WT: 69.3 ± 5.2%, KO: 80.1 ± 1.1%). 
Basal liver and plasma carboxylesterase levels were similar wildtype and CB1 
knockout mice. Parathion exposure led to extensive inhibition of liver carboxylesterases 
 88 
 
in both wildtype and CB1 knockouts (WT: 70 ± 3.9%, KO: 84 ± 1.2%). Significant 
inhibition of plasma carboxylesterase activity was observed following parathion exposure 
in both wildtype and CB1 knockout mice (WT: 56 ± 4.2%, KO: 62.5 ± 1.8%). Together 
these data suggest that CB1 knockout mice were more sensitive compared to wildtype 
mice to both functional and biochemical indicators of toxicity. 
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Figure 21: Effects of parathion on A) 
involuntary movements, B) SLUD signs, C) 
hippocampal cholinesterase activity in 
wildtype and CB1 knockouts.  
 
Mice (n = 4-6/group) were exposed to either 
vehicle or parathion (20mg/kg) and were 
graded for functional signs for 48 hrs as 
described in methods section. At the end of 
48 hrs mice were sacrificed and 
hippocampus collected to measure 
cholinesterase activity. Functional signs 
were expressed as median ± interquartile 
range. Cholinesterase data (mean ± standard 
error) represent enzyme activities (nmol of 
substrate hydrolyzed/minute/mg protein) and 
are expressed as percent of control values. 
An asterisk indicates significant difference 
compared to respective control and a dollar 
sign indicates a significant difference 
between knockout control and knockout 
treatment group. A pound indicates 
significant difference between wildtype and 
knockout mice. Cholinesterase activity in 
hippocampus of control animals was 30.5 ± 
0.5 nmol/min/mg protein in wildtypes and 
26.7 ± 1.4 nmol/min/mg protein in CB1 
knockouts. 
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B) Effect of chlorpyrifos on functional signs and esterase activities in wildtype and CB1 
knockout mice 
Wildtype and CB1 knockout mice were exposed to chlorpyrifos (300 mg/kg, sc) and 
observed for functional signs of cholinergic toxicity for 48 hrs.  
Figure 22 shows the effect of chlorpyrifos on involuntary movements, SLUD 
signs and cholinesterase inhibition in hippocampus in the different treatment groups. CB1 
knockouts showed marked tremor activity following chlorpyrifos exposure, with 
substantial lethality (5 of 7) occurring by 24 hours after treatment. However, in wildtypes 
treated with chlorpyrifos only mild tremors were noted. Severe SLUD signs were 
observed in CB1 knockout mice, while wildtype mice exhibited few SLUD signs. A 
statistical analysis was not performed on these data however, due to the low number of 
survivors (2 of 7) in the knockout group exposed to chlorpyrifos. 
Extensive inhibition of hippocampal cholinesterase activity was observed (WT: 
78.4 ± 4.9%, KO: 88%). Cholinesterase inhibition was also observed in other brain 
regions as shown in Table 4. There was a trend towards more extensive cholinesterase 
inhibition in the CB1 knockouts in hippocampus and cerebellum. However degrees of 
cholinesterase inhibition did not seem to be different between wildtype and CB1 
knockout mice in cortex (Table 4). Extensive inhibition was noted in heart in both 
treatment groups (WT: 76.1 ± 3.9%; KO: 82%). 
Chlorpyrifos exposure resulted in marked inhibition of liver (WT: 87 ± 0.5%; 
KO: 87.7%) and plasma (WT: 70 ± 2.2%; KO: 67%) carboxylesterases in both treatment 
groups. Again, statistical analysis was not possible as only 2 knockouts survived this 
initial study. Similar to findings in animals treated with parathion, CB1 knockout mice 
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appeared more sensitive to chlorpyrifos, although biochemical assays were only possible 
in limited numbers of survivors.  
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Figure 22: Effects of chlorpyrifos on A) 
involuntary movements, B) SLUD signs, 
C) hippocampal cholinesterase activity in 
wildtype and CB1 knockouts.  
 
Mice (n = 2-6/group) were exposed to 
either vehicle or chlorpyrifos (300mg/kg) 
and were graded for functional signs for 48 
hrs as described in methods section. At the 
end of 48 hrs mice were sacrificed and 
hippocampus collected to measure 
cholinesterase activity. Functional signs 
were expressed as median ± interquartile 
range. Cholinesterase data (mean ± 
standard error) represent enzyme activities 
(nmol of substrate hydrolyzed/minute/mg 
protein) and are expressed as percent of 
control values. Cholinesterase activity in 
hippocampus of control animals was 30.5 
± 0.5 nmol/min/mg protein in wildtypes 
and 26.7 ± 1.4 nmol/min/mg protein in 
CB1 knockouts. Statistical analysis was 
not performed owing to the less number of 
survivors in knockout treatment group. 
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Table 4: Effect of parathion and chlorpyrifos on cholinesterase activity in cortex and 
cerebellum from wildtype and CB1 knockout mice. 
 
 
 
 
 
 
 
 
 
 
Mice (n = 4-6/group) were exposed to either vehicle or parathion (20 mg/kg) or 
chlorpyrifos (300 mg/kg, sc) and were graded for functional signs for 48 hrs. Mice were 
sacrificed and tissues collected for cholinesterase assay. Data (mean ± standard error) 
represent enzyme activities in terms of nmol of substrate hydrolyzed/minute/mg protein. 
Values in parentheses indicate percent cholinesterase inhibition with respect to control 
values. 
a
 indicates a significant difference compared to respective control.  
b
 indicates a significant difference between wildtype and CB1 knockout mice.  
 
 
Tissue/genotype 
 
Control 
 
 
Parathion 
 
Chlorpyrifos 
Cortex/WT 38.1 ± 4.3 11.7 ± 1.6
a
 
(69) 
4.4 ± 1.02 
(88) 
Cortex/KO 39.3 ± 2.5 2.9 ± 0.4
ab
 
(93) 
4.6 (88) 
Cerebellum/WT 21.4 ± 1.8 5.8 ± 0.8
 a
 
(73) 
3.95 ± 0.88 
(82) 
Cerebellum/KO 17.2 ± 0.8 1.7 ± 0.2
 ab
 
(90) 
1.42 (92) 
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Specific Aim 2B: To evaluate the effects of CB1 receptor deletion on sensitivity to 
different OP compounds: Studies using +/+ and -/- littermates 
Similar to our initial studies in M2 receptor knockouts, the initial studies with 
CB1 knockouts compared acute sensitivity to OPs in homozygous CB1 knockout mice 
and control C57Bl/6 mice (obtained from Charles River, the vendor from which the 
knockout was derived). CB1 knockouts appeared more sensitive to both OPs but the 
degree of cholinesterase inhibition was different compared to the control intact mice. 
Additional studies using appropriate LM controls therefore appeared essential to model 
the role of CB1 receptor in sensitivity to OPs. Littermates of wildtype (+/+) and CB1 
knockout (-/-) mice were used in all subsequent studies. 
A) Effect of parathion on body weight, functional signs and esterase activities in 
wildtype/LM and CB1 knockouts. 
Wildtype/LM and CB1 knockout mice were treated with vehicle or parathion (20 
mg/kg, sc) and observed for functional signs of cholinergic toxicity for the following 24 
hrs. Parathion similarly decreased body weight in both wildtype/LM and CB1 knockout 
mice (WT/LM: 16.8 ± 3.3%; KO: 16.9 ± 6.1%).  
Figure 23 shows the effect of parathion on cholinergic signs of toxicity 
(involuntary movements and SLUD signs) and cholinesterase inhibition in cortex 
following parathion exposure in these same mice. Wildtype/LM and CB1 knockout mice 
exhibited increased involuntary movements at both 12 and 24 hrs after dosing. Parathion 
elicited moderate SLUD signs in both wildtype/LM and CB1 knockout mice at 12 and 24 
hrs after exposure. 
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Similar, marked inhibition of cortical cholinesterase activity was observed in both 
wildtype/LM and CB1 knockout mice (83 ± 4%). Relatively similar reductions in activity 
were also noted in both groups in the cerebellum as shown in Table 5 (WT/LM: 78.8 ± 
2.7%; KO: 83.7 ± 2.1%). Parathion also had essentially the same effect on heart 
cholinesterase activity in both wildtype and CB1 knockout mice (WT/LM: 75 ± 2%; KO: 
75 ± 13%). 
Similar, extensive degrees of liver carboxylesterase (WT/LM: 93.6 ± 0.5%; KO: 
92 ± 0.7%) and plasma carboxylesterase (WT/LM: 67.5 ± 4.6%; KO: 72.9 ± 3.8%) 
activities were also observed in wildtype/LM and CB1 knockout mice. Thus, in contrast 
to our previous studies without littermate controls, wildtype/LM and CB1 knockout mice 
appeared remarkably similar in sensitivity to parathion, with similar changes in esterase 
activities as well as functional signs of toxicity. 
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Figure 23: Effects of parathion on A) 
involuntary movements, B) SLUD signs, 
C) cortical cholinesterase activity in 
wildtype/LM and CB1 knockouts.  
Mice (n = 4-5/group) were exposed to 
either vehicle or parathion (20 mg/kg) and 
were graded for functional signs for 24 
hrs as described in methods section. At 
the end of 24 hrs mice were sacrificed and 
cortex collected to measure cholinesterase 
activity. Functional signs were expressed 
as median ± interquartile range. 
Cholinesterase data (mean ± standard 
error) represent enzyme activities (nmol 
of substrate hydrolyzed/minute/mg 
protein) and are expressed as percent of 
control values. An asterisk indicates 
significant difference compared to 
respective control and a dollar sign 
indicates a significant difference between 
knockout control and knockout treatment 
group. Cholinesterase activity in cortex of 
control animals was 35.5 ± 1.9 
nmol/min/mg protein in wildtype/LM and 
40.6 ± 2.3 nmol/min/mg protein in CB1 
knockouts. 
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B) Effect of parathion on body weight, functional signs and esterase activities in 
wildtype/LM and CB1 knockouts. 
In contrast to our earlier studies without littermate controls, we did not note 
significant differences in sensitivity to parathion (20 mg/kg, sc) with deletion of CB1 
receptor. One explanation for lack of differences in sensitivity in CB1 knockouts could be 
that endocannabinoid signaling only influences cholinergic transmission when there is 
more extensive acetylcholine accumulation. To evaluate this possibility, we increased the 
parathion dosage to 27.5 mg/kg in subsequent studies, a dosage that increases the extent 
of cholinergic toxicity and thus presumably leads to more extensive acetylcholine 
accumulation. Mice in these studies were exposed to this higher dosage of parathion 
(27.5 mg/kg) and observed for functional signs of toxicity for 24 hrs. 
Parathion caused relatively similar body weight reductions in both wildtype/LM 
and CB1 knockouts, with no significant difference between the groups (WT: 15 ± 3%; 
KO: 18 ± 1%). Figure 24 shows the effect of parathion on cholinergic signs of toxicity 
(involuntary movements and SLUD signs) and cholinesterase inhibition in cortex 
following parathion exposure in these same mice. Parathion elicited more severe tremors 
(compared to the lower dosage of 20 mg/kg) at 12 and 24 hrs after dosing. The extent of 
involuntary movements was significantly higher in the wildtype/LM, but only at the 12 hr 
timepoint. Parathion also elicited SLUD signs in both wildtype/LM and CB1 knockout 
mice at 12 and 24 hrs. Thus, both wildtype/LM and CB1 knockout mice showed more 
severe signs of cholinergic toxicity with this higher dosage of parathion, but their 
functional responses were relatively similar. The difference at the earliest timepoint (12 
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hrs) suggests there may be a difference in onset, but in general the expression of 
functional signs was similar in the presence and absence of CB1.   
Extensive, similar degrees of inhibition of cortical cholinesterase activity were 
observed in both wildtype/LM and CB1 knockouts (WT/LM: 94 ± 1%; KO: 93 ± 2%). 
Similar results were also found in cerebellum (Table 5) and heart (WT/LM: 92 ± 0.6%; 
KO: 91 ± 1.5%).   
Similar group-related effects were noted with carboxylesterase inhibition in liver 
(WT/LM: 94 ± 0.6%, KO: 92 ± 0.7%) and plasma (WT/LM: 74 ± 5%, KO: 73 ± 3%). 
Thus, as with the studies using the lower dosage of parathion (20 mg/kg), wildtype/LM 
and CB1 knockout mice treated with the higher dosage (27.5 mg/kg) exhibited relatively 
comparable signs of cholinergic toxicity and similar degrees of esterase inhibition.  
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Figure 24: Effects of parathion on A) 
involuntary movements, B) SLUD signs, C) 
cortical cholinesterase activity in 
wildtype/LM and CB1 knockouts.  
 
Mice (n = 4-5/group) were exposed to either 
vehicle or parathion (27.5 mg/kg) and were 
graded for functional signs for 24 hrs as 
described in methods section. At the end of 
24 hrs mice were sacrificed and cortex 
collected to measure cholinesterase activity. 
Functional signs were expressed as median ± 
interquartile range. Cholinesterase data 
(mean ± standard error) represent enzyme 
activities (nmol of substrate 
hydrolyzed/minute/mg protein) and are 
expressed as percent of control values. An 
asterisk indicates significant difference 
compared to respective control and a dollar 
sign indicates a significant difference 
between knockout control and knockout 
treatment group. A pound indicates 
significant difference between wildtype/LM 
and knockout mice. Cholinesterase activity 
in cortex of control animals was 35.5 ± 1.9 
nmol/min/mg protein in wildtype/LM and 
40.6 ± 2.3 nmol/min/mg protein in CB1 
knockouts. 
 
 
 
 
0 6 12 18 24
0
1
2
3
4
5
WT/PS KO/PS
* *
#A
Time after treatment (hrs)
Sc
o
r
e
0 6 12 18 24
0
1
2
3
4
WT/PS KO/PS
*
*
B
Time after treatment (hrs)
Sc
o
r
e
W
T/C
trl
KO
/Ct
rl
W
T/P
S
KO
/PS
0
20
40
60
80
100
120
* *
C
C
hE
 
a
c
ti
v
it
y 
(%
 
c
o
n
tr
o
l)
 100 
 
C) Effect of chlorpyrifos on body weight, functional signs and esterase activities in 
wildtype/LM and CB1 knockout mice 
Mice were treated with a high dosage (300 mg/kg, sc) of chlorpyrifos and 
observed for functional signs of cholinergic toxicity for 48 hrs. A significant reduction in 
body weight (WT/LM: 21 ± 2%, KO: 26 ± 3%) was observed in both wildtype/LM and 
CB1 knockout mice, but no significant difference was noted between the groups.  
Figure 25 shows the effect of chlorpyrifos on involuntary movements, SLUD 
signs and cortical cholinesterase activity in wildtype/LM and CB1 knockout mice. 
Tremors in wildtype/LM mice following chlorpyrifos exposure were significantly 
different from control at 12, 24 and 48 hrs. However, the onset of tremors in CB1 
knockout mice appeared somewhat delayed and was significantly different from control 
only at 24 and 48 hrs. Similar findings were also observed with SLUD signs as shown in 
Figure 25b.  
Chlorpyrifos elicited extensive, similar degrees of cortical cholinesterase 
inhibition in both wildtype/LM and CB1 knockout mice (WT/LM: 92 ± 1%; KO: 95 ± 
1%). Similar findings were also observed in cerebellum (Table 5) and heart (WT/LM: 88 
± 1%; KO: 88 ± 2%) 
Chlorpyrifos also elicited extensive inhibition of liver (WT/LM: 88 ± 0%; KO: 91 
± 0.5%) and plasma (WT/LM: 70 ± 3%; KO: 63 ± 8%) carboxylesterase activities, with 
no significant differences between the groups. Thus at this dosage, chlorpyrifos elicited 
severe signs of cholinergic toxicity (both involuntary movements and SLUD signs) in 
both wildtype/LM and CB1 knockout mice, with very similar degrees of esterase 
inhibition. While similar degrees of esterase inhibition were noted at the end of the 
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observation period, CB1 knockouts appeared to have a somewhat delayed expression of 
functional signs of toxicity. This could suggest that cholinesterase inhibition was also 
delayed within the timeframe of the study, or that neurochemical responses to 
cholinesterase inhibition were different between the groups, leading to an altered 
functional response. Cholinesterase was only measured at the end of the observation 
period however, and thus it is unclear whether this may have contributed.  
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Figure 25: Effects of chlorpyrifos on 
A) involuntary movements, B) SLUD 
signs, C) cortical cholinesterase 
activity in wildtype/LM and CB1 
knockouts.  
 
Mice (n = 4-5/group) were exposed to 
either vehicle or chlorpyrifos (300 
mg/kg) and were graded for functional 
signs for 48 hrs as described in 
methods section. At the end of 48 hrs 
mice were sacrificed and cortex 
collected to measure cholinesterase 
activity. Functional signs were 
expressed as median ± interquartile 
range. Cholinesterase data (mean ± 
standard error) represent enzyme 
activities (nmol of substrate 
hydrolyzed/minute/mg protein) and are 
expressed as percent of control values. 
An asterisk indicates significant 
difference compared to respective 
control and a dollar sign indicates a 
significant difference between 
knockout control and knockout 
treatment group. A pound indicates 
significant difference between 
wildtype/LM and knockout mice. 
Cholinesterase activity in cortex of control animals was 35.5 ± 1.9 nmol/min/mg protein in 
wildtype/LM and 40.6 ± 2.3 nmol/min/mg protein in CB1 knockouts. 
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Table 5: Effect of parathion and chlorpyrifos on cholinesterase activity in cerebellum 
from wildtype/LM and CB1 knockout mice. 
 
 
 
 
 
 
 
Mice (n = 4-5/group) were exposed to either vehicle or parathion (20 or 27.5 mg/kg) or 
chlorpyrifos (300 mg/kg, sc) and were graded for functional signs. Mice were sacrificed 
and tissues collected for cholinesterase assay. Data (mean ± standard error) represent 
enzyme activities in terms of nmol of substrate hydrolyzed/minute/mg protein. Values in 
parentheses indicate percent cholinesterase inhibition with respect to control values. 
a
 indicates a significant difference compared to respective control.  
 
 
 
 
 
 
 
 
 
 
Tissue/genotype 
 
Control 
 
 
Parathion 
(20 mg/kg) 
 
Parathion 
(27.5mg/kg) 
 
Chlorpyrifos 
(300 mg/kg) 
Cerebellum 
WT/LM 22.7 ± 1.8 
4.8 ± 0.6 a 
(79) 
1.4 ± 0.2 a 
(94) 
2.4 ± 0.3  a 
(89) 
Cerebellum 
KO 25 ± 2.0 
4.4 ± 0.6 a 
(82) 
1.9 ± 0.4 a 
(92) 
2.7 ± 0.7 a  
(89) 
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Specific Aim 3: To evaluate ACh release as affected by OP exposure ex vivo and in 
vitro in slices from CB1-/- and respective wildtype/LM mice. 
A) To evaluate effects of parathion and chlorpyrifos on ACh release ex vivo in wildtype 
and CB1 knockout mice 
 Mice were exposed to a high dosage of parathion (27.5 mg/kg, sc) or chlorpryrifos 
(300 mg/kg) and tissues were collected 24 hrs later (for parathion) or 48 hrs later (for 
chlorpyrifos) to measure ACh release ex vivo. Figure 26 shows ex vivo ACh release in 
hippocampal slices from wildtype/LM and CB1 knockout mice following treatment with 
parathion or chlorpyrifos. Parathion markedly decreased hippocampal ACh release in 
both wildtype/LM and CB1 knockout mice (WT/LM: 54 ± 3%, KO: 49 ± 4%), with no 
significant differences between the treatment groups. Chlorpyrifos also significantly 
decreased hippocampal ACh release in both wildtype/LM and CB1 knockouts (WT/LM: 
52 ± 5%, KO: 36 ± 7%), but in this case a significantly greater reduction in release was 
observed in tissues from wildtype/LM mice.  
Figure 27 illustrates ex vivo ACh release in striatum following exposure to 
parathion or chlorpyrifos. Parathion caused a significant reduction in ACh release in both 
wildtype/LM and CB1 knockouts (WT/LM: 12 ± 3%, KO: 25 ± 8%). Chlorpyrifos also 
elicited a significant and similar reduction in ACh release in tissues from both 
wildtype/LM and CB1 knockouts (24 ± 6%).   
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Figure 26: Effects of parathion and chlorpyrifos on ACh release ex vivo in hippocampal 
slices from wildtype/LM and CB1 knockout mice.  
Mice (n = 4-6/group) were exposed to either vehicle or OP and were graded for 
functional signs. Hippocampal slices were incubated with [3H]choline to label 
endogenous acetylcholine. Prelabelled slices were then loaded into a suprafusion 
apparatus and perfused with physiological buffer. Release was stimulated by exposing the 
slices to a depolarizing buffer containing high concentration of KCl (25 mM) as 
described in methods section. Data (mean ± standard error) represent peak ACh release 
(S1) and are expressed as percent of control values. An asterisk indicates a significant 
difference compared to respective control. A pound signs indicates a significant 
difference between wildtype/LM and knockout treatment groups. ACh release (S1) in 
hippocampus of control animals was 3.8 ± 0.3 in wildtype/LM and 3.5 ± 0.2 in CB1 
knockouts (calculated as a percentage of the total radioactivity).  
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Figure 27: Effects of parathion and chlorpyrifos on ACh release ex vivo in striatal slices 
in wildtype/LM and CB1 knockout mice.  
Mice (n = 4-6/group) were exposed to either vehicle or OP and were graded for 
functional signs. Striatal slices were incubated with [3H]choline to label endogenous 
acetylcholine. Prelabelled slices were then loaded into a suprafusion apparatus and 
perfused with physiological buffer. Release was stimulated by exposing the slices to a 
depolarizing buffer containing a high concentration of KCl (20 mM) as described in 
methods section. Data (mean ± standard error) represent ACh release (S1) expressed as 
percent of control. An asterisk indicates a significant difference compared to respective 
control. ACh release (S1) in striatum of control animals was 7.2 ± 0.5 in wildtype/LM 
and 8.1 ± 0.7 in CB1 knockouts.  
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B) To evaluate the effects of the cannabinoid receptor agonist WIN 55,212-2 and selected 
OPs on ACh release in vitro in tissues from wildtype/LM and CB1 knockout mice 
Mice were sacrificed by decapitation and brain was immediately removed. Slices 
were prepared as described earlier in methods section and ACh release measured in 
hippocampal and striatal slices as described above. The comparative effects of WIN 
55,212-2 (WIN, 1 µM), paraoxon (100 µM) and chlorpyrifos oxon (100 µM) on ACh 
release in vitro were evaluated. WIN was used as a positive control. 
Figure 28 shows the in vitro effects of WIN, paraoxon and chlorpyrifos oxon on 
ACh release in vitro in hippocampal slices. WIN can reduce ACh release in hippocampus 
but has no effect on ACh release in striatum (Gifford et al., 1997; Kathmann et al., 2001). 
In our hands, WIN reduced hippocampal ACh release in slices from wildtype mice, but 
had no effect on release in tissues from CB1 knockouts. Paraoxon significantly reduced 
ACh release in hippocampal slices from wildtype/LM mice (15.7 ± 3.1%), while it had 
essentially no effect in slices from CB1 knockouts. Chlorpyrifos oxon significantly 
reduced release in hippocampal slices from both groups (WT/LM: 20.3 ± 3.4%; KO: 10.3 
± 2.4%). It should be noted, however, that the magnitude of the reduction was 
significantly greater in slices from wildtype/LM mice. Thus in vitro, paraoxon appeared 
to have a greater effect on hippocampal ACh release in tissues from the wildtype mice, 
suggesting a possible role of CB1 in these comparative neurochemical responses.  
Figure 29 shows the in vitro effects of WIN and both oxons on ACh release in 
striatal slices. As expected, WIN did not influence striatal ACh release in tissues from 
either wiltypes or knockouts. In contrast, paraoxon significantly reduced ACh release in 
tissues from both wildtype/LM and CB1 knockout mice (WT/LM: 14.1 ± 2.9%; KO: 8.7 
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± 3.8%). Interestingly, chlorpyrifos oxon significantly increased ACh release in tissues 
from both groups (WT/LM: 10.7% ± 5.6; KO: 10.2 ± 6.4%). In striatum, there was 
therefore no suggestion of a differential effect of chorpyrifos oxon on ACh release, 
mediated in some way by CB1.  
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Figure 28: In vitro effects of paraoxon and chlorpyrifos oxon on hippocampal ACh 
release in slices from wildtype/LM and CB1 knockout mice.  
Hippocampal slices were incubated with [3H]choline to label endogenous acetylcholine. 
Prelabelled slices were then loaded into a suprafusion apparatus and perfused with 
physiological buffer. Release was stimulated twice (S1 and S2) by exposing the slices to 
a depolarizing buffer containing high concentration of KCl (25 mM). Drugs were added 
20 minutes before the second pulse of potassium. The ratio of S2/S1 is a normalized 
index of ACh release. Data (mean ± standard error) represent ACh release expressed as 
percent control. An asterisk indicates a significant difference compared to respective 
control. A pound sign indicates a significant difference between wildtype/LM and CB1 
knockout brain slices. ACh release (S2/S1) in hippocampus of control animals was 0.8 ± 
0.1 in wildtype/LM and 0.9 ± 0.1 in CB1 knockouts.  
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Figure 29: In vitro effects of WIN, paraoxon and chlorpyrifos oxon on striatal ACh 
release in tissues from wildtype/LM and CB1 knockout mice.  
Striatal slices were incubated with [3H]choline to label endogenous acetylcholine. 
Prelabelled slices were then loaded into a suprafusion apparatus and perfused with 
physiological buffer. Release was stimulated twice (S1 and S2) by exposing the slices to 
a depolarizing buffer containing high concentration of KCl (25 mM). Drugs were added 
20 minutes before the second pulse of potassium. The ratio of S2/S1 is a normalized 
index of ACh release. Data (mean ± standard error) represent ACh release expressed as 
percent control. An asterisk indicates a significant difference compared to respective 
control. ACh release (S2/S1) in striatum of control animals was 0.8 ± 0.01 in both 
wildtype/LM and CB1 knockouts.  
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CHAPTER IV 
DISCUSSION 
 
EVALUATION OF THE ROLE OF M2 MUSCARINIC RECEPTOR FUNCTION 
IN OP TOXICITY 
Effects of acute parathion and chlorpyrifos in wildtype and M2 knockout mice 
OPs typically elicit cholinergic toxicity by inhibiting acetylcholinesterase, leading 
to accumulation of the neurotransmitter ACh in neuronal synapses and neuromuscular 
junctions throughout the body. ACh activates post-synaptic cholinergic receptors to 
mediate neurotransmission, and can also activate pre-synaptically located autoreceptors 
to modulate ACh release. Typically, activation of M2 autoreceptors on the pre-synaptic 
cholinergic terminal leads to decreased ACh release (Quirion et al., 1995; Stillman et al., 
1996; Galli et al., 2001; Zhang et al., 2002). We hypothesized that genetic deletion of the 
M2 receptor would increase sensitivity to OP toxicity by blocking the adaptive inhibition 
of ACh release during conditions of ACh accumulation. Genetic deletion of the M2 
receptor had little effect on overt phenotype in mice (Gomeza et al., 1999; Tzavara et al., 
2004). We thus proposed that this model would be appropriate for evaluating the 
receptor’s role in neurochemical and neurotoxicological responses to OP challenge.  
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A considerable number of studies from multiple laboratories have evaluated many 
aspects of OP toxicity in rats (Eells and Brown, 2009; Lassiter et al., 2008; Nallapaneni et 
al., 2008; Karasova et al., 2009; Masoud et al., 2009; Ray et al., 2009). In contrast, 
relatively few studies on OP toxicity have been conducted in mice. Thus, preliminary 
studies were necessary to determine appropriate dosing conditions. The dosages we 
selected for further study were in some cases (e.g. paraoxon and parathion) relatively 
high compared to those used in rats. Rats showed higher acute sensitivity and 
cholinesterase inhibition than mice following exposure to the OP toxicant 
diisopropylphosphorofluoridate (Kamp and Collins, 1992). Several species of fish were 
less sensitive than rats to both paraoxon and parathion but similarly sensitive to 
chlorpyrifos oxon (Murphy et al., 1968; Benke et al., 1974; Johnson and Wallace, 1987).   
With rats, 27 mg/kg has been reported to be the maximum tolerated dosage of 
parathion in our laboratory (Karanth et al., 2007). Dose-response studies in mice were 
initially conducted with parathion dosages bracketing this exposure level (0, 15, 25 or 35 
mg/kg, sc). We observed a dose-related increase in involuntary movements, a classical 
sign of OP toxicity, in wildtype mice (Figure 7). In contrast, the M2 knockouts exhibited 
involuntary movements only at the highest dosage evaluated, and the extent of tremors 
was lower than noted in WT with either 25 or 35 mg/kg parathion exposure (Figure 7). 
Relatively similar findings were also observed with SLUD signs (Figure 8). All three 
dosages elicited relatively similar degrees of cholinesterase inhibition (~85-90%) in 
wildtype mice. In contrast, lesser inhibition was noted in M2 knockouts with the lowest 
dosage (15 mg/kg, ~50% inhibition) and with higher dosages (25 and 35 mg/kg, ~75% 
inhibition; Figure 9). Thus, these initial findings suggested that wildtypes were more 
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sensitive than M2 knockouts to parathion, but possibly due to differential cholinesterase 
inhibition. Based on these pilot studies, we selected 35 mg/kg parathion for subsequent 
evaluations.  
 Comparative sensitivity of wildtype and M2 knockout mice to the parent 
insecticides parathion (35 mg/kg, sc) and chlorpyrifos (300 mg/kg) were then evaluated. 
Numerous studies from our laboratory have studied the effects of high dosages (250-280 
mg/kg, sc) of chlorpyrifos in rats (Pope et al., 1991, 1992; Chaudhuri et al., 1993; Liu and 
Pope, 1998; Karanth and Pope, 2003; Karanth et al., 2006). Mice were observed for 
cholinergic signs of toxicity for either 24 hrs (parathion) or 72 hrs (chlorpyrifos), based 
on differences in functional recovery between the two pesticides.  
Studies by Churchill et al., (1985) suggested that body weight reduction can be a 
sensitive indicator of organophosphate toxicity in rats. Parathion exposure led to 
relatively similar body weight reductions in both wildtype and M2 knockout mice; 
however wildtype mice exhibited more functional signs of toxicity (both involuntary 
movements and tremors) compared to the M2 knockout mice (Figure 10). These data 
provided further evidence of higher sensitivity to the acute toxicity of parathion in 
wildtype mice compared to M2 knockouts. 
 Cholinesterase activity was extensively inhibited in all brain regions evaluated 
(hippocampus, cortex and cerebellum, Figure 10 and Table 1) and in heart, in both 
wildtype and M2 knockout mice. There were no differences in basal cholinesterase levels 
between wildtype and M2 knockout mice. Surprisingly, as seen in our initial pilot study, 
more extensive cholinesterase inhibition was noted in wildtype mice in most tissues 
(hippocampus and cortex) following parathion exposure.  
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Soranno and Sultatos (1992) reported that mouse liver had remarkably high 
detoxification capacity against parathion. A number of studies have shown that 
carboxylesterase plays an important role in the detoxification of some organophosphate 
compounds, including paraoxon (Fonnum et al., 1985; Dettbarn et al., 1999; Karanth and 
Pope, 2000; Li et al., 2000). Basal carboxylesterase levels were similar in liver of both 
wildtype and M2 knockout mice. Parathion had relatively similar effects on liver 
carboxylesterase in both wildtype and M2 knockout mice. Interestingly, basal levels of 
plasma carboxylesterase were significantly higher in tissues from M2 knockouts 
compared to wildtype mice. The relative degree of inhibition plasma carboxylesterase 
following parathion exposure was similar between wildtype and M2 knockout mice, 
however. As plasma carboxylesterase levels have been negatively correlated with age-
related sensitivity to parathion (Karanth and Pope, 2000), this difference in plasma 
carboxylesterase activity in M2 knockouts could have toxicological relevance.  
Chlorpyrifos elicited a significant reduction in body weight in wildtype mice but had 
no effect on body weight in M2 knockout mice. The degree of body weight reduction in 
these mice was relatively similar to reductions noted in adult rats following exposure to 
279 mg/kg chlorpyrifos (Karanth et al., 2006). Chlorpyrifos elicited mild tremors in 
wildtype mice, but tremors were completely absent in the M2 knockouts (Figure 11). 
Exposure to chlorpyrifos had no effect on SLUD signs in either wildtype or M2 knockout 
mice. Chlorpyrifos elicited few signs of cholinergic toxicity in either wildtype or M2 
knockout mice. Previous studies from our laboratory using rats have reported similar 
findings (Pope et al., 1991, 1992; Chaudhuri et al., 1993; Liu and Pope, 1998; Karanth 
and Pope, 2003; Karanth et al., 2006). As noted before, this relative absence of typical 
 115 
 
signs of cholinergic toxicity in rats following chlorpyrifos exposure, in the presence of 
extensive brain cholinesterase inhibition, has been the basis for a long-term research 
project in our laboratory. It was previously hypothesized that these differences in toxicity 
could be due to differential direct effects on autoreceptor function following exposure to 
these OPs. 
Similar to results in mice treated with parathion, chlorpyrifos exposure elicited 
greater brain cholinesterase inhibition in both hippocampus and cerebellum in wildtype 
mice compared to M2 knockout mice (Figure 11, Table 1). Surprisingly, we did not see 
any cholinesterase inhibition in the cortex of M2 knockout mice while inhibition was 
noted in the cortex of wildtype mice. We have relatively little information on the time 
course of inhibition and recovery of cholinesterase following chlorpyrifos exposure in 
mice. It could be that greater inhibition would have been detected at earlier timepoints 
after exposure. In general, however, this dosage of chlorpyrifos did cause extensive 
inhibition of brain regional cholinesterase activity at the time-points evaluated. 
Wildtype mice also exhibited more extensive cholinesterase inhibition in the heart 
compared to M2 knockout mice. Relatively similar degrees of liver and plasma 
carboxylesterase inhibition were observed in both wildtype and M2 knockout mice. Thus, 
similar to findings in mice treated with parathion, the wildtypes appeared more sensitive 
to the functional toxicity of chlorpyrifos, and these differences appeared to correlate with 
differential cholinesterase inhibition.  
In contrast to our hypothesis, wildtype mice exhibited higher sensitivity than M2 
knockouts to both parathion and chlorpyrifos. Although basal tissue cholinesterase levels 
appeared similar between wildtypes and M2 knockouts, more extensive inhibition of 
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brain regional and heart cholinesterase activity was noted in wildtypes following 
exposure to either parathion or chlorpyrifos. Differential cholinesterase inhibition 
between wildtypes and knockouts could be due to a strain-related change in 
biotransformation (bioactivation and/or detoxification). For example, if the M2 receptor 
gene deletion was in some way associated with a change in P450-mediated oxidative 
desulfuration, paraoxon production could be affected, leading to differential degrees of 
cholinesterase inhibition. On the other hand, if expression of detoxification enzymes (e.g. 
carboxylesterases) was altered, paraoxon could circulate longer, allowing more extensive 
tissue cholinesterase inhibition.  
Carboxylesterases are important in the detoxification of many OPs including 
parathion, but have relatively little influence on chlorpyrifos toxicity (Karanth et al., 
2001). Studies from our laboratory have shown that carboxylesterases appear to play an 
important role in the detoxification of paraoxon (and thus in parathion toxicity) (Karanth 
and Pope, 2000; Karanth et al., 2001). We therefore evaluated the effect of these OP 
toxicants on tissue carboxylesterase levels to determine if they may be differentially 
affected. The degree of carboxylesterase inhibition did not differ between wildtypes and 
M2 knockouts following exposure to either parathion or chlorpyrifos. Thus, these data 
suggest that the differences in cholinesterase inhibition noted between wildtypes and M2 
knockouts were not likely based on differences in detoxification (at least via 
carboxylesterase) capacities. Differences in bioactivation of the parent compounds 
between wildtype and M2 knockouts could play a role, however. Several studies have 
shown that cytochrome P450 enzymes mediate the bioactivation of phosphorothioate 
compounds such as parathion and chlorpyrifos to the respective oxons (Sultatos, 1985; 
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Forsyth and Chambers, 1989; Murray and Butler, 1994; Chambers and Carr, 1995; 
Furlong, 2007). Differences in cholinesterase inhibition between wildtype and M2 
knockout mice noted herein could therefore be due to strain-related differences in 
bioactivation. Toxicity studies with the direct acting oxons were therefore conducted to 
determine if similar differences in toxicity would also be noted following exposure to the 
active metabolites of these insecticides.  
Comparative effects of paraoxon and chlorpyrifos oxon in wildtype and M2 
knockout mice 
Based on the findings from our toxicity studies we hypothesized that strain 
differences between the wildtypes and M2 receptors knockouts led to differential 
biotransformation of the parent insecticides. If these differences in response were due to 
differences in bioactivation, comparative toxicological responses of the oxons would be 
devoid of this confound and the role of the M2 receptor in OP toxicity under these 
conditions may be more clearly evident. Sensitivity of wildtype and M2 knockout mice to 
the metabolites of both parent compounds, i.e., paraoxon and chlorpyrifos oxon, was 
studied.  
Paraoxon (1 mg/kg, sc) led to significant body weight reductions in both wildtype 
and M2 knockout mice, but the degree of reduction was greater in the knockouts. 
Paraoxon elicited relatively similar signs of toxicity (severe tremors and SLUD signs) in 
wildtype and M2 knockout mice (Figure 12). Thus, wildtype and M2 knockout mice 
appeared similarly sensitive to paraoxon-induced cholinergic toxicity. Paraoxon inhibited 
cholinesterase activity in all brain regions evaluated (Figure 12 and Table 1) and in the 
heart of both wildtype and M2 knockout mice. Interestingly, the degree of brain 
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cholinesterase inhibition was now significantly higher (90 vs 80% inhibition) in tissues 
from the M2 knockouts compared to wildtype mice.  
Paraoxon inhibited liver and plasma carboxylesterase activity in M2 knockout 
mice, but had no effect in wildtypes. As carboxylesterases represent stoichometric 
binding sites for these OPs, their inhibition suggests that fewer oxon molecules would be 
available for binding to cholinesterase molecules. This would lead to less inhibition of 
cholinesterase in the M2 knockout tissues, but in fact, the reverse was noted. Thus, these 
findings suggested that the higher sensitivity to parathion in wildtypes was not reflected 
in higher sensitivity to paraoxon. In contrast to the above studies with parathion wherein 
wildtype mice exhibited more extensive signs of toxicity and higher brain cholinesterase 
inhibition, relatively similar signs of cholinergic toxicity were observed in wildtype and 
M2 knockout mice following paraoxon dosing and if anything, more esterase inhibition 
was noted in the knockouts suggesting that the differences in toxicity seen earlier with 
parathion could be at least partially due to strain-dependent differences in bioactivation.  
Chlorpyrifos oxon treatment elicited a significant decrease in body weight in 
wildtype mice but no effect in the M2 knockouts. Involuntary movements were also seen 
in both groups following chlorpyrifos oxon exposure. In this case, the onset of signs was 
somewhat earlier in the wildtypes compared to M2 knockouts (Figure 13). There were 
relatively few SLUD signs in wildtype mice and no SLUD signs in the M2 knockouts 
(Figure 13). Together, these results suggested that wildtype mice were more sensitive 
than the M2 knockouts to chlorpyrifos oxon, with a delay in onset of functional signs and 
a significant reduction in body weight in wildtypes but not in knockouts. 
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Chlorpyrifos oxon significantly inhibited brain (Figure 13 and Table 1) and heart 
cholinesterase activity, with essentially no difference between the groups. Interestingly, 
while wildtypes and M2 knockouts showed differences in the extent of functional signs 
following chlorpyrifos oxon exposure, there were no differences in brain cholinesterase 
inhibition between the groups. Significant liver carboxylesterase inhibition was seen in 
M2 knockout mice with no effect in wildtype mice. In contrast, plasma carboxylesterase 
was inhibited similarly in both wildtype and M2 knockout mice. Again, although liver 
carboxylesterases were inhibited in the knockouts, potentially removing oxon molecules 
from possible interaction with cholinesterase molecules, similar degrees of cholinesterase 
inhibition were generally noted between wildtype and M2 knockout mice. These results 
suggest that differences in toxic response could be elicited between these two groups 
under conditions of similar changes in cholinesterase activity. The studies with both 
oxons revealed that the differences in toxicity seen with parent compounds could be due 
to differences in bioactivation. As the M2 receptor (in the CNS) is primarily considered 
an autoreceptor, there could be differences in ACh release between these groups that 
contribute to these functional differences.  
We hypothesized that mice lacking the muscarinic M2 receptor would be more 
sensitive to OP anticholinesterases. Surprisingly, wildtype mice appeared more sensitive 
to parathion and chlorpyrifos, while both groups appeared similarly sensitive to 
paraoxon, and the wildtypes appeared only slightly more sensitive to chlorpyrifos oxon. 
There were, however, differences in esterase inhibition between wildtypes and knockouts 
that confounded interpretations of relative responses to the toxicants. Together, the 
studies with parent compounds and the oxon metabolites suggested that continuous 
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inbreeding of the M2 knockouts may have led to genetic variation resulting in changes in 
biotransformation that could contribute to differential responses. Further studies using 
control animals that were littermates of the knockouts were needed to investigate further 
the role of M2 receptor in OP toxicity. Wildtype/LM and M2 knockout mice were 
obtained by breeding of heterozygous mice, and confirmed by subsequent genotyping. 
Effects of acute parathion and chlorpyrifos exposure in wildtype and M2 knockout 
mice: studies with +/+ and -/- littermate controls 
Comparative sensitivity of wildtype/LM and M2 knockouts following selection of 
+/+
 and -/- mice was evaluated using the same dosages of OPs that were used in our 
preliminary studies above. Wildtype/LM and M2 knockouts appeared phenotypically 
similar (body weight, color, fur, etc) at the time of initiating studies (eight weeks of age). 
Parathion (35 mg/kg) led to relatively similar reductions in body weight in both wildtypes 
and M2 knockouts, with no significant differences between the groups. Previous studies 
suggested that adult rats lost approximately 15% of their pre-treatment body weight 
following exposure to 27 mg/kg dose of parathion (Karanth et al., 2007), very similar to 
the degree of reduction we observed here. Severe signs of cholinergic toxicity 
(involuntary movements and SLUD signs) were observed in both wildtype and M2 
knockout mice following treatment with parathion, but with no significant difference 
between the groups (Figure 14). Relatively similar signs of cholinergic toxicity were 
observed in adult rats exposed to 27 mg/kg parathion (Karanth et al., 2007). Marked 
lethality was observed in both wildtype/LM and M2 knockout mice following parathion 
dosing (WT: 5/9; KO: 7/13), again with no significant difference between the groups. 
The reason for lethality seen in the knockouts here as opposed to the initial studies with 
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non-littermates could be due to increased cholinergic signs of toxicity and higher 
cholinesterase inhibition. These data suggested that mice lacking the M2 receptor, when 
compared to wildtype littermates, exhibited relatively similar sensitivity to parathion 
toxicity.  
Extensive cholinesterase inhibition in brain (Figures 14 and Table 2) and heart 
was observed in both wildtype/LM and M2 knockouts following parathion dosing, again 
with no significant differences between the groups. It appeared that while M2 -/- and +/+ 
littermates exhibited relatively similar degrees of cholinesterase inhibition in brain and 
heart, the extent of inhibition was somewhat higher compared to the previous studies 
lacking littermate controls. This degree of brain cholinesterase inhibition is relatively 
similar, however to that reported by Karanth and coworkers (2007) in rats treated with 
parathion (27 mg/kg, sc).  
In contrast to our initial studies, there was little evidence of differences in acute 
sensitivity to parathion between wildtype/LM and M2 knockouts. Wildtype/LM and M2 
knockouts exhibited relatively similar signs of cholinergic toxicity, similar degrees of 
brain and heart cholinesterase inhibition, and relatively similar inhibition of 
carboxylesterases. In these studies, parathion (35 mg/kg) elicited very high (>95%) 
inhibition of brain regional cholinesterase activity. We postulated that M2 autoreceptor 
function may not sufficiently counteract cholinergic toxicity if excessive 
acetylcholinesterase inhibition and consequent ACh accumulation occurs. We therefore 
conducted subsequent studies using a lower dosage of parathion (27.5 mg/kg, sc). The 
lower dosage of parathion (27.5 mg/kg, sc) elicited a significant decrease in body weight 
(~19%) in both wildtype/LM and M2 knockouts. Moderate signs of cholinergic toxicity 
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were observed in both wildtype/LM and M2 knockout mice with no differences in the 
degree of signs between the groups (Figure 15). Lethality appeared higher in 
wildtype/LM mice (4/10), however than in M2 knockouts (1/7).  
Marked inhibition of brain (Figure 15 and Table 2) and heart (Figure 51) 
cholinesterase was observed in both wildtype/LM and M2 knockouts, with no differences 
between the groups. Inhibition of liver and plasma carboxylesterase was noted in both 
wildtype/LM and M2 knockouts, again with no differences between the groups. From 
these studies, it is relatively clear that deletion of the muscarinic M2 receptor had little 
influence on acute sensitivity to parathion, but may actually decrease lethality following 
exposure to lower dosages. This is in contrast to our hypothesis, i.e., that loss of M2 
autoreceptor function would increase sensitivity to OP toxicity. It should also be noted 
that these results are different than findings from our initial studies that did not include 
M2+/+ littermate controls for comparison. In those studies, differential inhibition of 
cholinesterase was noted, while in the studies with appropriate littermate controls, we 
noted very similar changes in esterase activities. Thus, the later studies with better control 
conditions provides the strongest evidence that the M2 receptor appears to have relatively 
little influence on cholinergic toxicity elicited by parathion in mice.  
Mice treated with chlorpyrifos showed essentially no signs of cholinergic toxicity 
or any effects on body weight, regardless of the genetic status of the M2 receptor. There 
was marked inhibition of cortical, cerebellar (Figure 16 and Table 2) and heart 
cholinesterase activity, however, in both wildtype and M2 knockout mice. Liver and 
plasma carboxylesterase was also inhibited similarly between groups. Similar to findings 
following parathion exposure, there were no statistical differences in the degree of 
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inhibition of either tissue cholinesterase or carboxylesterase activities between the 
treatments groups. Again, as noted above, these findings were in contrast to those studies 
evaluating chlorpyrifos toxicity without M2+/+ littermate controls. It should be noted that 
the dosage of chlorpyrifos used herein was the same as used in our studies with CB1 
knockouts, where extensive, typical signs of cholinergic toxicity, significant body weight 
reductions and extensive cholinesterase inhibition were noted. It is apparent that the 
genetic background of the mice can dramatically influence the expression of cholinergic 
toxicity following chlopyrifos exposure.  
The M2 knockouts were a cross between CF1 and 129J1 mice, whereas the CB1 
knockout mice had a C57Bl/6 background. Several studies have shown that genetic strain 
differences can contribute to differences in toxicity following exposure to cholinergic 
compounds (Van Abeelen, 1972; Marks et al., 1981; 1983). Out of three different strains 
of mice exposed to the same dosage of the organophosphate anti-cholinesterase 
diisopropylphosphorofluoridate, C57Bl/6 mice were the most sensitive (Smolen et al., 
1985, 1986). Previous studies in outbred rats have noted relatively few signs of toxicity 
following high subcutaneous dosages (280 mg/kg) of chlorpyrifos (Pope et al., 1991, 
Chaudhuri et al., 1993; Karanth and Pope, 2003). It was previously hypothesized that 
selective, enhanced activation of M2 autoreceptor function by chlorpyrifos impaired the 
expression of toxicity in the presence of extensive acetylcholinesterase inhibition (Pope 
et al., 1995). Earlier studies suggested that chlorpyrifos oxon directly bound to M2 
receptors (Huff and Abou-Donia, 1994; Bomser and Casida, 2001; Howard and Pope, 
2002), had qualitatively different effects on striatal ACh release in vitro compared to 
paraoxon (Liu et al., 2002), and selectively blocked M2 receptor internalization and 
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phosphorylation (by G-protein receptor kinase 2) in in vitro cell models (Zamora et al. 
2008). Our findings reported herein with M2 knockouts suggest that the relative absence 
of signs of cholinergic toxicity following chlorpyrifos exposure is not based on selective 
effects on the M2 autoreceptor and mediated by lesser ACh release.  
Comparative effects of the tremorigenic muscarinic agonist oxotremorine in 
wildtype/LM and M2 knockouts  
Both wildtype/LM and M2 knockouts exhibited marked tremors following 
parathion exposure (Figures 14 and 15). Studies by Gomeza and coworkers (1999) 
reported that tremors were absent in M2 knockout mice exposed to the muscarinic 
agonist oxotremorine. As the involuntary movements following parathion are considered 
to be mediated by prolonged/excessive stimulation of muscarinic receptors as a 
consequence of acetylcholinesterase inhibition, we wanted to confirm the comparative 
effects of oxotremorine in wildtype/LM and M2 knockouts. Wildtype/LM and M2 
knockout mice were given a tremorigenic dosage of oxotremorine (0.5 mg/kg) and 
subsequently evaluated for tremors.  
A marked tremor response was seen consistently in all wildtype/LM mice, while 
no tremors were noted in the M2 knockouts (Figure 17). These findings agree with those 
of Gomeza et al (1999) suggesting that the M2 receptor is essentially for expression of 
muscarinic receptor-mediated tremors in mice. Together these data indicate that the 
tremors seen in M2 knockouts following parathion exposure were mediated either 
through nicotinic receptor activation or through other non-cholinergic signaling 
pathways. Previous studies have reported the involvement of serotonergic signaling in 
addition to cholinergic receptors in the expression of tremors following exposure to an 
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anti-cholinesterase compound (Kumar et al., 1989, 1990; Sarkar et al., 2000; Mehta et al., 
2005). Acetylcholinesterase inhibition may initially selectively affect cholinergic 
signaling, but recruitment of other transmitter systems, e.g. glutamatergic signaling, has 
been reported (Shih and McDonough, 1997; Solberg and Belkin, 1997; Weissman and 
Raveh, 2008). Some studies have also reported glutamate receptor involvement in 
tremors elicited in mice following exposure to the muscarinic agonist, arecoline 
(Lukomskaya et al 2008). Future studies could characterize the neurochemical basis of 
tremors in M2 knockouts following OP exposure that might lead to better therapeutic 
strategies for treating OP intoxications.  
Mild SLUD signs were observed in both wildtype/LM and M2 knockout mice 
following exposure to oxotremorine, with no significant differences between the groups 
(Figure 17). The muscarinic M3 receptor is widely involved in parasympathetic actions, 
including some responses measured in the assessment of SLUD signs, while the M1 
receptor subtype may also play a role. It is well known that M3 receptors are involved in 
the contraction of smooth muscles in the gastric fundus, urinary bladder and ileum (Eglen 
et al., 2001; Stengel et al., 2002; Uchiyama and Chess-Williams, 2004; Tran et al., 2006; 
Unno et al., 2006; Kitazawa et al., 2007). Using M1/M3 receptor double knockout mice, 
it was shown that both are important for salivary secretion (Matsui et al., 2000; Gautam 
et al., 2004; Yamada et al., 2006). A greater reduction in body temperature was noted in 
wildtype compared to M2 knockout mice (Figure 17). The central M2 subtype plays an 
important role in the regulation of body temperature, although other muscarinic receptors 
participate (Spencer et al., 1965; Gomeza et al., 1999; Schwarz et al., 1999).  
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With appropriate littermate controls, parathion elicited relatively similar degrees 
of functional toxicity in both wildtype/LM and M2 knockouts as well as similar degrees 
of esterase inhibition. There was no suggestion of possible differences in bioactivation of 
the parent insecticides (as opposed to our preliminary studies). We anticipated that lack 
of M2 receptors and their associated feedback control of ACh release would allow greater 
ACh accumulation following extensive cholinesterase inhibition, leading to more 
extensive signs of cholinergic toxicity: little evidence for this was found. The toxicity 
results indicated that ACh release following OP exposure may not be substantially 
different in mice lacking the M2 receptor. The relative lack of effects of M2 deletion on 
cholinergic signs following either parathion or chlorpyrifos exposure could be due to a 
developmental adaptation elicited by the absence of the receptor. To investigate this 
possibility, we studied the effects of parathion (27.5 mg/kg) on ACh release ex vivo as 
well as in vitro effects of both paraoxon and chlorpyrifos oxon in brain slices from 
wildtype/LM and M2 knockouts.  
Comparative effect of parathion on acetylcholine release ex vivo in slices from 
wildtype/LM and M2 knockouts 
Parathion (27.5 mg/kg) elicited moderate signs of toxicity and extensive 
cholinesterase and carboxylesterase inhibition with no significant difference between 
wildtype/LM and M2 knockout mice (Figure 15, Table 2). Surprisingly, there was no 
reduction in brain regional ACh release ex vivo following parathion exposure (Table 3). 
The dosage of parathion used was the same as that used in studies with CB1 knockouts, 
where a reduction in release was noted in hippocampus and striatum from both 
wildtype/LM and CB1 knockout mice (Figures 26 and 27). Previous studies have 
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reported that both parathion and chlorpyrifos affect striatal acetylcholine release ex vivo 
in rats (Pope et al., 1995; Liu and Pope, 1996). The basis for the absence of ex vivo 
effects of parathion on brain regional ACh release in these studies is therefore unclear. 
Comparative in vitro effects of paraoxon and chlorpyrifos oxon on acetylcholine 
release in slices from wildtype/LM and M2 knockouts 
Douglas and coworkers (2001) reported that the M2 receptor is the major 
autoreceptor regulating ACh release in the prefrontal cortex of C57Bl/6 mice. Several 
other researchers had a similar conclusion (Mash et al., 1985; Quirion et al., 1989; 1994). 
Using cortical, hippocampal and striatal slices from wildtype, M2, M4 and M2/M4 
receptor knockout mice, it was shown that M2 receptor is the major autoreceptor in 
cortex and hippocampus while the M4 receptor appears to be the major autoreceptor in 
striatum (Zhang et al., 2002). Activation of autoreceptors leads to adenylate cyclase 
inhibition and decreased cAMP formation, incluencing further release of ACh into the 
synapse (Olivier et al., 2001). The muscarinic antagonist atropine increased ACh release 
whereas muscarinic agonists (carbachol and cis-dioxalane) decreased ACh release in 
striatal slices from adult rats (Pope et al., 1995). As noted above, the M4 receptor is 
thought to be the predominant autoreceptor in striatum (Olianas et al., 1997; Zhang et al., 
2002; Tzavara et al., 2004). The decrease in ACh release seen here in cortical and 
hippocampal slices could be due to effects at the M2 receptor since such effect was 
absent in slices from M2 knockouts. In contrast, reductions in ACh release seen in 
striatum could be due to increased activation of the M4 receptor, present in both 
wildtype/LM and M2 knockout mice.  
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Pilot studies evaluated concentration-related effects of both paraoxon and 
chlorpyrifos oxon on ACh release in slices from the different brain regions. We 
determined that a high concentration (100 µM) of either paraoxon or chlorpyrifos was 
maximally effective for influencing ACh release. This was also an effective concentration 
in studies evaluating OP effects on ACh release in rat striatal slices (Liu et al., 2002). 
Oxotremorine was used as a positive control in all assays. Paraoxon had no significant 
effect on ACh release in cortical (Figure 18) or hippocampal (Figure 19) slices from 
either wildtype/LM or M2 knockout mice. Paraoxon did however decrease ACh release 
in striatal slices from both groups (Figure 20). Relatively few studies have evaluated ACh 
release following OP exposure either in vivo, ex vivo or in vitro, and the majority of those 
studies have been conducted in rat striatum (Sims et al., 1982; Whalley and Shih, 1989; 
Pope et al., 1995; Jacobsson et al., 1997; Liu and Pope, 1998; Karanth et al., 2006, 2007). 
As noted before, paraoxon decreased ACh release in vitro in striatal slices from adult rats 
(Liu et al., 2002). Since several studies have reported that the M4 receptor subtype is 
likely the primary muscarinic autoreceptor in striatum (Zhang et al., 2002; Tzavara et al., 
2004), we conclude that the paraoxon-induced decrease in ACh release in striatal slices 
from wildtype and M2 knockout mice is mediated through activation of M4 receptors, 
and thus the M4 receptor may play a role in modulating ACh release following paraoxon 
(or parathion) exposure. As both wildtype/LM and M2 knockout mice have intact M4 
receptors, and the effect of paraoxon on ACh release was similar, the absence of the M2 
receptor appeared to have little influence on either ACh release or cholinergic toxicity 
following parathion. 
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 In contrast, chlorpyrifos oxon (100 µM) decreased ACh release in cortical slices 
from both wildtype/LM and M2 knockout mice (Figure 18). While chlopyrifos oxon 
appeared to have a differential effect on cortical ACh release compared to paraoxon, 
these results suggest that this differential effect was not related to M2 receptor activity. 
Several studies have reported that chlorpyrifos oxon can interact directly with muscarinic 
autoreceptors and affect cAMP levels in cortical slices from rats and cell models (Ward 
and Mundy, 1996; Olivier et al., 2001; Liu et al., 2002; Zamora et al., 2008). A number 
of studies have also shown that although the M1 receptor subtype is the predominant 
muscarinic receptor subtype in cortex, M2 and M4 receptors are present in this region 
(Lapchak et al., 1989; Waelbroeck et al., 1990; Onali and Olianas, 1998; Iannazo and 
Majewski, 2000). The reduction in cortical ACh release in vitro following chlorpyrifos 
oxon exposure in tissues from both wildtype/LM and M2 knockouts could also be due to 
direct interaction with M4 receptors, as proposed above with striatal effects of paraoxon.  
Interestingly, chlorpyrifos oxon increased ACh release in hippocampal and striatal 
slices in tissues from wildtype/LM, but had no effect on release in slices from the 
knockouts (Figures 19 and 20). Similar findings were also obtained in striatal slices from 
both CB1+/+ and CB1-/- mice following exposure to chlorpyrifos oxon in vitro. Liu and 
coworkers (2002) reported that while chlorpyrifos oxon appeared to act as a muscarinic 
agonist at low concentrations, decreasing ACh release in striatal slices from adult rats, at 
high concentrations (100-300 µM; when cholinesterase was preinhibited and in the 
presence of atropine to competitively block the autoreceptor) chlorpyrifos oxon acted as 
an antagonist, increasing ACh release. In mouse tissues, this enhancement of ACh release 
by chlorpyrifos oxon appears possible in the absence of physostigmine and atropine. 
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Several studies have shown that the striatum also expresses M2 receptors (Levey et al., 
1991; Zhang et al., 2002; Warren et al., 2007). Chlorpyrifos decreased ACh release ex 
vivo in rats early after exposrue, but increased release at later timepints (Won et al., 
2001). Chlorpyrifos oxon may decrease ACh release in one brain region yet increase 
release in another brain region, depending on the relative contribution of different 
muscarinic receptor subtypes to ACh release. The increase in ACh release observed here 
could be due to the antagonism of M2 autoreceptors in slices from wildtype mice.  
As noted above, oxotremorine was used as a positive control in the in vitro release 
studies. Oxotremorine decreased ACh release in cortical and hippocampal slices from 
wildtype/LM mice, but had no effect in tissues from M2 knockouts (Figures 18 and 19). 
However, significant reductions in ACh release were observed in striatal slices from both 
wildtype/LM and M2 knockouts, with no difference between the groups (Figure 20). 
There is some suggestion that oxotremorine has selectivity for M2 over M4 receptors. 
These results thus generally agree with previous reports (Mash et al., 1985; Quirion et al., 
1989; 1994; Douglas et al 2001; Zhang et al., 2002), suggesting the M2 receptor is the 
primary muscarinic autoreceptor in cortex and hippocampus, while the M4 is the primary 
autoreceptor in striatum. These findings also demonstrate that if chlorpyrifos or parathion 
(or chlorpyrifos oxon or paraoxon) had an effect on M2 autoreceptor function, our assay 
should have detected that modulatory action.  
Our initial studies evaluating OP toxicity in wildtype and M2 knockouts 
suggested that wildtypes may be more sensitivity. These studies were confounded by lack 
of +/+ littermate controls and differential degrees of cholinesterase inhibition between the 
groups following exposure to either parathion or chlorpyrifos. These differences were not 
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noted with paraoxon or chlorpyrifos oxon, suggesting that strain differences in 
bioactivation could have been responsible for differences in sensitivity instead of any 
difference related to M2 receptor function. We therefore used M2+/+ and M2-/- littermate 
controls for further studies. In contrast to the initial studies, we observed few differences 
in sensitivity or in the extent of cholinesterase inhibition between wildtype/LM and 
knockout mice under these conditions. Both wildtype/LM and knockout mice appeared 
relatively similar in sensitivity to both parent insecticides, i.e., M2 receptor deletion 
appeared to have relatively little effect on sensitivity to either OP.  Parathion (ex vivo) 
and paraoxon (in vitro) had relatively little effect on brain regional ACh release in cortex 
or hippocampus from either wildtype/LM or M2 knockout mice, but did reduce release in 
striatum, possibly through M4 receptor interactions. Chlorpyrifos oxon decreased ACh 
release in cortical slices from both wildtype/LM and knockouts, but increased ACh 
release in hippocampal and striatal slices, but only in tissues from wildtype/LM mice. 
Overall, these findings suggest that the M2 receptor has generally little influence on 
expression of classical signs of cholinergic toxicity in mice following OP exposure. The 
differential effects of paraoxon and chlopyrifos oxon on ACh release and its modulation 
through M2 and M4 receptors may however be important in other neurobehavioral 
consequences of OP intoxication.  
 
EVALUATION OF THE ROLE OF CB1 RECEPTOR FUNCTION IN OP 
TOXICITY 
The classic mechanism of OP toxicity is initiated by inhibition of 
acetylcholinesterase, leading to accumulation of ACh, prolonged/excessive activation of 
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cholinergic receptors, and subsequent signs of cholinergic toxicity. A number of studies 
suggest that activation of post-synaptic muscarinic receptors can increase synthesis and 
release of endocannabinoids (Kim et al., 2002; Ohno-Shosaku et al., 2003). Activation of 
pre-synaptic CB1 receptors on the cholinergic terminal can decrease ACh release in 
selected brain regions (Gessa et al., 1998; Gifford et al., 1997, 2000; Kathmann et al., 
2001b. We therefore hypothesized that deletion of the CB1 receptor would increase 
sensitivity to OP toxicity by disrupting the endocannabinoid-mediated inhibition of ACh 
release in mice lacking this neuromodulatory signaling pathway.  
CB1 receptor knockout mice used in these studies were generated from the 
C57Bl/6 strain (Charles River) and appeared relatively similar in phenotype to wildtype 
C57Bl/6 mice. Wildtypes obtained from Charles River were slightly but significantly 
heavier (~3 grams) than CB1 knockouts. Differences in body weight with CB1 deletion 
were previously reported by Trillou and coworkers (2004). CB1 knockout mice exhibit 
reduced food intake when compared to wildtypes (Wiley et al., 2005). It appears that 
deletion of the CB1 receptor can affect food intake and in turn body weight. It should be 
stressed here that the wildtype C57Bl/6 mice used in our initial studies were purchased 
from Charles River, i.e., they were not CB1+/+ littermates.  
 We evaluated the comparative sensitivity of wildtypes and CB1 knockouts to 
both parathion and chlorpyrifos. Parathion (20 mg/kg, sc) significantly reduced body 
weight in the CB1 knockout mice while having no effect in wildtypes. Based merely on 
body weight changes, these initial results suggested higher sensitivity in mice lacking 
CB1 receptor signaling. Parathion also elicited tremors and SLUD signs (Figure 21) in 
CB1 knockout mice, while there was no effect in wildtype mice. Thus, CB1 receptor 
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deletion appeared to increase the extent of functional signs of cholinergic toxicity 
following parathion exposure, as hypothesized.  
There were no differences between wildtype and CB1 knockout mice in basal 
cholinesterase levels in any of the brain regions evaluated.  Parathion exposure led to 
significant inhibition of cholinesterase activity in all brain regions (Figure 21, Table 4) 
and in heart in both wildtype and CB1 knockout mice. Surprisingly, the degree of 
cholinesterase inhibition was significantly higher in CB1 knockout mice compared to 
wildtypes in all brain regions evaluated (Figure 21, Table 4). Thus, similar to initial 
studies using M2 knockouts, these initial findings suggested differential degrees of target 
enzyme inhibition between the mouse strains, confounding the interpretation of the role 
of CB1 receptor in expression of OP toxicity.  
We also measured liver and plasma carboxylesterase activities to determine if the 
CB1 knockouts also exhibited different degrees of non-target enzyme inhibition. 
Parathion significantly inhibited liver and plasma carboxylesterases. The degree of 
inhibition was relatively similar to findings in previous studies on parathion toxicity in 
rats (Karanth and Pope, 2000). There were no significant differences noted in 
carboxylesterase inhibition, however, between the groups. These findings suggested that 
the two strains of mice likely did not have differences in OP biotransformation as 
originally considered between M2 knockouts and separately-bred wildtypes purchased 
from Charles River. As paraoxon is the active metabolite of parathion, responsible for 
inhibition of both cholinesterases and carboxylesterases, the lack of differential 
carboxylesterase inhibition between wildtypes and CB1 knockouts argues against a net 
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difference in metabolism of parathion and/or paraoxon. The basis for differences in 
cholinesterase inhibition between the groups was unclear, however.  
Chlorpyrifos (300 mg/kg) elicited tremors and SLUD signs (Figure 22) in CB1 
knockout mice and marked lethality (5/7). Less extensive signs were noted in wildtype 
mice. Extensive cholinesterase inhibition in brain (Figure 22 and Table 4) and heart were 
noted following chlopyrifos exposure. The degree of brain cholinesterase inhibition was 
relatively similar to that noted in adult rats exposed to chlorpyrifos (280 mg/kg; Karanth 
et al., 2006). Extensive inhibition of liver and plasma carboxylesterase was also noted in 
both wildtype and CB1 knockout mice following exposure to chlorpyrifos. The extent of 
carboxylesterase inhibition was also relatively similar to previous findings with 
chlorpyrifos exposure in rats (Karanth and Pope 2000).   
Thus, CB1 knockout mice generally appeared more sensitive to OP toxicity 
(parathion and chlorpyrifos). Both OPs elicited more extensive brain regional 
cholinesterase inhibition in CB1 knockouts, however. With more extensive brain 
cholinesterase inhibition, one would expect more extensive signs of toxicity. We 
anticipated more severe signs of toxicity in the CB1 knockouts, but with similar changes 
in cholinesterase activity. A possible explanation for differences in cholinesterase 
inhibition between groups following exposure to the same dosage of an OP is that 
biotransformation (either activation or inactivation) is different between these groups. In 
contrast to our findings in the initial studies on M2 receptor knockouts, however, no 
differences in carboxylesterase inhibition were noted in tissues from these same animals. 
This suggested that the same amount of oxon was at least reaching the peripheral tissues, 
and thus a difference in biotransformation between wildtypes and knockouts was unlikely 
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a contributing factor. The results suggested, however that strain differences were in some 
way modifying the extent of target enzyme inhibition and thus confounding the 
evaluation of the role of CB1 receptor in OP toxicity. Similar to our studies with M2 
knockouts, we concluded that subsequent studies using CB1+/+ and CB1-/- littermates 
would be needed to evaluate better the role of CB1 receptor in expression of OP toxicity. 
We therefore began a breeding program to produce littermate wildtype, heterozygous and 
homozygous mice in order to minimize confounding factors that could influence the 
study outcome and its interpretations.  
Comparative effects of acute parathion and chlorpyrifos exposure in wildtype/LM 
and CB1 knockouts 
CB1-/- males were bred to C57Bl/6 (CB1+/+) mice obtained from Charles River to 
derive heterozygotes. These heterozygotes were then bred to obtain homozygous 
wildtype and knockouts. Under these conditions, wildtype/LM and CB1 knockout mice 
did not differ in body weight at the time of the experiments (eight weeks of age). Mice 
were exposed to parathion (20 mg/kg, sc) and graded for functional signs of cholinergic 
toxicity as before.  
Parathion elicited a significant reduction in body weight in both wildtype/LM and 
CB1 knockout mice, with no difference in degree of reduction between the treatment 
groups. Parathion elicited tremors in both wildtype/LM and CB1 knockout mice and 
SLUD signs (Figure 23), but again there were no differences in the degree of toxicity 
between wildtype/LM and CB1 knockouts. Thus, when +/+ and -/- littermates were used to 
evaluate parathion toxicity, no influence of CB1 receptor in the expression of toxicity 
was noted.  
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Parathion caused extensive inhibition of brain (Figures 23 and Table 5) and heart 
cholinesterase activity, with no significant differences between the treatment groups. 
Significant inhibition of liver and plasma carboxylesterase was also observed in both 
wildtype/LM and CB1 knockout mice following exposure to parathion, with no 
differences between treatment groups. Thus, in contrast to our earlier studies without 
littermate CB1+/+ controls, there was little suggestion of a role for CB1 receptor signaling 
in the expression of parathion toxicity. One explanation for these findings could be that 
endocannabinoid signaling only plays a prominent role in the expression of cholinergic 
toxicity when acetylcholine accumulation is extensive, i.e., with higher dosages of 
parathion. To evaluate this possibility, we increased the parathion dosage to 27.5 mg/kg 
in subsequent studies, a dosage that markedly increases the extent of cholinergic signs.  
At this higher dosage, parathion elicited relatively similar body weight reductions 
in both wildtype/LM and CB1 knockouts, with no significant difference between the two 
groups. Both wildtype/LM and CB1 knockout mice showed more severe signs of 
cholinergic toxicity than with 20 mg/kg dosing, but again no significant differences were 
noted between the treatment groups (Figure 24). More extensive inhibition of brain 
(Figure 24 and Table 5) and heart cholinesterase activity was observed in both 
wildtype/LM and CB1 knockouts compared to the lower dosage, but no differences were 
noted between groups. Similarly, carboxylesterases were inhibited to similar degrees in 
both groups. Together, these results suggested that CB1 deletion has little influence on 
either esterase inhibition or functional signs of toxicity in response to parathion exposure 
in mice.  
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We then evaluated the comparative sensitivity of CB1 knockouts to chlorpyrifos. 
Body weight was reduced in both groups, with no significant difference. Chlorpyrifos 
elicited severe signs of cholinergic toxicity (both SLUD signs and involuntary 
movements) in both wildtype/LM and knockouts (Figure 25). In this case, however, there 
was a statistical difference in the onset of signs, with CB1 knockouts showing 
significantly lesser toxicity at the earliest timepoint (12 hours after dosing). This was 
evident with both involuntary movements and SLUD signs. Chlorpyrifos elicited 
extensive inhibition of brain (Figure 25 and and Table 5) and heart cholinesterase 
activities and carboxylesterase activities, but no differences between groups. Thus, in 
contrast to our initial studies without littermate controls, wildtype/LM and CB1 knockout 
mice appeared relatively similar in sensitivity to chlorpyrifos except that the onset of 
functional signs was delayed in the CB1 knockouts. Similar degrees of brain regional and 
heart cholinesterase inhibition as well as tissue carboxylesterase inhibition were also 
noted between the groups.  
Studies from our laboratory have reported that endocannabinoid signaling can 
play an important role in reducing cholinergic toxicity in rats (Nallapaneni et al., 2006, 
2008). Our studies with CB1 knockout mice suggested little role for CB1 in the 
expression of OP toxicity, however. Parathion and chlorpyrifos elicited similar signs of 
cholinergic toxicity in both wildtype/LM and CB1 knockouts with similar levels of 
cholinesterase inhibition. The differences between these studies could be based on 
different species used (rats vs. mice) between the two sets of studies. The OPs used in the 
previous studies involving rats were paraoxon and diisopropylphophorofluoridate (DFP). 
Paraoxon and DFP are both direct-acting anti-cholinesterases and elicit rapid onset of 
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cholinergic signs, whereas the studies herein used parathion and chlorpyrifos, which 
require bioactivation and thus lead to relatively slower onset expression of toxicity. In 
addition, studies with rats used either direct or indirect cannabinomimetics (administered 
at the same time as the OP) to activate the intact endocannabinoid signaling pathway, 
while our studies reported here used CB1 receptor gene knockout mice to block 
endocannabinoid signaling.  
Both wildtype/LM and CB1 knockout mice exhibited similar signs of toxicity. 
This suggested that ACh release (and in turn ACh accumulation following OP exposure) 
may not be influenced by deletion of the CB1 receptor, and thus its loss would have no 
influence on OP toxicity. We therefore evaluated the effects of OP exposure on ACh 
release in tissues from wildtype/LM and CB1 knockout mice.  
 
Comparative effects of parathion and chlorpyrifos exposure on acetylcholine release 
ex vivo in slices from CB1 knockout mice and wildtype/LM mice 
Wildtype/LM and CB1 knockout mice were exposed to parathion (27.5 mg/kg) or 
chlorpyrifos (300 mg/kg) and tissues subsequently collected to measure ACh release ex 
vivo. ACh release was measured in slices from hippocampus (where ACh release has 
been shown to be modulated by endocannabinoids) and striatum (where ACh release does 
not appear to be modulated by endocannabinoids) (Kathmann et al., 2001a.  
Depolarization-induced release of ACh in hippocampal slices was not 
significantly different between wildtype/LM and CB1 knockout mice. This suggests that 
endocannabinoids do not constitutively modulate ACh release in our system. Kathmann 
et al (2001a) reported however a 2-fold increase in depolarization-induced ACh release in 
 139 
 
hippocampal slices from CB1 knockout mice compared to tissues from wildtypes, and 
these investigators concluded that endocannabinoids tonically inhibited ACh release in 
hippocampus. The basis for the discrepancy in results between these studies is unclear.  
Parathion decreased depolarization-induced hippocampal ACh release ex vivo in 
both wildtype/LM and CB1 knockout mice, but no significant differences were noted 
between the groups (Figure 26). Chlorpyrifos also significantly reduced depolarization-
induced hippocampal ACh release in both wildtype/LM and CB1 knockouts, but in this 
case the extent of reduction was significantly greater in the wildtypes (Figure 26). This 
provides the first evidence that CB1 deletion indeed may influence cholinergic signaling 
in an OP-selective manner.  
 Activation of postsynaptic muscarinic (M1 and M3) as well as metabotropic 
glutamate receptors during OP intoxication can trigger the “on demand” synthesis of 
endocannabinoids in cholinergically innervated cells. OP exposure in both wildtype/LM 
and CB1 knockout mice should therefore lead to enhanced endocannabinoid synthesis 
and release, regardless of the presence or absence of the CB1 receptor. Recent studies 
(Pope et al., in press) suggest that extracellular 2-arachidonyl glycerol (2-AG, but not 
anandamide) increases in rat hippocampus following exposure to chlorpyrifos (279 
mg/kg), while parathion failed to elicit changes in extracellular levels of either 
endocannabinoid, even though cholinesterase inhibition was marked and similar between 
the two treatment groups. Increased 2-AG levels could more effectively activate CB1 
receptors, leading to reduced hippocampal ACh release. Such a neuromodulatory 
response could not occur in CB1 knockouts, however because of the absence of CB1. 
There is uncertainty in this extrapolation however, because the studies demonstrating 
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selective changes in extracellular endocannabinoid levels were conducted in rats while 
the studies evaluating CB1 receptor deletion involved mice.  
All of our studies have been based on the premise that without the CB1 receptor, 
endocannabinoid signaling could not modulate ACh release and thereby influence OP 
toxicity. Several studies have shown, however that endocannabinoids may directly 
interact with pre-synaptic voltage gated calcium channels and potassium channels, 
potentially regulating the release of neurotransmitters in a receptor-independent manner. 
Kofalvi and coworkers (2007) reported that the cannabinoid receptor agonist WIN 
55,212-2, at low micromolar concentrations, was capable of inhibiting neurotransmitter 
release by directly acting on calcium channels, i.e., independent of the CB1 or CB2 
receptor. Similar findings were also reported by Nemeth et al (2008), in this case low 
micromolar concentrations of WIN 55,212-2 reduced glutamate release from 
hippocampus by blocking of N-type voltage gated calcium channels. As noted before, 
increased intracellular calcium is required for exocytosis and thus the release of 
neurotransmitters from the pre-synaptic terminal. It may be that WIN 55,212-2 and 
possibly other cannabinoids/endocannabinoids, at lower concentrations, inhibit 
transmitter release through CB1 receptor activation whereas at higher concentrations, 
both through direct interaction with CB1 and by direct modification of voltage-gated 
calcium channels. Thus, reductions in ACh release ex vivo seen in hippocampal slices 
from CB1 knockouts following exposure to parathion and chlorpyrifos could be due to 
direct modification of calcium channels in the absence of any interaction with the CB1 
receptor. 
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With chlorpyrifos, CB1 deletion did appear to influence ACh release in the 
hippocampus, but this effect was not associated with an obvious change in sensitivity to 
chlorpyrifos-induced cholinergic toxicity. On the other hand, the hippocampus is likely to 
play little role in the expression of either SLUD signs or involuntary movements (the 
functional endpoints of cholinergic toxicity evaluated herein). Thus, other 
functional/neurobehavioral endpoints that are thought to be dependent on hippocampal 
cholinergic signaling (e.g. cognition) may be differentially affected in wildtype/LM and 
CB1 knockout mice exposed to OPs, and thus such effects may be sensitive to 
modulation by endocannabinoid-active drugs under normal conditions. Studies by 
Reibaud et al (1999) reported that CB1 knockout mice performed better in a two-trial 
object recognition cognitive test. Several studies evaluated the role of CB1 receptor in 
memory using various behavioral tests such as the Morris water maze and radial maze 
(Terranova et al., 1996; Chaperon and Thiebot, 1999; Castellano et al., 2003). The role of 
CB1 and endocannabinoid signaling in persistent neurobehavioral consequences of OP 
intoxication obviously requires different experimental approaches than used here. Such 
neurochemical interactions could be important, however in long-term neurological 
consequences of OP exposures.  
In the striatum, a significant reduction in ACh release was observed following 
parathion and chlorpyrifos exposure in both wildtype/LM and CB1 knockouts (Figure 
27). Extensive accumulation of extracellular ACh was observed in rat striatum following 
exposure to parathion or chlorpyrifos (Karanth et al., 2006, 2007).  As noted before, 
studies using striatal slices from M2 knockout, M4 knockout, or double M2/M4 knockout 
mice suggested that the M4 receptor is the primary muscarinic autoreceptor in striatum 
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(Zhang et al., 2002).  Dolezal and Tucek (1998) reported that M4 acts as an autoreceptor 
and decreases ACh release in rat striatum. The cannabinoid receptor agonist WIN 55,212-
2 a) had no effect on ACh release in striatal slices from either wildtype or CB1 knockout 
mice, b) reduced ACh release in hippocampal slices from wildtypes, but c) had no effect 
in slices from CB1 knockouts.  Thus CB1 appears to have little role in regulating ACh 
release in striatum (Kathamnn et al., 2001a). We observed a decrease in striatal ACh 
release ex vivo following parathion or chlorpyrifos exposure. Accumulation of ACh in 
striatum may have activated M4 receptors, resulting in further reduction in release of 
ACh into the synapse in both wildtype/LM and CB1 knockout mice.  
 
Comparative in vitro effects of paraoxon and chlorpyrifos oxon on  acetylcholine 
release in slices from CB1 knockouts and wildtype/LM mice 
Hippocampal and striatal slices from wildtype/LM and CB1 knockout mice were 
exposed to paraoxon (100 µM) or chlorpyrifos oxon (100 µM) prior to depolarization and 
effects on ACh release subsequently evaluated. WIN was used as a positive control. WIN 
reduced release in hippocampal slices from wiltype mice, but had no effect on release in 
tissues from the CB1 knockouts. As expected, WIN had no effect on ACh release in 
striatum from either wildtypes or knockouts. These findings provided support for intact 
endocannabinoid signaling in the hippocampus of wildtype mice coupled to ACh release 
regulation. Paraoxon decreased ACh release in hippocampal slices from wildtype/LM 
(Figure 28), but there was no effect in slices from CB1 knockouts. With chlorpyrifos 
oxon, a significant reduction was noted in both wildtype/LM and knockouts, but the 
degree of reduction was greater in tissues from wildtype/LM mice (Figure 28). These 
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findings with chlorpyrifos oxon were generally similar to results obtained in hippocampal 
slices ex vivo following chlorpyrifos exposure (Figure 26).  
Both paraoxon and chlorpyrifos oxon reduced hippocampal ACh release to a 
greater degree in slices from wildtype/LM compared to CB1 knockout mice, suggesting 
such differences could be due to the presence or absence of the CB1 receptor. Several 
studies from other laboratories have shown that cannabinoids modulate the release of 
ACh from the pre-synaptic cholinergic terminal (Gifford and Ashby, 1996; Steffens et al., 
2003; Tzavara et al., 2003b; Degroot et al., 2006). Thus, in the presence of CB1, 
acetylcholinesterase inhibition can lead to ACh accumulation, stimulation of M1/M3 
receptors, enhanced release of endocannabinoids, and finally activation of CB1 to reduce 
ACh release.  
ACh release was reduced in striatal slices from both wildtype/LM and CB1 
knockout mice by paraoxon in vitro (Figure 29). Interestingly, chlorpyrifos oxon 
significantly increased ACh release in striatal slices from both wildtype/LM and CB1 
knockout mice, with no significant differences between the groups (Figure 29). As noted 
before, the striatum expresses an abundance of M4 and lesser M2 receptors (Olianas et 
al., 1997; Zhang et al., 2002; Tzavara et al., 2004). Studies by Liu et al (2002) reported 
that paraoxon and chlorpyrifos oxon interact differentially with the striatal autoreceptor. 
Under some conditions, paraoxon acted as a cholinomimetic to decrease ACh release 
while chlorpyrifos oxon acted as an antagonist to increase ACh release. Similar actions 
may occur here, where paraoxon activated the M4 receptor while chlorpyrifos oxon 
blocked the M4 receptor. As CB1 is thought to play a minimal role in ACh release in 
striatum, the primary response may be mediated by M4.  
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Together, these results suggest that genetic deletion of the CB1 receptor in mice 
has relatively little influence on classical signs of OP toxicity. The CB1 receptor is the 
primary receptor involved in endocannabinoid signaling in the nervous system 
(Herkenham et al., 1990; Matsuda et al., 1993; Tsou et al., 1998; Coutts et al., 2001). The 
second identified cannabinoid receptor (CB2) appears primarily involved in immune 
regulation and located on immune cells. In addition to these two receptors, emerging 
evidence suggests the presence of another cannabinoid receptor sometimes referred to as 
non-CB1/non-CB2 or the CB3 receptor. The identity of this receptor has not been 
confirmed, however. Kofalvi and coworkers (2003) reported that glutamate release was 
similarly reduced in hippocampal slices from both wildtype and CB1 knockout mice 
exposed to WIN 55,212-2. Similarly, WIN 55,212-2 reduced glutamatergic transmission 
in hippocampal pyramidal neurons from both wildtype and CB1 knockout mice (Hajos et 
al., 2001; Hajos and Freund, 2002). Some behavioral responses sensitive to 
endocannabinoids, e.g. an analgesic response and immobility, were similarly affected in 
both wildtype and CB1 knockout mice (Di Marzo et al., 2000). Using the [35S]GTPγS 
binding technique to identify agonist action, Breivogel and coworkers (2001) reported 
that WIN 55,212-2 stimulated [35S]GTPγS binding in tissues similarly from both 
wildtype and CB1 knockout mice. All of these findings suggest that some actions of 
endocannabinoids (primarily based on studies using WIN 55,212-2) may be mediated by 
a novel cannabinoid receptor (Monory et al., 2002), or as noted before direct binding to 
ion channels. If WIN 55,212-2 can modify functional signs of cholinergic toxicity by 
binding to a novel (non CB1) receptor, this could explain the ability of WIN 55,212-2 to 
reduce cholinergic toxicity in rats (Nallapaneni et al., 2006, 2008) but the lack of any 
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substantial effect of CB1 deletion on OP toxicity in mice. Future in vivo studies with 
WIN 55,212-2 and OPs in mice could provide more evidence for the role of a novel 
cannabinoid receptor in modulating OP toxicity. 
Our in vitro release studies suggest that the CB1 receptor does have a role in 
regulating hippocampal ACh release following OP exposure. Our studies focused on the 
hippocampus because of substantial endocannabinoid signaling in this region (Maejima et 
al., 2001; Kathmann et al., 2001a; Ohno-Shosaku et al., 2002, 2003). In studies 
performed in vivo, however, extensive acetylcholinesterase inhibition will likely lead to 
recruitment of other neurotransmitter systems and signaling pathways in different regions 
of the brain. The nervous system is an incredibly complicated organ with numerous 
different types of neurotransmitters and neuronal circuits. This complexity leaves the 
evaluation of selective transmitter signaling pathways difficult to study in context. 
Moroever, endocannabinoids are known to act as global neuromodulators regulating the 
release of a variety of neurotransmitters including ACh, dopamine, glutamate, GABA and 
others. Understanding the interactions between cholinergic and cannabinergic signaling 
may be important not only for improving the treatment strategies for OP poisoning but 
also in other neurological disorders such as Alzheimer’s disease or Parkinson disease.  
The neuroprotective role of endocannabinoids in neurological disorders is 
currently receiving considerable research attention. Some studies suggest a protective 
role for endocannabinoids in Alzheimer’s disease (Pazos et al., 2004; Ramirez et al., 
2005; Benito et al., 2007; Campbell and Gowran, 2007). While endocannabinoids are 
typically associated with inhibiting pre-synaptic neurotransmitter release, some studies 
suggest they enhance dopamine release in some pathways. In a C6 glioma-PC12 co-
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culture system, the dopaminergic neurotoxicant MPTP led to PC12 cell cytotoxicity that 
was blocked by pharmacological CB1 receptor activation (Iuvone et al. 2007). Kreitzer 
and Malenka (2007) reported that in animal models of Parkinson's disease, long-term 
depression was absent but rescued by inhibitors of endocannabinoid degradation. Further, 
administration of a dopamine D2 receptor agonist and a FAAH inhibitor together reduced 
motor deficits in these models, suggesting that endocannabinoid signaling has a critical 
role in the control of nigrostriatal coordinated movement. In contrast, van der Steldt and 
coworkers (2005) reported that endocannabinoid signaling may actually play a role in the 
development of Parkinson’s disease and in levodopa-induced dyskinesias. Obviously, a 
role for CB1 receptor signaling in disorders such as these could lead to improved therapy 
and possibly even prevention.  
Pre-synaptic modulation of cholinergic toxicity in M2 and CB1 knockout mice 
We hypothesized that deletion of either muscarinic M2 or cannabinoid CB1 
receptors would increase anticholinesterase toxicity by removing an adaptive 
neuromodulatory process that inhibits ACh release. In contrast to our hypothesis, we 
observed few differences in sensitivity between wildtype mice and either M2 or CB1 
knockouts. With knockout models, there is always a possibility for developmental 
compensation for the missing gene product. Although knockout mice can serve as viable 
models, several studies have shown that knockout mice can often “find a way” to 
compensate for the loss of a particular gene by modulation of related pathways. Godecke 
et al (1999) reported that myoglobin knockout mice compensated for the loss of 
myoglobin by increasing blood hemoglobin and blood flow. Similar findings were also 
observed with loricrin knockout mice where knockdown of this protein was compensated 
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for by upregulation of other related proteins (Koch et al., 2000). AChE knockout mice 
compensate for the loss of the enzyme by downregulating cholinergic muscarinic 
receptors, thus decreasing the responses to accumulated ACh (Volpicelli-Daley et al., 
2003; Li et al., 2003). Also, in the absence of AChE the other cholinesterase enzyme 
(butyrylcholinesterase) compensates for it and hydrolyzes ACh in AChE knockout mice 
(Hartmann et al., 2007). Studies by Myslivecek and Duysen (2007) have shown that 
AChE knockout mice adapt to increased levels of ACh in the lung by downregulating 
muscarinic and adrenergic receptors in the airways. Tai and coworkers (2004) reported 
that µ opioid receptor knockouts have increased levels of AChE and a decreased density 
of M2 receptors in striatum. Such compensatory mechanisms could occur in M2 and/or 
CB1 knockouts, and those alterations could potentially confound interpretations of the 
role of the respective receptor in OP toxicity.  
There are several aspects of the current project which can be investigated further. 
The logical extension of this project would be to do the in vivo studies in wildtype/LM 
and CB1 knockout mice with both OPs and challenge them with WIN to check if WIN 
could offer similar protection in both wildtype/LM and CB1 kncokut mice. If this 
happens, then the protective actions of WIN could explained by its activation of non CB1 
cannabinoid receptors. It would also be interesting to evaluate whether greater effects on 
ACh release seen following oxon exposure in WT/LM mice compared to CB1 knockout 
mice are sensitive to cannabinoid receptor antagonists. Tremors were not seen in M2 
knockout mice following oxotremorine treatment, but were evident in OP treated mice. 
Future studies using nicotinic, serotonergic or glutamatergic antagonists could reveal the 
role of these signaling pathways in OP-induced tremors. As differential changes in 
 148 
 
hippocampal ACh release were noted following chlorpyrifos exposure in CB1 knockouts, 
it would be interesting to study the long-term neurobehavioral effects of chlorpyrifos on 
higher order processing using selected neurobehavioral tests. In fact, ongoing studies in 
our laboratory (Wright et al., under revision) suggest that affective (depressive-like) 
behaviors may be elicited by OPs, and that these long-term behavioral changes are 
sensitive to modulation by cannabinomimetics. All studies reported herein were acute 
studies, thus repeated dosing studies may reveal differences in sensitivity based on 
genotype for either M2 or the CB1 receptor. As acute OP intoxications are getting less 
common (in the US) while potential long-term effects of low level OP exposures are of 
increasing concern, study of the role of pre-synaptic control mechanisms in modulating 
cholinergic signaling with long-term OP exposures would be a logical extension of this 
project.  
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
 
1. Studies of the comparative toxicity of organophosphorus cholinesterase inhibitors 
(OPs) in mice lacking one of two presynaptic receptors (muscarinic M2 receptors 
and cannabinoid CB1 receptors), with and without littermate controls, reinforced 
the importance of littermates in the experimental design for gene knockout 
studies.  
2. Initial studies without littermate controls suggested differential sensitivity to OP 
toxicity in mice lacking either the M2 receptor or the CB1 receptor. 
3. In both cases, however, different degrees of cholinesterase inhibition confounded 
the interpretation of the roles of each receptor in expression of toxicity and 
prompted studies with littermate controls. 
4. Using +/+ and -/- littermates, wildtype and M2 knockouts exhibited relatively 
similar acute sensitivity (based on functional signs of toxicity and cholinesterase 
inhibition) to both parathion and chlorpyrifos. 
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5. M2 receptor deletion may be associated with reduced lethality following 
parathion exposure. 
6. Parathion elicited tremors in M2 knockout mice, but these appeared to be 
mediated via a non-muscarinic mechanism as the M2 receptor appears essential 
for tremorigenic response to muscarinic agonists. 
7. Parathion had little effect on acetylcholine release ex vivo in tissues from either 
wildtype or M2 knockout mice, paraoxon had no apparent effect on acetylcholine 
release in vitro in hippocampal or cortical slices, but paraoxon decreased release 
in vitro in striatal slices. As the muscarinic agonist oxotremorine inhibited release 
in all tissues, these findings suggest that neither parathion nor paraoxon 
substantially modify muscarinic autoreceptor function in cortex or hippocampus.  
8. Chlorpyrifos oxon decreased acetylcholine release in vitro in cortical slices from 
both wildtype and M2 knockout mice, suggesting M2 receptor-independent 
modulation of ACh release. 
9. In contrast, chlorpyrifos oxon increased acetylcholine release in hippocampal and 
striatal slices from wildtype mice while having no effect in tissues from M2 
knockouts. These results suggest that chlorpyrifos oxon blocks M2 autoreceptor 
function in these tissues.  
10. Without +/+ and -/- littermates in the design, CB1 knockouts appeared more 
sensitive than wildtypes to both OPs (parathion and chlorpyrifos), but greater 
cholinesterase inhibition was observed in CB1 knockouts compared to wildtypes 
following either parathion or chlorpyrifos. Using CB1 +/+ and -/- littermates, 
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however, little difference in sensitivity to either parathion or chlorpyrifos was 
noted. 
11. Parathion decreased ex vivo acetylcholine release in hippocampal and striatal 
slices from wildtype and CB1 knockout mice suggesting decreased acetylcholine 
release was not CB1 dependent. 
12. In contrast, chlorpyrifos decreased acetylcholine release ex vivo in hippocampal 
and striatal slices but a significantly greater reduction was observed in wildtypes 
compared to CB1 knockouts in hippocampus. This difference in hippocampal 
acetylcholine release in wildtypes compared to CB1 knockouts following 
chlorpyrifos exposure appears due to endocannabinoid signaling. 
13. Paraoxon and chlorpyrifos oxon exposure resulted in a greater reduction in in 
vitro acetylcholine release in tissues from wildtype mice compared to CB1 
knockouts suggesting a role for the CB1 receptor in regulating acetylcholine 
release in vitro in response to these OPs. 
14. A significant decrease in acetylcholine release was observed in striatum of both 
wildtype and CB1 knockout mice following exposure to paraoxon suggesting a 
role for the M4 receptor in modulating ACh release in vitro following paraoxon. 
15. Chlorpyrifos oxon increased acetylcholine release in striatal slices of both 
wildtype and CB1 knockout mice presumably by directly blocking M4 
autoreceptors in striatum. 
16. Overall, deletion of either M2 or CB1 receptor had relatively little influence on 
expression of cholinergic signs of OP toxicity, but influenced some 
neurochemical responses in an OP-selective and brain regional manner.  
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cholinergic toxicity following OP exposure. ACh release ex vivo was differentially 
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and chlorpyrifos oxon had differential effects on ACh release in hippocampal slices of 
WT and KO mice. Together, these findings suggest that presynaptic muscarinic M2 and 
cannabinergic CB1-mediated signaling pathways have relatively little influence on 
expression of cholinergic toxicity, but may influence neurochemical responses elicited by 
OPs that affect other neurobehavioral/neuropsychological consequences of intoxication.  
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